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A B S T R A C T
Background
Staphylococcus aureus (S. aureus) can cause secondary infection in eczema, and may promote inflammation in eczema that does not look
infected. There is no standard intervention to reduce S. aureus burden in eczema. It is unclear whether antimicrobial treatments help
eczema or promote bacterial resistance. This is an update of a 2008 Cochrane Review.
Objectives
To assess the effects of interventions to reduce S. aureus for treating eczema.
Search methods
We updated our searches of the following databases to October 2018: Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE,
Embase and LILACS. We searched five trials registers and three sets of conference proceedings. We checked references of trials and reviews
for further relevant studies. We contacted pharmaceutical companies regarding ongoing and unpublished trials.
Selection criteria
Randomised controlled trials of products intended to reduce S. aureus on the skin in people diagnosed with atopic eczema by a medical
practitioner. Eligible comparators were a similar treatment regimen without the anti-staphylococcal agent.
Data collection and analysis
We used standard methodological procedures expected by Cochrane. Our key outcomes were participant- or assessor-rated global im-
provement in symptoms/signs, quality of life (QOL), severe adverse events requiring withdrawal, minor adverse events, and emergence
of antibiotic-resistant micro-organisms.
Interventions to reduce Staphylococcus aureus in the management of eczema (Review)









Cochrane Database of Systematic Reviews
Main results
We included 41 studies (1753 analysed participants) covering 10 treatment categories. Studies were conducted mainly in secondary care
in Western Europe; North America; the Far East; and elsewhere. Twelve studies recruited children; four, adults; 19, both; and six, unclear.
Fi$y-nine per cent of the studies reported the mean age of participants (range: 1.1 to 34.6 years). Eczema severity ranged from mild to
severe. Many studies did not report our primary outcomes. Treatment durations ranged from 10 minutes to 3 months; total study durations
ranged from 15 weeks to 27 months. We considered 33 studies at high risk of bias in at least one domain.
We present results for three key comparisons. All time point measurements were taken from baseline. We classed outcomes as short-term
when treatment duration was less than four weeks, and long-term when treatment was given for more than four weeks.
Fourteen studies evaluated topical steroid/antibiotic combinations compared to topical steroids alone (infective status: infected (two
studies), not infected (four studies), unspecified (eight studies)). Topical steroid/antibiotic combinations may lead to slightly greater global
improvement in good or excellent signs/symptoms than topical steroid alone at 6 to 28 days follow-up (risk ratio (RR) 1.10, 95% confidence
interval (CI) 1.00 to 1.21; 224 participants; 3 studies, low-quality evidence). There is probably little or no difference between groups for QOL
in children, at 14 days follow-up (mean difference (MD) -0.18, 95% CI -0.40 to 0.04; 42 participants; 1 study, moderate-quality evidence).
The subsequent results for this comparison were based on very low-quality evidence, meaning we are uncertain of their validity: severe
adverse events were rare (follow-up: between 6 to 28 days): both groups reported flare of dermatitis, worsening of the condition, and
folliculitis (325 participants; 4 studies). There were fewer minor adverse events (e.g. flare, stinging, itch, folliculitis) in the combination
group at 14 days follow-up (218 participants; 2 studies). One study reported antibiotic resistance in children at three months follow-up,
with similar results between the groups (65 participants; 1 study).
Four studies evaluated oral antibiotics compared to placebo (infective status: infected eczema (two studies), uninfected (one study), one
study’s participants had colonisation but no clinical infection). Oral antibiotics may make no difference in terms of good or excellent global
improvement in infants and children at 14 to 28 days follow-up compared to placebo (RR 0.80; 95% CI 0.18 to 3.50; 75 participants; 2 studies,
low-quality evidence). There is probably little or no difference between groups for QOL (in infants and children) at 14 days follow-up (MD
0.11, 95% CI -0.10 to 0.32, 45 participants, 1 study, moderate-quality evidence). The subsequent results for this comparison were based
on very low-quality evidence, meaning we are uncertain of their validity: adverse events requiring treatment withdrawal between 14 to
28 days follow-up were very rare, but included eczema worsening (both groups), loose stools (antibiotic group), and Henoch-Schönlein
purpura (placebo group) (4 studies, 199 participants). Minor adverse events, including nausea, vomiting, diarrhoea, and stomach and joint
pains, at 28 days follow-up were also rare and generally low in both groups (1 study, 68 infants and children). Antibiotic resistance at 14
days was reported as similar in both groups (2 studies, 98 infants and children).
Of five studies evaluating bleach baths compared to placebo (water) or bath emollient (infective status: uninfected (two studies), unspec-
ified (three studies)), one reported global improvement and showed that bleach baths may make no difference when compared with
placebo at one month follow-up (RR 0.78, 95% CI 0.37 to 1.63; 36 participants; low-quality evidence). One study showed there is probably
little or no difference in QOL at 28 days follow-up when comparing bleach baths to placebo (MD 0.90, 95% CI -1.32 to 3.12) (80 infants
and children; moderate-quality evidence). We are uncertain if the groups differ in the likelihood of treatment withdrawals due to adverse
events at two months follow-up (only one dropout reported due to worsening itch (placebo group)) as the quality of evidence was very
low (1 study, 42 participants). One study reported that five participants in each group experienced burning/stinging or dry skin at two
months follow-up, so there may be no difference in minor adverse events between groups (RR 1.00, 95% CI 0.35 to 2.87, 36 participants,
low-quality evidence). Very low-quality evidence means we are also uncertain if antibiotic resistance at four weeks follow-up is different
between groups (1 study, 80 participants ≤ 18 years).
Authors' conclusions
We found insufficient evidence on the effects of anti-staphylococcal treatments for treating people with infected or uninfected eczema.
Low-quality evidence, due to risk of bias, imprecise effect estimates and heterogeneity, made pooling of results difficult. Topical steroid/
antibiotic combinations may be associated with possible small improvements in good or excellent signs/symptoms compared with topical
steroid alone. High-quality trials evaluating efficacy, QOL, and antibiotic resistance are required.
P L A I N   L A N G U A G E   S U M M A R Y
Treatments to reduce infection with the bacteria Staphylococcus aureus in eczema
Background
The skin of people with eczema (atopic dermatitis) often contains high numbers of a type of bacteria called Staphylococcus aureus (S.
aureus), which can cause skin infections.
Eczema treatments intended to reduce S. aureus on the skin include antibiotics, treatments put on the skin, and antibacterial soaps/baths.
It is unclear which treatments are helpful.
Review question
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We reviewed the evidence about the effect of treatments aimed at reducing S. aureus on the skin in people with atopic eczema. Eligible
comparisons were similar treatments without anti-S. aureus actions. We included 41 studies involving 1753 participants (evidence is cur-
rent to October 2018).
Study characteristics
Included studies assessed a range of treatments, which they compared with placebos (an identical but inactive treatment), no treatment,
other treatment, vehicle (inactive ingredient(s) which help deliver an active treatment), or textile without the anti-S.aureus component.
Studies were conducted worldwide, and included males and females. Twelve studies recruited children; four, adults; 19, both; and six were
unclear; where reported, the average participant age ranged from 1.1 to 34.6 years. Eczema severity varied from mild to severe. Treatment
durations ranged from 10 minutes to 3 months; total study durations, from 15 weeks to 27 months.
Key results
Outcomes were measured from treatment start. We classed outcomes as short-term when treatment duration was less than four weeks,
and long-term when treatment was given for more than four weeks.
People may be more likely to experience slightly increased short-term improvement with topical steroid/antibiotic combinations than
with steroid only (low-quality evidence, one study of infected eczema and two studies with unspecified infection). There is probably little or
no difference between the combination group and the steroid only groups in short-term impact on quality of life (QoL) (moderate-quality
evidence, one study of infected children). Antibiotic resistance was similar between groups in the long term, but we are uncertain of this
result due to very low-quality evidence (one study of infected children).
When compared to placebo, oral antibiotics may make no difference to short-term improvement (low-quality evidence, two studies: one
in uninfected infants and children; the other in mainly infected infants and children). For short-term QoL, there is probably little or no
difference between the groups (moderate-quality evidence, one study of infected infants and children). Short-term antibiotic resistance
was similar in both groups, but we are uncertain if there is a true difference as the quality of evidence was very low (two studies of infants
and children, infected in one study and uninfected in the other).
Bleach baths may make no difference to short-term improvement when compared to placebo (low-quality evidence, one study of unin-
fected participants). There is also probably little or no difference in short-term QoL in children of unspecified infective status (one study;
moderate-quality evidence); based on the same study, we are uncertain if short-term antibiotic resistance was different between groups
(very low-quality evidence).
Side effects bad enough to stop treatment were rare in all studies; however, evidence was very low quality in all three comparisons, so
we are uncertain whether there is a difference between groups. Assessment ranged from six days to two months, participants included
children and adults with mixed infective status, and causes of withdrawal included worsening of eczema or itch and loose stools.
Participants in the topical steroid/antibiotic combination group experienced fewer minor side effects than those given steroids alone.
Comparing oral antibiotics to placebo, participants experienced equally low numbers of minor side effects. However, we are uncertain if
their are true differences between groups due to very low-quality evidence. Based on short-term assessment of mixed participants (chil-
dren and adults, with mixed infective status), reported side effects included sickness, diarrhoea, stomach/joint pains, and itching. For
bleach baths versus placebo, some long-term minor side effects (burning/stinging, dry skin) were reported in both groups, so there may
be no difference between treatment groups (low-quality evidence, uninfected participants (2 to 30 years)).
Quality of evidence
Evidence quality for improvement in symptoms or signs was low; for improvement in QoL, moderate; for antibiotic resistance, very low;
and for side effects, it was almost consistently very low. The studies were small, diverse, and at risk of bias.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Topical steroid plus topical antibiotic compared with topical steroid for eczema
Topical steroid plus topical antibiotic compared with topical steroid for eczema
Patient or population: children and adults with eczema
Settings: secondary care
Intervention: topical steroid plus topical antibiotic
Comparison: topical steroid
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes












Low risk populationGlobal outcome (good or excellent im-
provement in symptoms or signs, or
both)
Follow-up: 6-28 days






One further study (n




Change from baseline in quality of life
IDQoL ranges from 0 to 30 with higher
values indicating more impaired quality
of life
Follow-up: 14 days
The mean IDQoL in the
control group at the end
of treatment decreased
by
3.46 from the baseline
value.
The mean IDQoL in the
intervention group de-
creased by
0.18 less (0.40 less to
0.04 more).











ic. There was no sig-
nificant difference
with either instru-
ment at 28 days or at
3 months.
Low risk populationAdverse events requiring withdrawal
from treatment
Follow-up: 6-28 days






events were very low


















































































































































(7 to 225) and consequently
the result is very un-
certain.
Low risk population
36 per 1000e 11 per 1000
(4 to 28)
High risk population
Minor adverse events not requiring
withdrawal from treatment
Follow-up: 14 days






The risk in the con-
trol group varied
hugely between the
two studies that as-
sessed this outcome.
Emergence of antibiotic-resistant mi-
cro-organisms
Follow-up: 3 months
See comment See comment - 65 (1) ⊕⊝⊝⊝
very lowg
This study report-
ed the proportion of
strains of S. aureus
that were resistant
to the antibiotic used
- these were similar
between the groups.
Two other studies re-
ported results that




Global change in composite ratings
scale
EASI ranges from 0 to 72, objective SCO-
RAD ranges from 0 to 83 and SCORAD
ranges from 0 to 108, with higher values
indicating greater severity.
Follow-up: 14-56 days
The mean scores in the
control groups were
2.5 (standard devia-
tion 5.2 to 5.6) for EASI,
18.8 (standard deviation
13.1) for objective SCO-
RAD, and 25.4 (standard
deviation 15.9) for SCO-
RAD.




tions lower (0.33 low-
er to 0.33 higher).
- 256 (4) ⊕⊕⊝⊝
lowh
As a rule of thumb,





there was unlikely to
be more than a small
effect, either positive
or negative.
High risk populationNo of participants in whom S. aureus
was isolated
Follow-up: 7-56 days







*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the as-


















































































































































CI: Confidence interval; RR: Risk Ratio; EASI: Eczema Area and Severity Index; SCORAD: SCORing Atopic Dermatitis
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aAssumed risk based on the median control group risk across studies
bDowngraded two levels due to risk of bias (attrition bias, performance bias, and possible selective reporting) and imprecision of estimate
cDowngraded one level due to risk of bias (attrition bias and baseline imbalance)
dDowngraded three levels due to risk of bias (attrition and performance bias) and imprecision of estimate (two levels due to very low number of events)
eAssumed risk based on lowest and highest control group risk across studies
fDowngraded three levels due to risk of bias (attrition bias), imprecision of estimate and heterogeneity in control group risk
gDowngraded three levels due to risk of bias (attrition bias and baseline imbalance) and imprecision of estimate (two levels due to very low numbers of events)
hDowngraded two levels due to risk of bias (attrition and performance bias) and heterogeneity in control group means
iDowngraded one level due to risk of bias (performance bias, possible selective reporting and baseline imbalance)
 
 
Summary of findings 2.   Oral antibiotic compared with placebo for eczema
Oral antibiotic compared with placebo for eczema
Patient or population: children and adults with atopic dermatitis
Settings: primary and secondary care
Intervention: oral antibiotic
Comparison: placebo
















Low risk populationGlobal outcome (good or excellent im-
provement in symptoms or signs, or
both)
Follow-up: 14-28 days
























































































































































Change from baseline in quality of life
IDQoL ranges from 0 to 30 with higher














0.11 less (0.32 less
to 0.10 more).
- 45 (1) ⊕⊕⊕⊝
moderatec
A different instrument (CDLQI)
was used for children aged 4
years and over and also showed
no significant difference. There
was also no significant differ-
ence with either instrument at
28 days or at 3 months.
Adverse events requiring withdrawal
from treatment
Follow-up: 14-28 days
See comment See comment - 199 (4) ⊕⊝⊝⊝
very lowd
Rates of adverse events were
very low (with either zero or
one event in each arm of each
study) and consequently the re-
sult was too uncertain to pro-
duce a meaningful estimate.
Minor adverse events not requiring
withdrawal from treatment
Follow-up: 28 days
See comment See comment - 68 (1) ⊕⊝⊝⊝
very lowd
One further study reported a
number of specific individual
adverse events, but not the
overall proportion of partic-
ipants in each group experi-
encing any adverse event. The
events included nausea, vom-
iting, diarrhoea, stomach pain,
joint pains and new rash. Num-
ber of events were generally
low in both groups.
Emergence of antibiotic-resistant mi-
cro-organisms
Follow-up: 14 days
See comment See comment - 98 (2) ⊕⊝⊝⊝
very lowd
One study reported the propor-
tion of strains of S. aureus that
were resistant to the antibiot-
ic used - these were similar be-
tween the groups. One other
study reported an increase in
MRSA until 14 days following
treatment but did not give nu-
merical results. A third study re-
ported no resistance to the an-
tibiotic used in either treatment
group.
Global change in composite ratings
scale
EASI ranges from 0 to 72 with higher val-
ues indicating greater severity.
The mean EASI
score in the con-




score in the inter-
vention group de-
creased by
0.20 less (0.52 less
to 0.12 more).
- 68 (1) ⊕⊕⊕⊝
moderatec
There was also no significant



















































































































































Follow-up: 14 days 3.29 from the
baseline value.
High risk populationNo of participants in whom S. aureus
was isolated
Follow-up: 14-28 days







*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the as-
sumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk Ratio; IDQoL: Infants' Dermatology Quality of Life Index; CDLQI: Children's Dermatology Life Quality Index; EASI: Eczema Area and Severity
Index
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aAssumed risk based on the median control group risk across studies
bDowngraded two levels due to risk of bias (attrition bias) and imprecision of estimate
cDowngraded one level due to risk of bias (high risk of attrition bias and baseline imbalance)
dDowngraded three levels due to risk of bias (attrition bias and baseline imbalance), and imprecision of estimate (two levels due to very low number of events)
 
 
Summary of findings 3.   Bleach bath compared with placebo or bath emollient for eczema
Bleach bath compared with placebo or bath emollient for eczema
Patient or population: children and adults with atopic dermatitis
Settings: secondary care
Intervention: bleach bath
Comparison: placebo or bath emollient



































































































































































High risk populationGlobal outcome (good or excellent
improvement in symptoms or signs,
or both)
Follow-up: 1 month






One further study assessed this
outcome using the mean IGA score
and also found no significant dif-
ference.
Change from baseline in quality of
life
CDLQI ranges from 0 to 30 with higher

















- 80 (1) ⊕⊕⊕⊝
moderatec
-
Adverse events requiring withdraw-
al from treatment
Follow-up: 2 months
See comment See comment - 42 (1) ⊕⊝⊝⊝
very lowd
Rates of adverse events were too
low to produce meaningful esti-
mates. One further study report-
ed no adverse events and two oth-
er studies also reported very low
rates of adverse events requiring
withdrawal from treatment but re-
sults could not be combined due to
differing study designs.
Medium risk populationMinor adverse events not requiring
withdrawal from treatment
Follow-up: 2 months






Two further studies reported no
adverse events and one other
study reported adverse events but
results could not be combined due




See comment See comment - 80 (1) ⊕⊝⊝⊝
very lowe
One further study reported no sig-
nificant difference in antibiotic re-
sistance patterns but no numerical
results were presented.
Global change in composite ratings
scale
EASI ranges from 0 to 72 with higher
values indicating greater severity.
Follow-up: 1 month
The mean EASI
score in the con-










- 54 (2) ⊕⊝⊝⊝
very lowg
One further study assessed this
outcome using the change from
baseline in mean SCORAD and also
found no significant difference be-
tween the groups. One study addi-
tionally followed up EASI score at



















































































































































SCORAD at 3 months; both report-
ed significantly lower scores in the
intervention group.
No of participants in whom S. aureus
was isolated
- - - - - No studies reported this outcome,
although two studies reported no
significant difference in S. aureus
colony counts.
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% CI) is based on the as-
sumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk Ratio; IGA: Investigator global assessment; CDLQI: Children's Dermatology Life Quality Index; EASI: Eczema Area and Severity Index; SCO-
RAD: SCORing Atopic Dermatitis
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aAssumed risk based on control group of the one study reporting this outcome
bDowngraded two levels due to risk of bias (performance bias, baseline imbalance) and imprecision of estimate
cDowngraded one level due to imprecision of estimate
dDowngraded three levels due to risk of bias (performance bias, baseline imbalance) and imprecision of estimate (two levels due to very low number of events)
eDowngraded three levels due to imprecision (small study) and study limitations due to selective reporting of results (two levels as numerical data not reported) so we were
unable to obtain an estimate of the effect from the available evidence
fControl group mean based on median across the studies reporting this outcome
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B A C K G R O U N D
Description of the condition
Eczema (syn: atopic eczema, atopic dermatitis) is a chronic, relaps-
ing, intensely itchy, inflammatory skin disease (see Figure 1), which
involves the skin creases such as the folds of the elbows or behind
the knees (Williams 1994). Symptoms usually appear below the age
of two years and around 60% of cases will be clear by early adoles-
cence, although some will relapse or continue into adult life. Preva-
lence ranges from 2 to 20% and varies considerably from one coun-
try to another, and also within countries (Odhiambo 2009). The
prevalence has also increased substantially across developed and
less well developed countries worldwide for reasons that are still
unclear (Williams 2008; Deckers 2012). One review suggests that
eczema affects around 7% to 10% of adults in the US (Silverberg
2017).
 
Figure 1.   Eczema. Copyright © 2009 Centre of Evidence Based Dermatology: reproduced with permission.
 
Eczema often occurs in families with atopic diseases including
asthma, allergic rhinitis/hay fever (and food allergy), and atopic
eczema. These diseases share a common pathogenesis (mecha-
nism of disease), and are frequently present together in the same
individual and family. The word atopy refers to the genetic tenden-
cy to produce immunoglobulin E (IgE) antibodies in response to
small amounts of common environmental proteins such as pollen,
house dust mite, and food allergens (Stone 2002; Thomsen 2015).
Around 30% of people with eczema develop asthma and 35% devel-
op allergic rhinitis (Luoma 1983). However, it is known that atopy
does not concurrently occur in all patients with atopic eczema.
In view of this, there have been recent proposals to use the term
'eczema' to define patients both with and without atopy. Various
terms are used for eczema; however, despite these synonyms, we
will refer to the condition as just 'eczema' throughout the rest of
this review. This is in agreement with the 'Revised nomenclature
for allergy for global use' (Johansson 2004) and similar to other
Cochrane Reviews evaluating eczema therapies (Van Zuuren 2017).
The causes of eczema are not fully understood; however, both ge-
netic and environmental factors are important in determining both
the occurrence and the severity of disease (Williams 1992). Skin
barrier dysfunction and immunological abnormalities play a role
in its pathogenesis (Wollenberg 2014; Benetti 2015). The identifica-
tion of mutations in the gene coding for the skin barrier protein, fi-
laggrin, confirmed the role of an underlying genetic predisposition
(Irvine 2006), however, filaggrin mutations do not occur in all cas-
es of eczema and other genes are likely to play a role. Environmen-
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tal factors are important in the initial development of the condition
and in triggering flares (George 2015).
Staphylococcus aureus and eczema
An association between S. aureus and eczema has been recognised
for many years. It has been demonstrated that S. aureus can be iso-
lated from 70% of eczema skin lesions (Totté 2016) and the densi-
ty of S. aureus tends to increase with the clinical severity (Williams
1990). In contrast, S. aureus is rarely found on healthy skin (< 5%),
and it is less common to have severe colonisation or infection in
other skin diseases, so eczema does appear to be a special case.
Whilst this association is well recognised, the role of S. aureus in
causing eczema or making it worse, as opposed to simply colonis-
ing the skin, is still under debate. However, there is increasing ex-
perimental evidence for its role in the pathogenesis of eczema.
Clinically infected eczema
At one end of the spectrum, there is undoubtedly a clinical condi-
tion of 'infected eczema' manifest by oozing, crusting and presence
of pus spots overlying the areas of pre-existing eczema. This corre-
sponds with heavy growth of bacteria in the laboratory on swabs
taken from the affected areas, usually of S. aureus, but there are
also reports of beta-haemolytic streptococci (a type of streptococ-
ci that can split open red blood cells; some types can cause skin
infections, while others live harmlessly on the skin) being isolated
either alone or in combination with S. aureus (Ong 2016). In this
situation, the overt infection responds to antibiotic treatment, al-
though the eczema itself may not. Clinical infection is a major prob-
lem for some eczema sufferers (David 1986). It has been reported
that flares in eczema are preceded by a decrease in microbial diver-
sity and that S. aureus is the main species found during a flare (Ong
2016).
Staphylococcus aureus and non-clinically infected eczema:
coloniser or pathogen?
In eczema that is not overtly clinically infected, the role of S. aureus
is much less clear. It may be that S. aureus simply colonises the skin,
taking advantage of a favourable environment for growth. This is
supported by the fact that treatment of the underlying eczema with
topical steroid alone drastically reduces the number of colonies of
S. aureus (Stalder 1994).
The role of S. aureus in eczema has been discussed in several re-
view articles (Lin 2007; Lee 2014; Ong 2016; Hepburn 2017). There
are numerous ways in which S. aureus may potentially contribute
to the pathogenesis of eczema, including via production of various
proteins such as superantigens and proteases (Lee 2014). Super-
antigens penetrate the skin barrier and cause chronic inflammation
through a variety of mechanisms, including:
1. stimulation of cytokine (a type of protein used for signalling in
the immune system) release from T-cells;
2. acting as an allergen by induction of IgE antibodies, which cause
release of inflammatory mediators from mast cells (cells that re-
lease histamine during inflammatory or allergic reactions) and
basophils (a type of white blood cell)
3. stimulation of antigen-presenting cells and keratinocytes (a
type of skin cell) to release pro-inflammatory cytokines, thereby
increasing T-cell infiltration;
4. increasing cutaneous lymphocyte-associated antigen receptor
(a skin-homing receptor) on T-cells, causing migration to the
skin and increasing inflammation; and
5. increasing skin inflammation caused by other allergens.
Superantigens also increase adherence of S. aureus to the skin
by exposing extracellular matrix adhesins (a type of protein) and
cause corticosteroid resistance (Lee 2014; Benetti 2015). In a clini-
cal study, application of one specific superantigen to the skin has
been shown to induce skin changes of erythema (redness) and
thickening of the skin (Strange 1996).
S. aureus also produces proteases, which cause skin barrier break-
down, allowing penetration of allergens and irritants. S. aureus-de-
rived proteases cleave endogenous protease inhibitors (proteins
produced by the body that prevent the breakdown of proteins by
enzymes called proteases), induce pro-inflammatory and pro-aller-
gic responses, promote Th2 immune response and result in IgE pro-
duction (Lee 2014).
Other S. aureus-derived proteins may also contribute to skin in-
flammation in eczema. Phenol-soluble modulins (a type of bacte-
rial toxin) attract and lyse (break up) neutrophils (a type of white
blood cell), making S.aureus more likely to cause harm (Benetti
2015; Syed 2015). Fibronectin-binding protein, a type of protein
produced by S. aureus that enables it to stick to and enter cells of
the host organism, activates T–cells (a type of cell from the immune
system, that plays a key role in skin inflammation). This activation
results in the release of chemical messengers called cytokines that
also promote skin inflammation (Reginald 2011).
Description of the intervention
A number of products with anti-staphylococcal properties have
been developed for the treatment of eczema, both clinically infect-
ed and uninfected, ranging from antibacterial soaps, impregnated
clothing, to additives such as bath oils and topical corticosteroids.
Some of these treatments are classed as antiseptics, substances
applied to the skin which either kill or inhibit the growth of microor-
ganisms, and others are antibiotics, which have specific effects on
certain bacteria.
Common anti-staphylococcal interventions that are used in clinical
practice include oral antibiotics, topical antibiotics used alone or
in combination with a topical steroid (e.g. “Fucidin H” fusidic acid
and hydrocortisone), and topical antiseptics, which can be used as
a leave-on emollient (moisturiser), soap or bath additive. Any of
these interventions may be used in a primary or secondary care set-
ting.
The decision to use an anti-staphylococcal intervention may be
made on the observation of overt signs of clinical infection such
as oozing on a background of intense erythema and pus spots, or
during a flare of eczema, when staphylococcal colonisation is con-
firmed on bacterial culture from a skin swab. Exact regimens for
topical preparations used in eczema are likely to vary depending
on the patient’s condition and clinician experience. However, more
specific recommendations for staphylococcal skin infection sug-
gest using fusidic acid cream three to four times per day (BNF 2019).
Combination steroid and antibiotic preparations are popular in the
UK and are usually prescribed at a maximum frequency of twice
daily for two weeks (NICE 2013).
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For more widespread or severely infected eczema, oral antibiotics
may be chosen. For an adult, this would usually be flucloxacillin
at a dose of 250 mg or 500 mg four times per day for a week. For
patients allergic to flucloxacillin, a macrolide antibiotic, e.g. ery-
thromycin, can be used. Flucloxacillin commonly causes gastroin-
testinal side effects, such as nausea and diarrhoea (BNF 2019). Oth-
er less common side effects include hypersensitivity reactions, skin
reactions and thrombocytopenia (low blood platelet count) (BNF
2019). Flucloxacillin can potentially interact with numerous other
drugs, which can increase the risk of hepatotoxicity (liver damage)
(BNF 2019).
Many emollients are available which contain an antiseptic ingredi-
ent, such as chlorhexidine and benzalkonium chloride, present in
brands such as Dermol. Some of the products are intended to be
used as leave-on emollients, which would usually be used twice a
day and either prescribed for overt or suspected infection or as part
of a normal emollient regimen regardless of infective status. Others
are used as soap substitutes or bath additives when bathing. Skin
irritation or allergic reactions may occur to the active ingredients or
excipients (i.e. other inactive ingredients in the topical preparation
such as a vehicle).
Bath additives may also contain antiseptic ingredients such as
chlorhexidine and benzalkonium chloride. These may be recom-
mended for use when bathing, often as part of a normal skin care
regimen for patients with eczema, especially those with recurrent
skin infections. Skin irritation or allergic reactions may occur to the
active ingredients or excipients. “Bleach baths” with dilute sodium
hypochlorite solution are recommended for twice weekly use (St
John's Institute of Dermatology 2016). These may be recommend-
ed for patients with overt, suspected or frequently infected eczema.
Therapeutic textiles with anti-staphylococcal properties, although
described in clinical trials, are not routinely used in a clinical setting
for treating eczema.
How the intervention might work
The aim of treatment with anti-staphylococcal interventions in
eczema is to decrease bacterial load, thereby decreasing the
amount of S. aureus superantigen, proteases and other protein
products produced, which result in damage and inflammation of
the skin barrier.
Possible concern about anti-staphylococcal treatment in
eczema
Quite apart from the fundamental question of whether anti-staphy-
lococcal therapies work in eczema, there are special concerns
about their routine use in non-clinically infected eczema. For the
individual patient, irritant and allergic contact dermatitis can occur
from topically-applied antiseptics or antibiotic-containing prepa-
rations. For example, allergic contact dermatitis is increasingly
recognised to occur with benzalkonium chloride (Hann 2007) and
chlorhexidine (Koch 2014) with rare reports of anaphylaxis with the
latter (Moka 2015). One study found that triclosan, a commonly
used microbial agent, acted as a liver tumour promoter in mice
(Yueh 2014).
The potential for development of bacterial resistance to antibi-
otics, which may be needed for systemic treatment of serious in-
fections, is also important. An increase in the prevalence of fusidic
acid resistant S. aureus has been observed in several areas of the UK
(Reed 1999; Ravenscroft 2000; Simpson-Dent 2000; Brown 2002). In
Harrogate, UK, fusidic acid resistance has been shown to be asso-
ciated with intensive use of oral and topical fusidic acid-contain-
ing preparations such as those marketed for eczema (Ravenscroft
2000). A subsequent study from Singapore confirmed an associa-
tion between recent use of fusidic acid and fusidic acid-resistant
S. aureus (Heng 2013). Widespread use in dermatological practice
may limit the use of fusidic acid combination therapies for the treat-
ment of more serious diseases including staphylococcal bone and
joint infections and systemic methicillin-resistant S. aureus (MRSA)
infections.
Resistant organisms also have implications for patients with
eczema. The prevalence of MRSA is increasing in patients with
eczema (Jagadeesan 2014; Chaptini 2015). Furthermore, the pres-
ence of resistant S. aureus was found to be associated with in-
creased disease severity (Jagadeesan 2014). Mupirocin may also be
used to reduce S. aureus carriage in patients with eczema. The use
of mupirocin has also been found to correlate with mupirocin-resis-
tant S. aureus in paediatric dermatology patients (Antonov 2015).
Why it is important to do this review
There is a plausible theoretical rationale for use of anti-staphy-
lococcal agents in eczema, especially if it appears to be clinical-
ly infected. Yet existing evidence to support clinical benefit of an-
ti-staphylococcal agents appears to be conflicting. There are con-
cerns regarding adverse event issues, e.g. contact and irritant der-
matitis, and promoting wider drug resistance in the community.
Despite these concerns, anti-staphylococcal products are widely
marketed and used by the clinical community.
This is an update of a review 'Interventions to reduce Staphylococ-
cus aureus in the management of atopic eczema' (Birnie 2008). The
previous review found that most studies were poorly reported and
study differences limited pooling of results. The authors failed to
find clear evidence of benefit for antimicrobial interventions for
people with eczema, despite their widespread use.
O B J E C T I V E S
To assess the effects of interventions to reduce S. aureus for treating
eczema.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs), including cross-over trials and
randomised within-patient trials.
Types of participants
Anyone who has been diagnosed with atopic eczema by a medical
practitioner. We regarded diagnostic criteria such as the Hanifin
and Rajka definition (Hanifin 1980) or the UK refinement (Williams
1994) as acceptable, as was diagnosis of atopic eczema by a der-
matologist using the terms 'atopic eczema' or 'atopic dermatitis'.
We only accepted the term 'eczema' when referring to children. Any
other terms, such as 'Besnier's prurigo' or 'neurodermatitis' had to
have additional descriptive evidence of atopic eczema in the flex-
ures before inclusion. It was noted whether the participants were
described as 'clinically infected' or otherwise.
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Studies in which not all participants had atopic eczema were only
included if separate results were reported for the participants with
atopic eczema.
Types of interventions
1. Oral antibiotic known to be active against staphylococcus
2. Topical antiseptic/antibiotic
3. Topical steroid plus antiseptic/antibiotic
4. Topical steroid plus antibiotic and antifungal
5. Topical calcineurin inhibitor plus antibiotic
6. Antibacterial soap
7. Antibacterial bath additive
8. Antibacterial bath additive plus antibiotic
9. Therapeutic textile
10.Protease inhibitor
We accepted as comparators a similar treatment regimen with-
out the anti-staphylococcal agent, i.e. placebo, no treatment, ve-
hicle only, or untreated textile where the intervention was an an-
ti-staphylococcal agent alone, or an active compound where the in-
tervention consisted of the active compound plus an anti-staphylo-
coccal agent (e.g. topical steroid/antibiotic combination compared
against the same topical steroid without the antibiotic). On this fi-
nal point, it was agreed that a vehicle was not an appropriate com-
parator for a steroid/antibiotic combination as it is well recognised
that topical steroids are an effective treatment for inflamed eczema
and thus one could not establish whether it was the addition of the
antibiotic, or the steroid itself that had efficacy.
For studies with two treatment groups of interventions from differ-
ent categories compared against a single comparator group, the
relevant treatment group and the same comparator group were in-
cluded in both categories.
Types of outcome measures
Primary outcomes
(a) Global degree of improvement in symptoms or signs, or both,
as rated by the participant or medical practitioner, i.e. percentage
with good or excellent improvement. We included both short-term
(less than or equal to a month) improvement and long-term (more
than one month) benefit.
(b) Improvement in Quality of Life questionnaires.
Secondary outcomes
(a) Severe adverse events, i.e. severe enough to require withdrawal
of treatment, including severe skin irritation.
(b) Minor patient-reported adverse events. This included mild skin
irritation not sufficient to require cessation of treatment.
(c) Emergence of antibiotic-resistant micro-organisms. Only S. au-
reus was considered, and we only included studies if swab data be-
fore and after the intervention were available. It was planned to
take duration of treatment into account when these data were in-
terpreted.
Tertiary outcome measures
(a) Global changes in composite rating scales, using a published
named scale.
(b) Changes in the individual signs of eczema as assessed by a physi-
cian, e.g. erythema (redness), papules (spots that protrude from the
skin surface), vesicles (water blisters), scaling.
(c) Duration of remission and/or prevention of subsequent flares.
(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated.
(e) Change in bacterial counts of S. aureus, i.e. an assessment of
quantity of S. aureus.
The Harmonising Outcome Measures for Eczema (HOME) initia-
tive recommends a core outcome set of four domains for trials in
eczema (Schmitt 2012):
1. Clinician-reported signs, with core outcome instrument Eczema
Area & Severity Index (EASI) (Schmitt 2014). This would be in-
cluded in our tertiary outcome, global changes in composite rat-
ing scales, with individual signs also captured as a separate ter-
tiary outcome.
2. Patient-reported symptoms, with core outcome instrument Pa-
tient Oriented Eczema Measure (POEM) (Spuls 2017). This would
also be included in our tertiary outcome, global changes in com-
posite rating scales.
3. Quality of life. This was one of our primary outcomes. HOME has
yet to recommend a core outcome instrument.
4. Long-term control. HOME recommends that this should be cap-
tured by repeated measurement of the other three domains. We
assessed all reported outcomes in both short- and long-term
timeframes.
Search methods for identification of studies
We aimed to identify all relevant RCTs regardless of language
or publication status (published, unpublished, in press, or in
progress).
Electronic searches
For this update, we revised all our search strategies in line with cur-
rent Cochrane Skin practices. Details of the previous search strate-
gies are available in Birnie 2008.
We searched the following databases up to 29 October 2018:
• the Cochrane Skin Group Specialised Register using the follow-
ing search terms: (dermatitis or eczema or neurodermatitis or
besnier*) and (staphylococc*)
• the Cochrane Central Register of Controlled Trials (CENTRAL);
2018, Issue 9, in the Cochrane Library using the search strategy
in Appendix 1;
• MEDLINE via Ovid (from 1946) using the strategy in Appendix 2;
• Embase via Ovid (from 1974) using the strategy in Appendix 3;
and
• LILACS (Latin American and Caribbean Health Science Informa-
tion database, from 1982) using the strategy in Appendix 4.
Trials registers
We searched the following trials registers up to 16 November 2018:
 
Trial registry Search terms
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ClinicalTrials.gov (www.clinicaltrials.gov) ("Eczema" OR "Dermatitis") AND "Staphylococcus"
the ISRCTN registry (www.isrctn.com/) ("Eczema" OR "Dermatitis") AND "Staphylococcus"
the EU Clinical Trials Register (www.clinicaltrialsregister.eu/) ("Eczema" OR "Dermatitis") AND "Staphylococcus"
the Australian New Zealand Clinical Trials Registry (www.anzctr.org.au) ("Eczema" OR "Dermatitis") AND "Staphylococcus"
the World Health Organization International Clinical Trials Registry Plat-
form (ICTRP) (apps.who.int/trialsearch/)





We checked the bibliographies of all of the studies that were ob-
tained for further references to relevant trials.
Correspondence
Where possible we corresponded with trial authors (Table 1), and
we contacted pharmaceutical companies who produce relevant
products, in order to identify unpublished and ongoing trials. For
the current update, the following companies were contacted:
• Dermal (Dermol 600, Dermol 200, Dermol wash emulsion, Der-
mol cream, Dermol 500, Emulsiderm);
• GSK (Trimovate, Bactroban, Retapamulin);
• Amdipharm mercury (Aureocort);
• Leo (Fucidin H, Fucibet, Fucidin);
• Typharm (Nystaform- HC);
• Alliance (Terra-Cortril, Timodene);
• Derma UK (Synalar N);
• PLIVA Pharma Ltd (TEVA) (Polyfax);
• Smith & Nephew (Flamazine);
• Genus (Eczmol);
• Stiefel (Oilatum Plus);
• Thornton and Ross (Zerolatum Plus).
Grey literature
Conference proceedings from the following meetings were
checked for RCTs and, where appropriate, the trial authors were
contacted for further information:
• British Association of Dermatologists annual meeting (from
1980 to 2018);
• American Academy of Dermatology annual meeting (2006 to
2018); and
• Congresses of the European Academy of Dermatology and
Venereology were searched using the term “staphylococcus au-
reus” for the following years: 1995, 1998, 1999, 2002, 2003, 2005,
2006, 2008-2018.
Data collection and analysis
Selection of studies
Two authors independently checked the titles and abstracts iden-
tified from the searches (JR and JP or AB for the original; SG and SK
or DH for the update). If it was clear that the study did not refer to a
RCT on eczema, it was excluded. If it was unclear, then the full text
of the study was obtained for independent assessment by two au-
thors (AB and HCW for the original; SG and SK or DH for the update).
The authors decided which trials fitted the inclusion criteria. For the
original review, any disagreement was resolved by discussion be-
tween AB and HCW and it was not necessary to refer to a third au-
thor. For the update, any disagreement was resolved by discussion
between SG and SK or DH; in some cases, a consensus among all
authors was obtained. We recorded excluded studies and reasons
for exclusion in the Characteristics of excluded studies table.
Data extraction and management
This was performed by two authors (AB and HCW for the original; SG
and SK or DH for the update), who independently entered data onto
a data extraction form. AB and HCW (SG and SK for the update) dis-
cussed discrepancies between themselves. Missing data were ob-
tained from trial authors, where possible. Data were checked and
entered into RevMan by AB and FBH (SG and DH for the update).
The authors were not blinded to the names of trial authors, journal
or institutions.
In the original published protocol, outcomes were considered at
the end of treatment and this was considered short-term where
treatment had been given for two weeks or less and long-term for
periods of one month or greater. After discussion (between AB and
HCW) however, it was decided that studies of a month's duration
or less would be considered as reflecting short-term benefit and
those of greater than a month as a reasonable minimal time to re-
flect some disease chronicity. Where the patient-rated global as-
sessment was not available, the medical practitioner global rating
was used. Both measures were taken into account where both were
available. No attempt was made to combine these measures, as
they are often not well correlated. In the published protocol, skin
irritation was to be reported separately as well as within the mi-
nor participant adverse events. After discussion (between AB and
HCW), it was decided that it was not necessary to report on skin irri-
tation twice and thus it was included in the "minor patient-report-
ed adverse events" section only.
Assessment of risk of bias in included studies
For the update, two authors (SG and either DH or SK) independent-
ly assessed the risk of bias of each study, including those from the
original review, using the Cochrane tool for assessing risk of bias
(Higgins 2011). Any disagreement was resolved by discussion be-
tween these three authors. The risk of bias tool addresses the fol-
lowing domains:
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• method of sequence generation;
• method of allocation concealment;
• blinding of investigators and participants;
• blinding of outcome assessors;
• presence of incomplete outcome data;
• presence of selective reporting; and
• other bias such as, for example, baseline imbalance.
For each study we categorised each domain as 'low risk of bias',
'high risk of bias' or 'unclear risk of bias'.
Measures of treatment e?ect
For studies with a similar type of intervention and control (e.g.
steroid/antibiotic combinations), a meta-analysis was performed
to calculate a weighted treatment effect across trials using a ran-
dom-effects model. The results were expressed as risk ratio (RR)
and 95% confidence intervals (CI) for dichotomous outcomes,
rather than odds ratio as the event rates were common and we did
not wish to overestimate the effect. Continuous outcomes were ex-
pressed as either mean differences (MD and 95% CI) for cases in
which the same instrument was used, or standardised mean dif-
ferences (SMD) for cases in which different instruments were used.
Where it had not been possible to perform a meta-analysis, the da-
ta were described qualitatively. Where appropriate, we expressed
results as number needed to treat for an additional beneficial out-
come (NNTB) with 95% CI and the baseline risk to which it applied.
Unit of analysis issues
We did not perform techniques appropriate for paired designs for
cross-over studies due to insufficient data; however, where data
from the first period were available from a cross-over study, then
they were analysed as if it were a parallel study as suggested in the
Cochrane Handbook for Systematic Reviews of Interventions (Hig-
gins 2011). For within-patient trials, we abstracted from the orig-
inal paper the paired analysis results, if available, and reported
these in the review. If cluster-randomised trials had been identi-
fied, we would have attempted to include them using the gener-
ic inverse-variance method, if appropriate results were reported.
Where studies with multiple treatment arms were identified, if two
interventions from different categories were compared against the
same control group, then both pairwise comparisons were includ-
ed within the relevant categories.
Dealing with missing data
If results from intention-to-treat analyses were given, then we used
them as such (see Characteristics of included studies). Where a per
protocol analysis was performed by the study in question or it was
clear that the number of participants completing the study were
not the same as those randomised, then we performed an available
case analysis (i.e. we included only those participants for whom the
outcome was reported).
Assessment of heterogeneity
Heterogeneity was assessed using I2. Where substantial hetero-
geneity (I2 > 50%) existed between studies for the primary outcome,
we explored reasons for heterogeneity, such as differing inclusion
criteria (Higgins 2011).
Assessment of reporting biases
We would have performed funnel plots if greater than 10 pooled
studies were available (Higgins 2011).
Data synthesis
A random-effects model was used when conducting a meta-analy-
sis as the studies were deemed to be clinically heterogeneous.
Subgroup analysis and investigation of heterogeneity
We would have performed subgroup analysis where adequate in-
formation was given. The planned subgroups were 'clinically infect-
ed eczema', 'mixed infection/colonisation with S. aureus and beta
haemolytic Streptococcus', and 'non-infected or unspecified.' Het-
erogeneity was assessed as above (Assessment of heterogeneity).
Sensitivity analysis
We explored reasons for heterogeneity in studies and, if neces-
sary, we would have performed sensitivity analyses examining the
effects of excluding study subgroups, e.g. those studies with low
methodological quality.
Summary of findings tables
Summary of findings tables were generated for all comparisons
for which we were able to pool evidence. The outcomes selected
for inclusion in the 'Summary of findings' tables were all prima-
ry and secondary outcomes, and two tertiary outcomes that were
considered most important (changes in composite rating scales
and changes in S. aureus isolation rates). For each outcome includ-
ed in the 'Summary of findings' tables, the quality of the body of
evidence was assessed using the Grades of Recommendation, As-
sessment, Development and Evaluation (GRADE) approach (GRADE
Working Group 2004), which specifies four levels of quality (high,
moderate, low and very low). As all studies included in the review
were RCTs, the starting level for all assessments was high quali-
ty. The level was then downgraded according to the presence of
the following factors: risk of bias; indirectness of evidence; un-
explained heterogeneity; imprecision of results; and likelihood of
publication bias. The number of levels to downgrade each body of
evidence was decided by discussion and agreement between two
authors (SG and DH).
R E S U L T S
Description of studies
Results of the search
We updated the searches to October 2018. We screened 307 records
from the following databases: Cochrane Skin Specialised Register,
CENTRAL, MEDLINE, Embase, and LILACS. A further 88 records were
identified through trial registries (52), the GREAT database (34), cor-
respondence with authors (1), and conference abstracts (1). This
gave a total of 395 records.
After duplicates were removed, there were 343 records. We ex-
cluded 285 records based on titles, abstracts and trial registration
records. After screening the remaining 58 records, we included 18
new studies (see Characteristics of included studies), and excluded
33 (Characteristics of excluded studies). We identified one ongoing
study, and six studies awaiting classification.
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We combined the new studies with those previously identified for
this review, and for this update we have included a total of 41 trials
(18 new), and excluded 57 trials (33 new).
A summary of the search results is provided in Figure 2.
 
Figure 2.   Study flow diagram.
 
Included studies
Twenty-one studies were included in the original review. Of three
studies awaiting classification in the original review, two were in-
cluded for this update (Gauger 2006; Huang 2009), and one was ex-
cluded (Senti 2006), giving a total of 23 trials from the original re-
view. From the update searches, 18 additional studies were includ-
ed, resulting in a total of 41 studies with 1753 evaluable participants
included in this review and described in the Characteristics of in-
cluded studies tables.
Study design
All studies were RCTs: 27 parallel group RCTs (including one 2 x 2
factorial), six cross-over, and eight within-patient studies. The stud-
ies involved sample sizes between four and 174 evaluable partici-
pants.
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Setting
Setting was specified in 38 studies and they were conducted in sec-
ondary care, except one study (Francis 2016), which predominantly
recruited from primary care. Three studies did not specify the set-
ting. Twenty-one of the studies were conducted in Western Europe,
nine were in North America, seven were from the Far East and four
elsewhere in the world. Nine of the studies were conducted using
multiple centres, 27 were single centre and five did not specify.
Participants
Twelve studies looked specifically at children and four specifical-
ly at adults, 19 included both, and, in six studies, it was not clear.
Mean age ranged from 1.1 to 34.6 years across the 24 studies that
reported this, with a median across studies of 14.9 years (eleven of
the studies that did specify whether they recruited adults or chil-
dren did not report the mean age). All of the studies included both
males and females. The proportion of males ranged from 20% to
65% across the 28 studies that reported this, with a median of 48%.
Four studies were in clinically infected eczema, 15 in uninfected
eczema, and two reported a mix of infected and uninfected cases,
while 20 did not specify infective status. In five studies, colonisa-
tion or infection with S. aureus was specified as an inclusion crite-
rion, and across the other 18 studies that reported the proportion
colonised (usually assessed on lesional skin), this varied from 38%
to 100%, with a median of 83%.
Funding sources
In 22 studies, the funding sources were not stated. In one study,
funding was reported as "none". Nine studies were commercial-
ly funded, five studies were funded by non-commercial research
grants or institutions and one study was explicitly reported to have
been funded by both a non-commercial research grant and a phar-
maceutical company. In three studies, the intervention, placebo or
other research support was commercially supplied.
Interventions
The included studies fell into 10 broad categories of interventions:
1. Oral antibiotic (four studies);
2. Topical antiseptic/antibiotic (five studies);
3. Topical steroid plus antiseptic/antibiotic (14 studies);
4. Topical steroid plus antibiotic and antifungal (one study);
5. Topical calcineurin inhibitor plus antibiotic (one study);
6. Antibacterial soap (one study);
7. Antibacterial bath additive (seven studies);
8. Antibacterial bath additive plus antibiotic (one study);
9. Therapeutic textile (eight studies);
10.Protease inhibitor (one study).
One three-arm study had two interventions included in different
categories (oral antibiotic and topical steroid plus antiseptic/an-
tibiotic) (Francis 2016), and the factorial trial also had two inter-
ventions included in different categories (topical steroid plus an-
tiseptic/antibiotic and topical calcineurin inhibitor plus antibiot-
ic) (Hung 2007). Two further studies included a third randomised
arm that was not eligible for inclusion in the review (Wachs 1976;
Juenger 2006), one study had two additional randomised arms that
were not eligible (Polano 1960) and one study included an addition-
al non-randomised control group (Canpolat 2012). Three of the pa-
pers additionally reported a second study, which in all cases was
not eligible for inclusion in the review (Leyden 1977; Nilsson 1992;
Ramsay 1996).
Control groups for the studies of oral interventions were all oral
placebos and topical interventions were compared against vehicle
alone, another topical placebo, or no treatment. Studies of topi-
cal steroid (or topical calcineurin inhibitor) plus antiseptic/antibi-
otic (with or without antifungal) were only included if the controls
used a topical steroid (or calcineurin inhibitor) without the antisep-
tic/antibiotic added. Antibacterial bath emollients were compared
against the same emollient without the antibacterial component
and bleach baths were compared against water or bath emollient.
Therapeutic textiles were all compared against untreated placebo
textiles.
In 16 studies, plus two arms of the factorial RCT, all participants re-
ceived topical steroids. In five studies, plus the other two arms of
the factorial RCT, topical steroids were not permitted. In seven stud-
ies, participants could continue to use topical steroids as needed,
and in four studies participants were strongly discouraged from us-
ing topical steroids or they were only permitted as ‘rescue medica-
tion’. The remaining eight studies did not report on use of topical
steroids.
Outcomes
The studies had multiple stated outcomes, a number of which
were not reported in the results. Twenty studies reported on glob-
al improvement and five reported on quality of life, using the DLQI
(Dermatology Life Quality Index, Finlay 1994) (two studies), CDLQI
(Children's Dermatology Life Quality Index, Lewis-Jones 1995) (two
studies), IDQoL (Infant's Dermatology Quality of Life Index, Lewis-
Jones 2001) (one study) and DIELH (German Instrument for the as-
sessment of Quality of Life in Skin Diseases, Schafer 2001) (one
study). The DLQI, CDLQI and IDQoL range from 0 to 30 and DIELH
ranges from 0 to 180, with higher values on all scores indicating
more impaired quality of life. Twenty-seven studies reported on ei-
ther severe and/or minor patient-reported adverse events. A large
number of studies looked at microbiological data including re-
sistant organisms (seven studies), isolation rates (19 studies) and
colony counts (17 studies) of S. aureus. Twenty studies assessed
outcomes based on a published named scale including SCORAD
(SCORing Atopic Dermatitis, European Task Force on Atopic Der-
matitis 1993) (15 studies), EASI (Hanifin 2001) (five studies), SASSAD
(Six Area, Six Sign Atopic Dermatitis, Schmitt 2007) (one study) and
POEM (Charman 2004) (one study). SCORAD ranges from 0 to 103 (0
to 83 for the objective component), EASI from 0 to 72, SASSAD from
0 to 108, and POEM from 0 to 28, with higher values on all scores
indicating greater severity.
For comparisons of oral antibiotic versus placebo and topical
steroid plus topical antibiotic versus topical steroid, we were able
to pool studies in groups of up to seven studies for some outcome
measures. For the remaining categories, either the studies were not
sufficiently similar to pool or the studies did not report the same
outcome measures. For the initial pooling we did not take into con-
sideration whether it was infected or non-infected eczema that was
being treated.
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Trial periods
Treatment durations ranged from 10 minutes to 3 months (mean:
26 days). Three studies had less than one week duration of treat-
ment, seven were of one week, 11 of two weeks, one of three weeks,
10 of four weeks, and nine of greater than four weeks duration. On-
ly the nine studies with greater than four weeks treatment dura-
tion were considered a reasonable time to reflect disease chronici-
ty (Breneman 2000; Hung 2007; Fluhr 2009; Huang 2009; Tan 2009;
Leins 2013; Portela Araujo 2013; Wong 2013; Lopes 2015). We con-
sidered the remainder to provide short-term data. Seven studies re-
ported follow-up data beyond the final day of treatment: Breneman
2000 (3 weeks follow-up after 6 weeks treatment); Canpolat 2012
(7 weeks follow-up after 1 week treatment); Ewing 1998 (8 weeks
follow-up after 4 weeks treatment); Fluhr 2009 (4 weeks follow-up
after 8 weeks treatment); Francis 2016 (3 months follow-up after
1 week treatment); Korting 1994 (4 weeks follow-up after 5 days
treatment); and Schuttelaar 2005 (6 weeks follow-up after 2 weeks
treatment). Only 15 studies reported the total study duration, rang-
ing from 15 weeks to 27 months (median: 10 months).
Excluded studies
We excluded 57 studies and their details can be found in the Char-
acteristics of excluded studies tables. Twenty-one were not RCTs,
and 19 were excluded as they were not studies of atopic eczema or
there were no separate results for atopic eczema. Fourteen studies
were not of anti-staphylococcal interventions and 11 were exclud-
ed as they only compared anti-staphylococcal agents against each
other or against an inappropriate control. Some studies were ex-
cluded for more than one reason.
Ongoing studies
One study, to evaluate the efficacy of a combination of topical an-
tibiotic, steroid and moisturiser (supiroban 2% cream and fluoci-
nolone acetonide) compared to steroid alone in children aged two
to nine years with severe atopic dermatitis (SCORAD 50 or above),
was registered on Clinicaltrials.gov in 2017 (NCT03052348). The in-
vestigators planned to assess change in SCORAD from baseline to
weeks 4, 8 and 12, frequency of atopic dermatitis relapse episodes,
and change in IDQoL index from baseline to weeks 4, 8, and 12.
However, at the last update of Clinicaltrials.gov in September 2017,
this had not yet begun recruitment.
Studies awaiting classification
Six studies are included in the section of studies awaiting classi-
fication. ACTRN12610000438055 is a parallel group RCT of partici-
pants aged 18 to 50 years with mild to moderate atopic dermatitis
(SCORAD 20-50), colonised with S. aureus. The intervention was Re-
combinant Human ß Defensin 2 cream, which was being compared
to placebo cream. The study planned to collect data on safety and
tolerability, change in local SCORAD at end of treatment (day 14),
change in S. aureus colonisation rate at end of treatment, change in
the colonisation rate of any bacteria at end of treatment, and symp-
tomatic relief using a Likert scale. Recruitment was reported to be
complete in September 2011. The trials authors were emailed, but
there was no response.
EudraCT 2006-004233-15 is a within-patient (le$/right) RCT of pa-
tients aged 6 months to 50 years with eczema affecting the limbs
with an ESCORAD (SCORAD of extremities) between 5 and 12 and
staphylococcus superinfection. The participants were randomised
to triclosan cream versus placebo. The trial evaluated changes in
ESCORAD from baseline to day 14, changes in log staphylococcus
count and changes in ESCORAD from baseline to day 7, changes
in single-ESCORAD of erythema, oedema/papulation, oozing/crust-
ing, excoriation, lichenification and clinical and microbiological re-
sponse rates for day 7 and 14, evaluation of skin parameters, side
effects, tolerance, efficacy, and compliance. Recruitment was re-
ported to be complete in May 2009 and, in July 2019, the EU Clinical
Trials Register was updated with the addition of a link to the results
in German.
EudraCT 2008-005890-37 is a within-patient RCT of patients aged 18
or older with mild to moderate atopic eczema and two comparable
lesional areas of 20-50 cm2 and TEWL (transepidermal water loss) of
at least 12 g/m2h in lesional areas. The study compared K201 cream
[Lactic acid (5%), Propylene glycol (20%), Urea (5%)] and place-
bo. Outcomes assessed were barrier impairment (TEWL measure-
ments), clinical skin condition (corneometric measurements and
clinical assessments) and bacterial colonisation of S. aureus over a
four-week treatment period. Recruitment was reported to be com-
plete in April 2009 and in February 2019 a synopsis of the results
was added to the EU Clinical Trials Register.
NCT03009734 is a parallel group RCT of patients aged 18 to 70 years
with localised atopic dermatitis with two separate lesions of 10-200
cm2 each of which has an IGA (Investigator Global Assessment) of
1-3 and an additional localised lesion of the same size and severi-
ty range, total localised disease not > 20% BSA (body surface area)
and colonisation with S. aureus. The trial was comparing a topical
antibiotic, ATx201, with placebo. Outcomes were treatment-related
adverse events, IGA score, treatment success (100-fold reduction in
S. aureus colony count), and local dermal tolerability. Recruitment
was reported to be complete in March 2018.
NCT03047954 is a parallel group RCT involving children aged 6
months to 7 years with atopic dermatitis with affected BSA 15-70%
and SCORAD 25-70. The trial is comparing Broncho-Vaxom 1 cap-
sule (3.5 mg) per day and placebo. Outcomes were number of
atopic dermatitis flares and changes in SCORAD over nine months
of treatment, area of eczema involvement and amount of corticos-
teroids used. Recruitment was reported to be complete in Decem-
ber 2006, although the trial was not registered until February 2017.
Totté 2017 is a parallel group RCT of adults aged 18 or older with
moderate to severe atopic dermatitis (EASI 7.1 to 50). The trial was
comparing Staphefekt SA 100 cream (Gladskin) and placebo. The
outcomes assessed were corticosteroid use and changes in EASI,
POEM, IGA, Pruritus Numerical Rating Scale, Skindex 29, reduction
in bacteria and serious adverse events. Recruitment was reported
to be complete in February 2018.
Risk of bias in included studies
The overall methodological quality of the studies was variable, and
was generally better in more recent studies. 'Risk of bias' assess-
ment for each individual study is reported in the Characteristics of
included studies and summarised in Figure 3 and Figure 4. Since no
meta-analyses were performed involving more than four studies,
sensitivity analysis based on methodological quality was not per-
formed.
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Figure 3.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
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Figure 4.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 4.   (Continued)
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Figure 4.   (Continued)
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Allocation
The method of random sequence generation was frequently not
specified (two-thirds of studies). For the remaining one third of
studies (n = 13), random sequence generation was judged to have
a low risk of bias.
Eleven of the 41 studies were judged to have a low risk of selec-
tion bias from allocation concealment. In one study, risk of bias was
assessed as high as one of the investigators had an opportunity
to influence the sequence of treatments (Polano 1960). The other
29 studies were considered as having unclear risk of selection bias
from allocation concealment.
Blinding
The majority of studies attempted to blind participants and person-
nel. However, in nine studies, either participants and/or personnel
were not blinded and these studies were therefore judged to have
a high risk of bias (Nilsson 1992; Hizawa 1998; Juenger 2006; Hung
2007; Koller 2007; Fluhr 2009; Canpolat 2012; Leins 2013; Berman
2018). One study noted that the creams were different colours and
was therefore judged to have a high risk of bias (Fattah 1976). Of
five studies evaluating bleach baths versus placebo, only one study
(Hon 2016) gave an adequate description of how they had attempt-
ed to blind participants to the different odours of the bleach and
placebo. This study was therefore judged to have a low risk of bias,
whereas the other four (Huang 2009; Wong 2013; Gonzalez 2016;
Shi 2016) were judged to have a high risk of bias. In addition to
Hon 2016, sixteen other studies (Hjorth 1985; Korting 1994; Ewing
1998; Breneman 2000; Boguniewicz 2001; Masako 2005b; Schutte-
laar 2005; Gong 2006; Stinco 2008; Tan 2009; Daeschlein 2010; Foel-
ster Holst 2010; Lembo 2011; Portela Araujo 2013; Lopes 2015; Fran-
cis 2016) were judged to have a low risk of bias. In the remaining 10
studies, the success of blinding was unclear.
In over half of studies (n = 23), the blinding of outcome assessment
was judged to be unclear as the success of blinding of participants
could not be guaranteed and the results included patient-reported
outcomes. The remaining 18 studies were judged to have a low risk
of bias.
Incomplete outcome data
Seventeen studies were judged to have a low risk of bias for incom-
plete outcome data as either all participants were accounted for
in the analysis or numbers of dropouts were low and reasons were
similar between the groups. Twelve studies were judged to have a
high risk due to very high rates of attrition overall, disproportion-
ately high numbers between the groups, or different reasons for
dropouts between the groups (Polano 1960; Weinberg 1992; Kort-
ing 1994; Holland 1995; Ramsay 1996; Ewing 1998; Gauger 2006;
Gong 2006; Fluhr 2009; Huang 2009; Lembo 2011; Francis 2016). For
the remaining 12 studies, the reasons for dropouts or distribution
between the groups were unclear.
Selective reporting
Trial registrations were only available for six studies (Huang 2009;
Foelster Holst 2010; Leins 2013; Lopes 2015; Francis 2016; Shi 2016).
Of these, for only one study (Francis 2016) were all outcomes clear-
ly described in the registration and reported in the paper. This
study was therefore judged to have a low risk of bias. For one study
(Huang 2009), the primary outcome was changed between the reg-
istration and reporting, and for one study (Lopes 2015), a "co-pri-
mary outcome" from the registration was reported as a secondary
outcome. These two studies were therefore judged to have a high
risk of bias. For the other three studies with registrations available,
there was insufficient information to make a judgement.
Of the remaining studies, some outcomes described in the methods
were frequently either not reported at all (Wachs 1976; Breneman
2000; Masako 2005b; Gauger 2006; Hung 2007; Canpolat 2012), not
reported at all stated time points (Wachs 1976; Gauger 2006; Gong
2006; Fluhr 2009; Canpolat 2012), or reported only in terms of sta-
tistical significance, precluding pooling (Hjorth 1985; Harper 1995;
Holland 1995; Ewing 1998; Masako 2005b; Hon 2016; Berman 2018).
All these studies were judged to have a high risk of bias, with the
remaining 20 studies judged as unclear.
Other potential sources of bias
Unsurprisingly, given the small sample sizes, substantial imbalance
in potentially important baseline characteristics was present in a
number of studies. Six studies (Lever 1988; Juenger 2006; Huang
2009; Leins 2013; Francis 2016; Gonzalez 2016) reported baseline
imbalance in severity of eczema and three studies (Leyden 1977;
Wong 2013; Francis 2016) reported baseline imbalance in presence
or colonisation density of S. aureus. These were judged to have a
high risk of bias. Baseline severity was not reported in 12 studies
(Fattah 1976; Leyden 1977; Harper 1995; Ramsay 1996; Breneman
2000; Boguniewicz 2001; Masako 2005b; Daeschlein 2010; Foelster
Holst 2010; Shi 2016; Berman 2018) and 17 studies did not report
presence of S. aureus at baseline (Fattah 1976; Harper 1995; Ram-
say 1996; Gauger 2006; Gong 2006; Juenger 2006; Koller 2007; Stin-
co 2008; Fluhr 2009; Tan 2009; Daeschlein 2010; Foelster Holst 2010;
Lembo 2011; Leins 2013; Portela Araujo 2013; Shi 2016; Berman
2018). These were judged to have an unclear risk of bias (unless oth-
er potential sources of bias were identified, as described below).
The remaining studies, which were well-balanced on both severity
and presence of S. aureus, were judged to have a low risk of bias
(unless other potential sources of bias were identified, as described
below).
Gong 2006 performed subgroup analysis at the end of the study
which was not part of the predetermined outcomes. Harper 1995
and Hizawa 1998 report statistical comparisons only as significant
differences from baseline and not between groups. Korting 1994
changed inclusion criteria after recruitment to exclude participants
aged < 18 years. Lever 1988 and Polano 1960 did not include a
washout period between treatments in cross-over trials. In addi-
tion, Polano 1960 used an unusual (inverse sine) data transforma-
tion and it was not clear if this was preplanned. All these studies
were therefore graded as having a high risk of bias.
We were unable to assess for publication bias as there were not
enough studies to perform a funnel plot. There were two duplicate
publications. In both cases, identical results were published in both
English and German (Korting 1994 and Schempp 2003).
E?ects of interventions
See: Summary of findings for the main comparison Topical
steroid plus topical antibiotic compared with topical steroid for
eczema; Summary of findings 2 Oral antibiotic compared with
placebo for eczema; Summary of findings 3 Bleach bath compared
with placebo or bath emollient for eczema
Please see table of Characteristics of included studies.
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Subgroup analysis was not performed due to the limited number of
studies available to pool in a meta-analysis.
1. Oral antibiotic - four studies
We included four studies comparing oral antibiotics against place-
bo; results for this comparison are reported in Summary of findings
2. Boguniewicz 2001 was a cross-over study evaluating cefuroxime
axetil among 20 patients (children and adults) with moderate to
severe eczema with S. aureus isolated from the skin, but exclud-
ing overt clinical infection. The duration of the condition was not
stated. In this study, participants were randomised to either receiv-
ing cefuroxime axetil orally (dose not stated) twice daily or place-
bo orally twice daily for two weeks, each with one week washout
in between. A moderate potency topical steroid was used in all par-
ticipants.
Ewing 1998 was a parallel group RCT evaluating flucloxacillin in 50
children (46 evaluable) with uninfected eczema. The severity and
duration of the condition were not stated. In this study, participants
were randomised to receive either flucloxacillin 250 mg four times
daily (n = 25) or placebo (n = 25) for four weeks (dose halved for <
10 yrs old). Topical steroids were used as needed.
Francis 2016 was a three-arm parallel group RCT evaluating flu-
cloxacillin and 2% fusidic acid in 113 children (101 evaluable) with
clinically infected eczema (70 evaluable children in flucloxacillin
and placebo groups included in this category). The severity and du-
ration of the condition was not stated. This study used the following
regimens: oral antibiotic (flucloxacillin four times per day for 7 days,
125 mg in 2.5 mL for children aged three months to two years, 250
mg in 5 mL for children aged > two years to < eight years) and topi-
cal placebo (n = 36) versus topical antibiotic (2% fusidic acid cream
three times per day for seven days) and oral placebo (n = 37) ver-
sus oral and topical placebo (n = 40). All treatment groups received
topical steroids (clobetasone butyrate 0.05% cream or ointment for
use on trunk/limbs and/or hydrocortisone 1% cream or ointment
for use on face, applied once daily for 14 days) and were encouraged
to use emollients that did not contain antimicrobial agents.
Weinberg 1992 was a parallel group RCT evaluating cefadroxil in 33
children (30 evaluable) with eczema with S. aureus isolated from
the skin, with 28 of the 30 participants having clinical infection. The
severity of the condition was not stated. Patients in the interven-
tion group had eczema for a mean duration of 3.2 years and in the
placebo group 2.6 years. Participants were randomised to receive
either cefadroxil 50 mg/kg/day in two equal doses (n = 16) or place-
bo (n = 17) for two weeks. No information was provided on topical
steroid use.
Short-term:
(1) Primary outcome measures
(a) Global degree of improvement in symptoms and/or signs as rated
by participant or medical practitioner
Two studies (Ewing 1998; Weinberg 1992) reported global degree
of improvement in signs and symptoms as rated by the medical
practitioner. Ewing 1998 found a significantly lower rate of good or
excellent outcomes in the flucloxacillin group compared to place-
bo, whereas Weinberg 1992 found a non-significant improvement
in the cefadroxil group compared to placebo. Pooling these studies
gave an estimate of a non-significantly lower rate of good or excel-
lent outcomes with oral antibiotic compared to placebo, with sub-
stantial imprecision and statistical heterogeneity (RR 0.80; 95% CI
0.18 to 3.50, I2 = 92%) (Analysis 1.1). Differences between the studies
that may have contributed to the heterogeneity included the use of
different antibiotics, although both have activity against S. aureus,
and also one study recruited only patients with uninfected eczema
whereas, in the other study, most patients had clinical infection.
One study (Boguniewicz 2001) reported no change in clinical sever-
ity, but provided no data. Francis 2016 did not report any data for
this outcome.
(b) Improvement in Quality of Life questionnaires
One study (Francis 2016), comparing flucloxacillin to placebo, re-
ported changes in quality of life using the IDQoL questionnaire
for children aged three months to < four years and the CDLQI
questionnaire for children aged four years to < eight years. At two
weeks, there was no significant difference between the groups in
the change from baseline on either IDQoL (MD 0.11; 95% CI -0.10
to 0.32) (Analysis 1.2) or CDLQI (MD 0.43; 95% CI -0.16, 1.02) (Analy-
sis 1.3). The other three studies did not report any data for this out-
come.
(2) Secondary outcome measures
(a) Severe adverse events, i.e. severe enough to require withdrawal of
treatment, including severe skin irritation
One study (Boguniewicz 2001) reported no adverse events. Ewing
1998 reported one withdrawal in the oral antibiotic group (loose
stools) and one withdrawal in the placebo group (Henoch-Schön-
lein purpura). Francis 2016 reported one withdrawal in each group
due to the eczema worsening. Weinberg 1992 reported one with-
drawal in the oral antibiotic group due to an adverse event, but the
nature of the event was not specified. Pooled analysis of these stud-
ies showed no clear differences for adverse events requiring with-
drawal (RR 1.43; 95% CI 0.28 to 7.36, I2 = 0%) (Analysis 1.4).
(b) Minor patient-reported adverse events. These included mild skin
irritation not su?icient to require cessation of treatment
One study (Francis 2016) reported minor patient-reported adverse
events. There were no clear differences between the groups in any
of the adverse events reported (nausea 2/33 versus 3/35, vomiting
4/33 versus 6/35, diarrhoea 5/33 versus 5/35, stomach pain 3/33
versus 2/35, joint pains 1/33 versus 0/35, new rash 4/33 versus 8/35).
(c) Emergence of antibiotic-resistant micro-organisms
See long-term results.
(3) Tertiary outcome measures
(a) Global changes in composite rating scales, using a published
named scale
One study (Francis 2016) reported changes in both the POEM and
EASI scores. At two weeks, there was no clear difference between
the groups in the change from baseline on either POEM (MD 1.52;
95% CI -1.35 to 4.40) (Analysis 1.5) or EASI (MD 0.20; 95% CI -0.12 to
0.52) (Analysis 1.6).
(b) Changes in the individual signs of eczema as assessed by a
physician
Two studies (Weinberg 1992; Ewing 1998) found no significant dif-
ference in erythema in the control groups compared to oral antibi-
otic (MD in erythema scores: 0.40; 95% CI -0.03 to 0.83) (Analysis
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1.7), (number of people with erythema: RR 0.93; 95% CI 0.38 to 2.28)
(Analysis 1.8). The two studies could not be pooled because one
used a continuous and the other a dichotomous measure (score).
One study (Weinberg 1992) found significantly fewer clinically ap-
parent infections in the treatment group at the end of the study
compared to control (RR 0.06; 95% CI 0.00 to 0.94) (Analysis 1.9).
(c) Duration of remission and/or prevention of subsequent flares
There were no results given for this outcome.
(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated
Two studies (Ewing 1998; Francis 2016) found no significant differ-
ences in isolation rates of S. aureus for flucloxacillin compared with
placebo; one study (Weinberg 1992) found a significantly lower rate
of S. aureus among participants treated with cefadroxil compared
with placebo. The pooled result of all three studies was not signifi-
cant (RR 0.76; 95% CI 0.46 to 1.26, I2 = 66%) (Analysis 1.10). A poten-
tial source of the heterogeneity in this result was a baseline imbal-
ance in the rate of S. aureus colonisation in Francis 2016 resulting in
a higher isolation rate of S. aureus in the antibiotic group at the end
of the study despite a greater reduction from baseline. Francis 2016
reported a change from baseline at two weeks (end of treatment)
of -30.4% (95% CI -51.6% to -9.2%) in the flucloxacillin group com-
pared with -15.9% (-39.1% to 7.4%) in the placebo group; the dif-
ference between the groups was not statistically significant (mean
difference -14.5%; 95% CI -46.0% to 17.0%) (Analysis 1.11). In Ew-
ing 1998, the isolation rates of S. aureus from affected skin reduced
from 24/24 participants to 15/22 in the flucloxacillin group and from
24/25 to 22/24 in the placebo group, but a change from baseline
analysis was not undertaken.
(e) Change in bacterial counts of S. aureus, i.e. an assessment of
quantity of S. aureus
One study (Ewing 1998) found a non-significant difference in the log
S. aureus counts/cm2 in the flucloxacillin group compared to place-
bo (MD -1.40; 95% CI -3.09 to 0.29) (Analysis 1.12). They reported
that the difference between groups in change from baseline among
the 18 participants in each group with both baseline and follow-up
measurements recorded was statistically significant (P = 0.008), al-
though further details of this analysis were not reported. Another
study (Boguniewicz 2001) suggested that addition of an antibiotic
resulted in a reduction in colony counts, however, when the antibi-
otic was discontinued, the skin was quickly recolonised.
Long-term:
(1) Primary outcome measures
(a) Global degree of improvement in symptoms and/or signs as rated
by patient or medical practitioner
There were no results given for this outcome in any of the four stud-
ies.
(b) Improvement in Quality of Life questionnaires
One study (Francis 2016) continued to follow up participants to
three months. There was no significant difference between the
groups in the change from baseline on either IDQoL (MD -0.21; 95%
CI -0.44 to 0.02) (Analysis 1.13) or CDLQI (MD -0.14; 95% CI -0.97 to
0.69) (Analysis 1.14). The other three studies did not report any da-
ta for this outcome.
(2) Secondary outcome measures
(a) Severe adverse events, i.e. severe enough to require withdrawal of
treatment, including severe skin irritation.
There were no results given for this outcome.
(b) Minor patient-reported adverse events. This included mild skin
irritation not su?icient to require cessation of treatment.
There were no results given for this outcome.
(c) Emergence of antibiotic-resistant micro-organisms
Ewing 1998 reported that the number of methicillin-resistant
strains (MRSA) increased in the treatment group up until 14 days
after treatment, but did not give numerical results. Any increase
in the number of MRSA had returned to almost baseline at day
56. Another study Francis 2016 reported resistance of S. aureus to
flucloxacillin, erythromycin and fusidic acid at baseline, week two
(end of treatment) and three months. Erythromycin was included
for participants who were allergic to penicillin, however, no par-
ticipants received erythromycin. Fusidic acid was included as this
was the other active treatment in this three-arm trial. Among par-
ticipants treated with flucloxacillin with S. aureus identified from
skin swabs, 1/30, 0/18 and 1/8 strains were resistant to flucloxacillin
at baseline, two weeks and three months, respectively. No strains
were resistant to flucloxacillin in the placebo group (of 24, 16 and
10 positive skin swabs at each time point). No flucloxacillin-resis-
tant strains were identified from the nose or mouth. Weinberg 1992
reported on resistance to cephadroxil. Of 33 participants, 16 were
randomised to receive cephadroxil, but three were withdrawn, in
one case due to the presence of a resistant organism at baseline.
At the end of the study, none of the participants in either the inter-
vention or placebo group were found to have a resistant organism.
(3) Tertiary outcome measures
(a) Global changes in composite rating scales, using a published
named scale
Francis 2016 reported longer term changes in the POEM score.
At three months, there was no significant difference between the
groups in the change from baseline (MD -0.21; 95% CI -3.12, 2.70)
(Analysis 1.15).
(b) Changes in the individual signs of eczema as assessed by a
physician
Ewing 1998 reported no significant difference in erythema at 56
days post-treatment with oral flucloxacillin compared to placebo
(MD -0.10; 95% CI -0.59, 0.39) (Analysis 1.17).
(c) Duration of remission and/or prevention of subsequent flares
There were no results given for this outcome.
(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated
Francis 2016 reported a change from baseline in the percentage of
participants with S. aureus on the skin at three months of -52.6%
(95% CI -74.1% to -31.0%) in the flucloxacillin group compared with
-20.0% (-45.4% to 5.4%) in the placebo group; the difference be-
tween the groups was not statistically significant (mean difference
-32.6%; 95% CI -65.9% to 0.7%) (Analysis 1.16).
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(e) Change in bacterial counts of S. aureus, i.e. an assessment of
quantity of S. aureus
In one study (Ewing 1998), bacterial counts returned to almost pre-
treatment levels by 14 days after completion of treatment.
2. Topical antiseptic/antibiotic - five studies
Five studies compared topical antiseptics/antibiotics versus place-
bo. Of these, one study (Lembo 2011) evaluated a topical antibiotic.
This was a cross-over study evaluating 1% erythromycin in Vaseline
in 38 children (19 evaluable) with uninfected eczema. The severi-
ty and duration were not stated. In this study, there was no use of
topical or systemic medications during the first week with the in-
tervention beginning from day eight onwards. The intervention was
1% erythromycin (Sigma-Aldrich S.r.l., Milano) in white Vaseline on
the whole skin surface twice daily from day 8 to day 21 and Vase-
line from day 22 to 35 versus Vaseline from day 8 to 21 on the whole
skin surface twice daily and erythromycin from day 22 to 35. Partic-
ipants did not use topical steroids in this study.
The remaining four studies compared various topical products
with antiseptic/antibacterial properties, and no attempt was made
to pool them. Berman 2018 was a parallel group RCT evaluating
hypochlorous acid compared with no treatment in 30 patients with
eczema and itch (infective status not specified). Participants were
included if they scored more than 2 on an itch severity scale. The
duration of the condition was not stated. In this study, participants
were randomised to the application of hypochlorous acid-contain-
ing solution twice daily or, as required, for 72 hours versus no treat-
ment. No information was provided on topical steroid use.
Hizawa 1998 was a right-and-le$ comparison evaluating povidone
iodine 10% in 15 children and adults with mild to moderate eczema
(without purulent skin infection). The duration of the condition was
not stated. Povidone iodine 10% versus an unspecified placebo was
applied twice daily for one week. No information was provided on
topical steroid use.
Masako 2005b was a right-and-le$ comparison evaluating 0.2% far-
nesol + 5% xylitol in 17 patients with mild to moderate eczema (in-
fective status not specified). The duration of the condition was not
stated. In this study, participants were randomised to receive either
FX cream (0.2% farnesol + 5% xylitol) or a placebo cream (identi-
cal in appearance) for seven days. The frequency of application was
not stated. No information was provided on topical steroid use.
Schempp 2003 was a right-and-le$ comparison evaluating hyper-
forin 1.5% cream in 21 children and adults (18 evaluable) with 'sub-
acute' eczema (infective status not specified) with a SCORAD of <
80. The duration of the condition was not stated. In this study, par-
ticipants were randomised to receive either hyperforin 1.5% cream
or a placebo (identical vehicle with added chromogenic substances
to colour the vehicle for the purpose of blinding). These were ap-
plied twice daily for four weeks. No participants used concomitant
topical steroids.
Short-term:
(1) Primary outcome measures
(a) Global degree of improvement in symptoms and/or signs as rated
by patient or medical practitioner
None of the studies evaluating a topical antibiotic reported glob-
al degree of improvement. Berman 2018 reported that both par-
ticipant global assessment (PGA) and IGA improved between base-
line and 72 hours, in favour of the hypochlorous acid-treated group;
however, results were only reported as P values (PGA 0.128, IGA
0.012). Hizawa 1998 reported that there was a statistically sig-
nificant improvement in the povidone iodine group for appear-
ance of skin lesions; however, no numbers were given and no be-
tween-group analysis was done.
(b) Improvement in Quality of Life questionnaires
There were no results given for this outcome in any of the included
studies.
(2) Secondary outcome measures
(a) Severe adverse events, i.e. severe enough to require withdrawal of
treatment, including severe skin irritation
Lembo 2011 reported that none of the participants had any adverse
reaction to the 1% erythromycin in Vaseline or placebo.
Berman 2018 reported no treatment-related discontinuations or
severe adverse events in either the hypochlorous acid or no treat-
ment-group. Schempp 2003 reported that three participants in the
le$-and-right comparison of hyperforin 1.5% cream withdrew from
treatment due to acute episodes of atopic dermatitis; whether this
was present on the actively-treated or placebo-treated side of the
body was not specified.
(b) Minor patient-reported adverse events. This included mild skin
irritation not su?icient to require cessation of treatment.
Schempp 2003 reported that one participant developed contact
eczema in the placebo group.
(c) Emergence of antibiotic-resistant micro-organisms
There were no results give for this outcome.
(3) Tertiary outcome measures
(a) Global changes in composite rating scales, using a published
named scale
For the first period of the cross-over study, Lembo 2011 reported a
reduction in mean SCORAD from 47.6 (SD 12.0) to 43.2 (11.3) for the
1% erythromycin group compared with a reduction from 45.4 (11.4)
to 43.9 (10.6) for the placebo group; this difference was reported to
be statistically significant.
Schempp 2003 reported a significant difference in the median re-
duction in modified SCORAD on the Hyperforin 1.5%-treated side
of 6.5 compared to 2.5 on the placebo-treated side.
(b) Changes in the individual signs of eczema as assessed by a
physician
Masako 2005b stated that scores of dryness and scaling were signif-
icantly improved in both the 0.2% farnesol + 5% xylitol cream and
placebo groups, but no data were provided.
(c) Duration of remission and/or prevention of subsequent flares
There were no results given for this outcome.
(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated
Schempp 2003 reported a reduction in colonisation with S. aureus
from 17/18 to 16/18 on the Hyperforin 1.5%-treated side compared
with no change (17/18 to 17/18) on the placebo-treated side.
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(e) Change in bacterial counts of S. aureus, i.e. an assessment of
quantity of S. aureus
Hizawa 1998 reported that there was a statistically significant im-
provement in S. aureus colony counts in the povidone iodine group;
however, no numbers were given and no between-group analysis
was done. Masako 2005b reported that, at end of treatment, there
was a significant difference in the number of S. aureus in favour of
0.2% farnesol + 5% xylitol cream compared with placebo.
Long-term:
There were no long-term data presented relevant to our outcomes.
3. Topical steroid plus antiseptic/antibiotic - 14 studies
There were 14 studies, with a total of 895 evaluable participants in
the relevant arms, comparing topical steroids plus antiseptics/an-
tibiotics versus topical steroids alone. Twelve of these studies com-
pared a topical steroid plus topical antibiotic against topical steroid
alone, and results for this comparison are summarised in Summary
of findings for the main comparison.
Canpolat 2012 was a parallel group RCT evaluating hydrocortisone
plus mupirocin compared with hydrocortisone alone in 53 infants
with mild to moderate eczema (infective status not specified). The
duration of the condition was not stated. In this study, participants
were randomised to hydrocortisone plus mupirocin (n = 27) or hy-
drocortisone (n = 26) applied twice daily (hydrocortisone in the
morning and evening and mupirocin at noon and night) by parents
to areas affected with atopic dermatitis at least two hours before
bathing for up to seven days.
Francis 2016 was a three-arm parallel group RCT evaluating flu-
cloxacillin and 2% fusidic acid in 113 children (101 evaluable) with
clinically infected eczema, in which all children received clobeta-
sone butyrate 0.05% cream or ointment for use on trunk/limbs and/
or hydrocortisone 1% cream for use on face (67 evaluable children
in fusidic acid and placebo groups included in this category). The
duration and severity were not stated. This study used the following
regimens: oral antibiotic (flucloxacillin four times per day for seven
days, 125 mg in 2.5 mL for children aged three months to two years,
250 mg in 5 mL for children aged > two years to < eight years) and
topical placebo (n = 36) versus topical antibiotic (2% fusidic acid
cream three times per day for seven days) and oral placebo (n = 37)
versus oral and topical placebo (n = 40). All treatment groups re-
ceived topical steroids (clobetasone butyrate 0.05% cream or oint-
ment for use on trunk/limbs and/or hydrocortisone 1% cream or
ointment for use on face, applied once daily for 14 days) and were
encouraged to use emollients that did not contain antimicrobial
agents.
Gong 2006 was a parallel group RCT evaluating hydrocortisone bu-
tyrate plus mupirocin compared with hydrocortisone butyrate plus
vehicle ointment in 327 participants (children and adults), of whom
119 had atopic eczema and are included in the review (infective sta-
tus not specified). The severity and duration of the condition were
not stated. In this study, participants were randomised to hydrocor-
tisone butyrate ointment and mupirocin ointment (n = 58) or hydro-
cortisone butyrate ointment and vehicle ointment (n = 61) applied
once daily (with two to three hours between products) for 28 days.
Hjorth 1985 was a right-and-le$ comparison evaluating 0.1% be-
tamethasone 17-valerate plus 2% microcrystalline fusidic acid
compared with 0.1% betamethasone 17-valerate alone in 81 pa-
tients (children and adults), of whom 60 had atopic eczema and
were included in the review (infective status not specified). The
severity and duration of the condition were not stated. Treatments
were applied twice daily for seven days.
Hung 2007 was a 2 x 2 factorial RCT comparing fluticasone versus
tacrolimus with or without fusidic acid in 60 children and adults
(54 evaluable) with moderate to severe uninfected eczema. The du-
ration of the condition was not stated. In this study, the following
treatments were compared: 0.05% fluticasone propionate cream
(Cutivate) (n = 15) versus 0.05% fluticasone propionate cream with
2% fusidic acid cream (Fucidin) (n = 15) versus 0.03% tacrolimus
ointment (Protopic) (n = 15) versus 0.03% tacrolimus ointment with
2% fusidic acid cream (n = 15) applied twice daily for eight weeks.
Fusidic acid cream was applied first followed by fluticasone or
tacrolimus 20 minutes later without occlusive dressings. Oral an-
tihistamine was given to all participants. Twenty-eight evaluable
participants in the fluticasone plus fusidic acid versus fluticasone
alone comparison were included in this category.
Lever 1988 was a cross-over study evaluating 0.05% clobetasol bu-
tyrate ointment plus either 2% mupirocin or placebo in 49 children
and adults (45 evaluable) with eczema (infective status not speci-
fied). The duration and severity of the condition were not stated.
In this study, 2% mupirocin ointment followed by placebo (poly-
ethylene glycol ointment) or vice versa were applied once daily
for two weeks. All participants received 0.05% clobetasol butyrate
ointment twice daily during the two-week pre-trial period and once
daily while using mupirocin/placebo.
Leyden 1977 was a parallel group RCT evaluating fluocinolone ace-
tonide plus 0.5% neomycin sulphate compared with fluocinolone
acetonide cream in 36 patients (mainly children) with 'rather se-
vere' eczema (infective status not specified). The duration of the
condition was not stated. In this study, participants were ran-
domised to fluocinolone acetonide plus 0.5% neomycin sulphate
(Neo-Synalar) cream (n = 15) versus fluocinolone acetonide (Sy-
nalar) cream (n = 21) applied twice daily for one week.
Nilsson 1992 was a parallel group RCT evaluating the betametha-
sone plus neomycin cream compared with clobetasol in 30 chil-
dren and adults (28 evaluable) with moderate to severe uninfected
eczema. The duration of the condition was not stated. In this study,
participants were randomised to betamethasone plus neomycin
cream applied to all affected areas except the face twice daily for
one week then once daily for one week (n = 15 evaluable) or clobe-
tasol cream applied twice daily on days 1, 2, 3, 4, 8, 9, 12 and 14 (n
= 13 evaluable).
Polano 1960 was a four-arm, four-period cross-over study evalu-
ating 0.5% prednisolone plus 0.5% neomycin versus 0.5% pred-
nisolone versus 1% hydrocortisone versus petrolatum base in 24
patients (14 evaluable) with uninfected eczema (the 0.5% pred-
nisolone plus 0.5% neomycin versus 0.5% prednisolone being eligi-
ble for the review). The severity of the condition was not stated. Du-
ration was described as “longstanding.” Treatments were applied
for one week, or until the ointment was used up. The frequency of
application was not stated.
Ramsay 1996 was a parallel group RCT in 186 patients (174 evalu-
able) with mild to moderate eczema (infective status not specified).
The duration of the condition was not stated. In the trial, partici-
pants were randomised to fusidic acid 2% plus 1% hydrocortisone
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cream (n = 91 evaluable) or 1% hydrocortisone cream (n = 83 evalu-
able) for two weeks. The frequency of application was not stated.
Schuttelaar 2005 was a parallel group RCT in 44 adults with mod-
erate to severe uninfected eczema (SCORAD 25 or more). The du-
ration of the condition was not stated. The study evaluated 0.1%
triamcinolone acetonide in oculentum simplex FNA (an ointment
base containing cetostearylalcohol, lanolin, vaseline and paraffin)
plus 3% tetracycline (n = 22) compared with 0.1% triamcinolone
acetonide in oculentum simplex FNA alone (n = 22). The treatments
were applied all over the body twice daily for two weeks.
Wachs 1976 was a parallel group RCT in 83 patients (79 evaluable)
with moderate to severe clinically infected eczema. The duration
of the condition was not stated. The trial randomised participants
to betamethasone valerate (Betnovate) plus gentamicin cream (n =
25 evaluable) versus betamethasone valerate cream (n = 27 evalu-
able) versus gentamicin cream (n = 27 evaluable). Treatments were
applied three times daily for 22 days. Only the 52 evaluable partic-
ipants in the betamethasone valerate plus gentamicin versus be-
tamethasone valerate cream comparison were eligible for the re-
view.
The remaining two studies evaluated antiseptics.
Korting 1994, was a parallel group RCT. The severity and duration
of the condition were not stated. The study evaluated prednicar-
bate 0.25% cream plus the antiseptic didecyldimethylammonium
chloride 0.25% compared with prednicarbate 0.25% cream, in 143
adults (117 evaluable) with eczema with heavy S. aureus colonisa-
tion. The prednicarbate 0.25% cream plus didecyldimethylammo-
nium chloride 0.25% or prednicarbate 0.25% cream were applied
twice daily for five days.
Tan 2009 was a parallel group RCT evaluating 0.0025% betametha-
sone valerate cream plus either 1% triclosan or vehicle alone in 60
patients (children and adults) with mild to moderate eczema (in-
fective status not specified). The median duration of the condition
of patients in the intervention group was 12 years and in the con-
trol group, 9 years. Participants were randomised to an emollient
containing 1% triclosan (n = 30) or the vehicle alone (n = 30) applied
twice daily to the whole body for 27 days. Following a washout pe-
riod of one week, all participants were provided with 0.0025% be-
tamethasone valerate cream for the first 27 days and asked to ap-
ply a thin layer of the corticosteroid cream over the eczematous ar-
eas for the first 27 days followed by either study cream or vehicle on
the whole body. Following this, participants who still had persistent
eczema were allowed to continue use of the steroid, if necessary.
Participants were provided with emulsifying ointment as cleansers
and instructed not to use any systemics or topical antibiotics, an-
tibacterial soap or antibacterial shampoo.
The different studies used a number of different corticosteroid po-
tencies and the majority added an antibiotic to a corticosteroid
and compared it to the same corticosteroid. However, Nilsson 1992
evaluated a potent steroid (betamethasone) combined with an an-
tibiotic and compared it against a super-potent steroid (clobeta-
sol). Only two studies (Korting 1994; Tan 2009) evaluated an anti-
septic; we did not pool these with studies of antibiotics. Two stud-
ies (Polano 1960; Hjorth 1985) gave no data for the outcomes of in-
terest.
Short-term:
(1) Primary outcome measures
(a) Global degree of improvement in symptoms and/or signs as rated
by patient or medical practitioner
Five studies of antibiotic/steroid combination compared to steroid
alone (Wachs 1976; Leyden 1977; Nilsson 1992; Gong 2006; Canpo-
lat 2012) reported global degree of improvement, but results from
only three studies could be pooled. The other seven studies did not
report global degree of improvement. Three studies (Wachs 1976;
Gong 2006; Canpolat 2012) reported non-significantly greater im-
provements in global outcomes at the end of treatment for steroid
plus antibiotic versus steroid alone. When these three studies were
pooled (one in clinically infected eczema and two unspecified), the
combination treatment showed a borderline improvement com-
pared to steroid alone (RR 1.10; 95% CI 1.00 to 1.21, I2 = 0%) (Analy-
sis 2.1). Leyden 1977 reported a good or excellent response among
90% of those in the combination group compared with 70% in the
steroid-only group, but denominators were not reported and corre-
spondence with the author confirmed that these figures were like-
ly to have been rounded to the nearest 10%, making it impossible
to extract the raw values for pooling. Nilsson 1992 found a signifi-
cant improvement in global outcome in favour of steroid only using
a subjective interval scale self-evaluation (MD 1.20; 95% CI 0.25 to
2.15) (Analysis 2.2).
Korting 1994 reported a non-significantly greater improvement in
global outcomes at the end of treatment for steroid plus antiseptic
versus steroid alone; no numerical results were reported. Tan 2009
did not report global degree of improvement.
(b) Improvement in Quality of Life questionnaires
Francis 2016 reported changes in quality of life using the IDQoL
questionnaire for children aged three months to < four years and
the CDLQI questionnaire for children aged four years to < eight
years. At two weeks, there was no significant difference between
the groups in the change from baseline on IDQoL (MD 0.18; 95% CI
-0.04 to 0.40) (Analysis 2.3) but significantly less improvement of
symptoms in the combined treatment group for CDLQI (MD 0.70;
95% CI 0.12 to 1.28) (Analysis 2.4). None of the other studies report-
ed any data for this outcome.
(2) Secondary outcome measures
(a) Severe adverse events, i.e. severe enough to require withdrawal of
treatment, including severe skin irritation
Francis 2016 reported five withdrawals in the fusidic acid group
(four condition worsened, one intolerant to medication) and one
in the placebo group (condition worsened). There were no adverse
events requiring withdrawal of treatment in either of the two eli-
gible treatment combinations in Hung 2007. Ramsay 1996 report-
ed one adverse event requiring withdrawal from treatment in the
steroid plus antibiotic group ("flare of dermatitis" - no further infor-
mation provided) and three in the steroid-alone group (two "flare
of dermatitis", one burning and soreness). Schuttelaar 2005 report-
ed one adverse event requiring withdrawal from treatment in each
group (both folliculitis). Pooled results from these studies showed
no clear difference between groups (RR 1.24; 95% CI 0.21 to 7.25, I2 =
42%) (Analysis 2.5). In addition, Lever 1988 reported that one partic-
ipant in the cross-over trial reacted adversely to both 2% mupirocin
and placebo and stopped treatment.
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Tan 2009 reported no withdrawals due to adverse events in either
the 1% triclosan or placebo group.
(b) Minor patient-reported adverse events. This included mild skin
irritation not su?icient to require cessation of treatment.
Ramsay 1996 reported two adverse events not requiring cessation
of treatment in the steroid plus antibiotic group (one itching, one
flare of dermatitis) and three in the steroid-alone group (one sting-
ing and irritation, one folliculitis, one flare of dermatitis). Schutte-
laar 2005 reported three minor adverse events in the steroid plus
antibiotic group and 13 in the steroid alone group (all folliculitis).
Pooled results from these two studies showed significantly fewer
minor adverse events not requiring withdrawal from treatment in
the combination treatment group compared to the steroid-alone
control, (RR 0.30; 95% CI 0.12 to 0.78, I2 = 0%) (Analysis 2.6). In
addition, Francis 2016 reported individual minor patient-reported
adverse events; there were no significant differences between the
groups in any of the adverse events reported (nausea 1/29 versus
3/35, vomiting 2/29 versus 6/35, diarrhoea 5/29 versus 5/35, stom-
ach pain 3/29 versus 2/35, joint pains 2/29 versus 0/35, new rash
5/29 versus 8/35). This study could not have been included in the
pooled result as some participants experienced multiple different
events. Lever 1988 reported that, in addition to the one participant
that withdrew, one other participant reported stinging and an ex-
acerbation of symptoms with both 2% mupirocin and placebo.
Tan 2009 reported a total of 27 adverse events among 15 partici-
pants (not split by group), of which four (three stinging pain after
application in the 1% triclosan group, one pruritus after application
in the placebo group) were considered treatment-related.
(c) Emergence of antibiotic-resistant micro-organisms
See long-term outcomes.
(3) Tertiary outcome measures
(a) Global changes in composite rating scales, using a published
named scale
Francis 2016 reported changes in both the POEM and EASI scores. At
two weeks, there was no significant difference between the groups
in the change from baseline on POEM (MD 1.49; 95% CI -1.55 to 4.53)
(Analysis 2.8). The reduction in EASI in the fusidic acid group was
slightly less than that in the placebo group (MD 0.42; 95% CI 0.09 to
0.75) (Analysis 2.7). Gong 2006 reported that both hydrocortisone
and mupirocin and hydrocortisone alone showed significant with-
in-group improvement in EASI scores, however, at the end of treat-
ment there was no significant difference. Hung 2007 reported a re-
duction in mean SCORAD from 50.1 (SD 12.8) to 24.7 (16.5) in the flu-
ticasone plus fusidic acid group compared with 54.8 (16.5) to 25.4
(15.9) with fluticasone alone (data extracted from graph using Web-
PlotDigitizer, https://automeris.io/WebPlotDigitizer/). Schuttelaar
2005 reported no significant difference in objective SCORAD at the
end of treatment between 3% tetracycline plus 0.1% triamcinolone
and 0.1% triamcinolone. Pooling results of these four studies for
the mean composite rating (using EASI , SCORAD or objective SCO-
RAD) at the end of treatment using the standardised mean differ-
ence showed no difference between the groups (SMD -0.00; 95% CI
-0.33 to 0.33, I2 = 38%) (Analysis 2.9). Canpolat 2012 reported no sig-
nificant difference in SCORAD at the end of treatment but a signifi-
cant difference in EASI for hydrocortisone and mupirocin compared
with hydrocortisone alone; however standard deviations were not
reported precluding inclusion in the pooled analysis.
Tan 2009 reported a greater reduction from baseline in mean SCO-
RAD at day 14 for the 1% triclosan group compared with the place-
bo group (-8.86 versus -4.75; MD -4.11; 95% CI -8.58 to 0.32), but this
became non-significant at later time points.
(b) Changes in the individual signs of eczema as assessed by a
physician
Wachs 1976 reported a reduction in mean inflammation score (out
of 10) from 5.8 to 0.7 (standard deviations not reported) in the be-
tamethasone valerate plus gentamicin group compared with 5.9
to 1.4 in the betamethasone valerate-only group; other individual
signs were evaluated but not reported.
(c) Duration of remission and/or prevention of subsequent flares
There were no results given for this outcome.
(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated
Pooled analysis of seven studies (Wachs 1976; Leyden 1977; Lever
1988; Nilsson 1992; Schuttelaar 2005; Hung 2007; Francis 2016)
showed a 52% reduction in the isolation rate of S. aureus in the com-
bination group compared to steroid-alone at the end of treatment
(RR 0.48; 95% CI 0.27, 0.85, I2 = 47%) (Analysis 2.10). Francis 2016
reported a change from baseline at two weeks (end of treatment) of
-31.2% (95% CI -54.8% to -9.2%) in the fusidic acid group compared
with -15.9% (-39.1% to 7.4%) in the placebo group; the difference
between the groups was not statistically significant (mean differ-
ence -15.3%; 95% CI -48.4% to 17.8%) (Analysis 2.11). Nilsson 1992
reported that isolation rates of S. aureus reduced from 14/15 in the
combination group and 12/13 in the steroid group to zero in both
groups. Gong 2006 reported that the rate of S. aureus in the entire
trial cohort decreased from 59.7% at baseline to 14.8% at day seven
of treatment; however, results were not split by treatment group,
other than a statement that there was no significant difference be-
tween intervention and control groups, or reported for later time
points.
Korting 1994 reported that the number of participants with S. au-
reus at an initially lesional site reduced from 47 to 5 in the pred-
nicarbate 0.25% cream plus didecyldimethylammonium chloride
0.25% group and from 54 to 7 in the steroid-only group; denomina-
tors were not reported.
(e) Change in bacterial counts of S. aureus, i.e. an assessment of
quantity of S. aureus
In one study of 30 participants (Nilsson 1992), both steroid plus an-
tibiotic and steroid alone completely cleared S. aureus (presented
as log counts). Hung 2007 reported a greater decrease in colony
counts of S. aureus for participants treated with fusidic acid, but
results for the individual treatment combinations were not report-
ed. Leyden 1977 reported that the geometric mean counts/cm2 de-
creased from 420,000 to 350 for steroid plus antibiotic and from
200,000 to 65,000 for steroid alone.
Korting 1994 reported that the mean colony forming units/cm2 de-
creased from 50 (SD 130) to 34 (SD 170) in the prednicarbate 0.25%
cream plus didecyldimethylammonium chloride 0.25% group and
from 89 (200) to 7.1 (22) in the steroid-only group.
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Long-term:
(1) Primary outcome measures
(a) Global degree of improvement in symptoms and/or signs as rated
by patient or medical practitioner
There were no results given for this outcome in any of the 14 stud-
ies.
(b) Improvement in Quality of Life questionnaires
One study (Francis 2016) continued to follow up participants to
three months. There was no significant difference between the
groups in the change from baseline on either IDQoL (MD -0.07; 95%
CI -0.31 to 0.17) (Analysis 2.12) or CDLQI (MD -0.13; 95% CI -0.96 to
0.70) (Analysis 2.13). None of the other studies reported any data
for this outcome.
(2) Secondary outcome measures
(a) Severe adverse events, i.e. severe enough to require withdrawal of
treatment, including severe skin irritation
There were no results given for this outcome.
(b) Minor patient-reported adverse events. This included mild skin
irritation not su?icient to require cessation of treatment.
There were no results given for this outcome.
(c) Emergence of antibiotic-resistant micro-organisms
Francis 2016 reported resistance of S. aureus to flucloxacillin, ery-
thromycin and fusidic acid at baseline, week two (end of treatment)
and three months. Among participants treated with fusidic acid
with S. aureus identified from skin swabs, 8/24, 8/11 and 2/8 strains
were resistant to fusidic acid at baseline, two weeks and three
months, respectively, compared with 6/24, 5/16 and 2/10 in the
placebo group. Hung 2007 reported that, of five participants with
persistent S. aureus colonisation, two (40%) developed fusidic-acid
resistant strains after eight weeks of fusidic acid treatment. Re-
sults were not broken down into the fluticasone plus fusidic acid
and tacrolimus plus fusidic acid groups and no comparative fig-
ures were reported for the fluticasone alone or tacrolimus alone
groups. Lever 1988 included 45 participants in a cross-over trial of
mupirocin versus placebo. S. aureus resistant to mupirocin was iso-
lated in one participant four weeks after stopping mupirocin. Lever
1988 reported no cases of MRSA.
(3) Tertiary outcome measures
(a) Global changes in composite rating scales, using a published
named scale
Francis 2016 reported longer term changes in the POEM score.
At three months, there was no significant difference between the
groups in the change from baseline (MD -1.13; 95% CI -4.32 to 2.06)
(Analysis 2.14).
(b) Changes in the individual signs of eczema as assessed by a
physician
There were no results given for this outcome.
(c) Duration of remission and/or prevention of subsequent flares
There were no results given for this outcome.
(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated
Francis 2016 reported a change from baseline in the percentage of
participants with S. aureus on the skin at three months of -28.6%
(95% CI -55.3% to -1.9%) in the flucloxacillin group compared with
-20.0% (-45.4% to 5.4%) in the placebo group; the difference be-
tween the groups was not statistically significant (mean difference
-8.6%; 95% CI -45.4% to 28.2%) (Analysis 2.15).
(e) Change in bacterial counts of S. aureus, i.e. an assessment of
quantity of S. aureus
There were no results given for this outcome.
4. Topical steroid plus antibiotic and antifungal - one study
One study (Fattah 1976) compared 0.1% halcinonide with
neomycin plus nystatin versus 1% hydrocortisone cream in a right-
and-le$ comparison of eight people with uninfected steroid-re-
sponsive dermatoses, of whom four had atopic eczema and were
included in the review. The severity of the eczema was not stated.
The mean duration of the condition for all participants in the tri-
al was reported to be 14 weeks, but no breakdown of figures was
given for those with atopic eczema. In the trial, participants were
randomised to 0.1% halcinonide cream with 0.25% neomycin and
100000u/g nystatin versus 1% hydrocortisone both applied three
times daily for not more than three weeks.
Short-term:
(1) Primary outcome measures
(a) Global degree of improvement in symptoms and/or signs as rated
by patient or medical practitioner
The study showed no significant difference in global outcome; out
of a total of four participants, three achieved a good or excellent
response with the combination treatment and two with hydrocor-
tisone alone.
(b) Improvement in Quality of Life questionnaires
There were no results given for this outcome.
No results were reported for any of the other outcomes of interest.
Long-term:
There were no long-term data presented relevant to our outcomes.
5. Topical calcineurin inhibitor plus antibiotic - one study
One study (Hung 2007) evaluated a topical calcineurin inhibitor
plus antibiotic. This was a 2 x 2 factorial RCT comparing fluti-
casone versus tacrolimus with or without fusidic acid in 60 chil-
dren and adults (54 evaluable) with moderate to severe uninfected
eczema. The duration of the condition was not stated. In this study,
the following treatments were compared: 0.05% fluticasone propi-
onate cream (Cutivate) (n = 15) versus 0.05% fluticasone propionate
cream with 2% fusidic acid cream (Fucidin) (n = 15) versus 0.03%
tacrolimus ointment (Protopic) (n = 15) versus 0.03% tacrolimus
ointment with 2% fusidic acid cream (n = 15) applied twice daily
for eight weeks. Fusidic acid cream was applied first followed by
fluticasone or tacrolimus 20 minutes later without occlusive dress-
ings. Oral antihistamine was given to all participants. Twenty-six
evaluable participants in the tacrolimus plus fusidic acid versus
tacrolimus-alone comparison were included in this category.
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Short-term:
(1) Primary outcome measures
(a) Global degree of improvement in symptoms and/or signs as rated
by patient or medical practitioner
There were no results given for this outcome.
(b) Improvement in Quality of Life questionnaires
There were no results given for this outcome.
(2) Secondary outcome measures
(a) Severe adverse events, i.e. severe enough to require withdrawal of
treatment, including severe skin irritation
Hung 2007 reported that two participants receiving tacrolimus plus
fusidic acid withdrew because of intolerance to a burning sensation
(RR 5.00; 95% CI 0.26 to 96.13) (Analysis 3.1).
(b) Minor patient-reported adverse events. This included mild skin
irritation not su?icient to require cessation of treatment.
There were no results given for this outcome.
(c) Emergence of antibiotic-resistant micro-organisms
Hung 2007 reported that, of five participants with persistent S.
aureus colonisation, two (40%) developed fusidic acid-resistant
strains after eight weeks of fusidic acid treatment. Results were not
broken down into the fluticasone plus fusidic acid and tacrolimus
plus fusidic acid groups and no comparative figures were reported
for the fluticasone-alone or tacrolimus-alone groups.
(3) Tertiary outcome measures
(a) Global changes in composite rating scales, using a published
named scale
Hung 2007 reported a reduction in mean SCORAD from 60.0 (SD
15.8) to 31.5 (SD 17.6) in the tacrolimus plus fusidic acid group
compared with 56.8 (SD 14.0) to 32.9 (SD 19.4) with tacrolimus
alone (data extracted from graph using WebPlotDigitizer, https://
automeris.io/WebPlotDigitizer/). The difference in mean SCORAD
at the end of treatment was not significant (MD -1.4; 95% CI -15.6 to
12.8) (Analysis 3.2).
(b) Changes in the individual signs of eczema as assessed by a
physician
There were no results given for this outcome.
(c) Duration of remission and/or prevention of subsequent flares
There were no results given for this outcome.
(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated
Hung 2007 reported that the number of participants with S. au-
reus isolated reduced from 12/13 to 2/13 in the tacrolimus plus fu-
sidic acid group compared with a reduction from 12/13 to 7/13 with
tacrolimus alone. The difference at the end of treatment was not
significant (RR 0.29; 95% CI 0.07 to 1.13) (Analysis 3.3).
(e) Change in bacterial counts of S. aureus, i.e. an assessment of
quantity of S. aureus
Hung 2007 reported a greater decrease in colony counts of S. aureus
for participants treated with fusidic acid, but results for the individ-
ual treatment combinations were not reported.
Long-term:
There were no long-term data presented relevant to our outcomes.
6. Antibacterial soap - one study
One very poor quality study (Breneman 2000) compared daily
washing with a bar of 1.5% triclocarban soap versus placebo in
50 adults with moderately severe eczema (infective status and the
number in each group were not specified) and provided few data to
substantiate claims of efficacy. The duration of the condition was
not stated. During the trial, participants were required to wash the
whole body at least daily for 42 days. Topical steroids were used as
needed.
Short-term:
(1) Primary outcome measures
(a) Global degree of improvement in symptoms and/or signs as rated
by patient or medical practitioner
Global degree of improvement was presented as a mean score on
a scale from -5 (severe worsening) to 5 (total clearing) with 0 rep-
resenting no change from baseline. At the end of treatment, the
mean global improvement score was 2.7 in the 1.5% triclocarban
soap group compared with 2.2 in the placebo group (data extracted
from graph using WebPlotDigitizer, https://automeris.io/WebPlot-
Digitizer/); standard deviations or CIs were not reported.
(b) Improvement in Quality of Life questionnaires
There were no results given for this outcome.
(2) Secondary outcome measures
(a) Severe adverse events, i.e. severe enough to require withdrawal of
treatment, including severe skin irritation
One participant from the 1.5% triclocarban soap group withdrew
because of worsening dermatitis.
(b) Minor patient-reported adverse events. This included mild skin
irritation not su?icient to require cessation of treatment.
Other than the one withdrawal, there were no study-related ad-
verse events.
(c) Emergence of antibiotic-resistant micro-organisms
There were no results given for this outcome.
(3) Tertiary outcome measures
(a) Global changes in composite rating scales, using a published
named scale
There were no results given for this outcome.
(b) Changes in the individual signs of eczema as assessed by a
physician
Significant improvements were reported in individual signs, but no
numerical values were given.
(c) Duration of remission and/or prevention of subsequent flares
There were no results given for this outcome.
(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated
There were no results given for this outcome.
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(e) Change in bacterial counts of S. aureus, i.e. an assessment of
quantity of S. aureus
Among the 50% of participants with S. aureus at baseline, the
mean log10 colony forming units reduced from 2.0 to 0.5 in the
1.5% triclocarban soap group and from 2.6 to 1.1 in the placebo
group (data extracted from graph using WebPlotDigitizer, https://
automeris.io/WebPlotDigitizer/).
Long-term:
There were no long-term data presented relevant to our outcomes.
7. Antibacterial bath additive - seven studies
Two studies compared a mineral oil-based bath emollient incor-
porating triclosan and benzalkonium chloride (Oilatum Plus) ver-
sus the same emollient without the triclosan and benzalkonium
chloride (Oilatum) (Harper 1995; Holland 1995). Harper 1995 was
a cross-over study of 30 children (26 evaluable) with eczema with
recurrent infection and/or frequent exacerbations. The severity of
the condition was not stated. The duration of the condition was not
stated but, in 19 participants, onset of eczema occurred before one
year. In this study, participants were randomised to Oilatum Plus or
Oilatum (15 mL in an 8-inch bath of water, soaking for 10 to 15 min-
utes daily for four weeks). Topical steroids were used as needed.
Holland 1995 was a parallel group RCT of 15 patients (children and
adults) with moderate to severe eczema with S. aureus isolated
from the skin. The duration of the condition was not stated. Partici-
pants were randomised to either Oilatum Plus (containing triclosan
and benzalkonium chloride) (n = 7) or Oilatum (n = 8) (15 mL in eight
inches of water from 10 to 15 minutes, soaking daily for four weeks).
Information was not provided on topical steroid use.
Results for the first period of the cross-over study (Harper 1995)
were not given which precluded the pooling of results.
Five studies compared sodium hypochlorite (bleach) baths versus
placebo (water) (Wong 2013; Gonzalez 2016; Hon 2016; Shi 2016)
or bath emollient (Leins 2013), and results for this comparison are
summarised in Summary of findings 3.
Gonzalez 2016 was a parallel group RCT of 21 children (18 evalu-
able) with moderate to severe uninfected eczema. Duration of the
condition was not stated. Participants were randomised to receiv-
ing either bleach baths (bottle of bleach diluted with bath water 2
times per week to achieve a 0.005% sodium hypochlorite concen-
tration) plus topical corticosteroid (n = 10) or placebo (bottle of wa-
ter) plus topical corticosteroid (n = 11) for four weeks.
Hon 2016 was a cross-over study of 40 children with moderate to
severe eczema (as assessed by SCORAD) with previous S. aureus
colonisation. The duration of the condition was not stated. Partic-
ipants were randomised to bleach bath (0.005% sodium hypochlo-
rite) or placebo (water). Participants were instructed to bathe for 10
minutes two to three times per week. There was a four-week treat-
ment period, followed by a four-week washout then a four-week
cross-over treatment period. Topical steroids were used as rescue
medication only.
Leins 2013 was a parallel group RCT of 19 children with moder-
ate to severe eczema with SCORAD > 25 (infective status not spec-
ified). The duration of the condition was not stated. In this study,
patients were randomised to bleach bath (sodium hypochlorite
0.005%) three times per week or bath emollient (bath oil containing
liquid paraffin 95% volume per volume). All participants received
a course of oral antibiotics. Information on topical steroid use was
not provided.
Shi 2016 was a right-and-le$ comparison of 10 patients (children
and adults) with eczema (infective status not specified). The sever-
ity and duration of the condition were not specified. Participants
were randomised to a bleach bath (sodium hypochlorite 0.005%) or
placebo (tap water). Each arm was immersed for 10 minutes.
Wong 2013 was a parallel group RCT of 42 children and adults (36
evaluable) with moderate to severe uninfected eczema. The dura-
tion of the condition was not stated. Participants were randomised
to bleach baths (100 mL of sodium hypochlorite (bleach) in 100 L
(or roughly half a tub) of water, sodium hypochlorite 0.005%) (n =
21) or placebo (100 mL of distilled water in 100 L of water) (n = 21).
For children under twelve years old, 50 mL bleach was added to
a quarter tub of water. Participants were instructed to soak from
the neck down in the diluted baths for 10 minutes twice a week for
two months, rinsing oL with normal tap water after each bath. They
were maintained on a stable regimen of topical anti-inflammatory
and emollient therapy and used aqueous cream as a soap substi-
tute.
Short-term:
(1) Primary outcome measures
(a) Global degree of improvement in symptoms and/or signs as rated
by patient or medical practitioner
One study of Oilatum Plus (Harper 1995) suggested, in the text, that
there was no statistically significant difference between the treat-
ment groups. The results given are difficult to interpret since base-
line data were absent and no firm numbers were given for the indi-
vidual participant groups. The other study did not report any data
for this outcome (Holland 1995).
For bleach baths, two studies reported improvements in both
groups but with no significant difference between the groups. In
Wong 2013, seven of 18 participants reported being "better" or
"much better" in the bleach bath group at one month compared
with nine of 18 in the placebo group (RR 0.78; 95% CI 0.37 to 1.63)
(Analysis 4.1). Gonzalez 2016 reported results as the mean IGA score
at four weeks (data extracted from graph using WebPlotDigitizer,
https://automeris.io/WebPlotDigitizer/), with a mean of 0.54 in the
bleach bath group compared with 1.08 in the placebo group (MD
-0.54; 95% CI -1.79 to 0.71) (Analysis 4.2). The other two studies did
not report any data for this outcome.
(b) Improvement in Quality of Life questionnaires
No results on quality of life were reported for the studies of Oila-
tum Plus. Hon 2016 reported a reduction from baseline (improve-
ment) in the CDLQI of 0.53 following the bleach bath period com-
pared with 1.43 following the placebo period (MD 0.90; 95% CI -1.32
to 3.12) (Analysis 4.3). The other three studies of bleach baths did
not report any data for this outcome.
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(2) Secondary outcome measures
(a) Severe adverse events, i.e. severe enough to require withdrawal of
treatment, including severe skin irritation
Harper 1995 reported that one participant withdrew from the study
due to severe pruritus while receiving Oilatum Plus and one partic-
ipant withdrew due to a deterioration in eczema severity while re-
ceiving Oilatum.
Among the bleach bath studies, Leins 2013 reported no adverse
events. Wong 2013 reported that one participant withdrew from the
placebo group due to worsening itch; there were no withdrawals
due to adverse events in the bleach bath group (RR 0.33; 95% CI 0.01
to 7.74) (Analysis 4.4). Hon 2016 reported that one participant with-
drew from treatment during the bleach bath period due to itch and
one participant withdrew from treatment during the placebo peri-
od due to dryness; however, results were not presented for the first
period of the cross-over, so these could not be included in pooled
analysis. Shi 2016 reported no adverse events severe enough to re-
quire withdrawal of treatment in the le$-and-right comparison.
(b) Minor patient-reported adverse events. This included mild skin
irritation not su?icient to require cessation of treatment.
Harper 1995 reported that three participants experienced adverse
events (all pruritus) while receiving Oilatum Plus (it was unclear
whether this included the one participant that withdrew due to pru-
ritus) and five participants experienced adverse events (four pruri-
tus, one unspecified) while receiving Oilatum (including one partic-
ipant that experienced pruritus with both preparations).
Among the bleach bath studies, Leins 2013 reported no adverse
events. Wong 2013 reported that five participants in each group ex-
perienced burning/stinging or dry skin (RR 1.00; 95% CI 0.35 to 2.87)
(Analysis 4.5). Hon 2016 reported that seven participants experi-
enced one or more minor adverse events during the bleach bath
period (two stinging, three itch, two dry skin, one erythema, one
urticaria, one oozing) and 12 participants experienced one or more
minor adverse events during the placebo period (four stinging, five
itch, one erythema, one urticaria, one dizziness), but these were not
reported by period of the cross-over. Shi 2016 reported no adverse
events.
(c) Emergence of antibiotic-resistant micro-organisms
Hon 2016 reported no significant difference in antibiotic resistance
patterns between the bleach bath and placebo periods; numerical
results were not presented.
(3) Tertiary outcome measures
(a) Global changes in composite rating scales, using a published
named scale
Both studies of Oilatum Plus used non-standard rating scales. For
the bleach bath studies, Wong 2013 reported a significant with-
in-group reduction from baseline in mean EASI score at one month
in the bleach bath group but no significant difference between
the groups. On correspondence, the numerical values (presented
graphically in the paper) were confirmed as a reduction from 29.5
(SD 10.3) to 20.2 (SD 11.8) in the bleach bath group and from 34.3
(SD 14.3) to 25.4 (SD 13.1) in the placebo group. Gonzalez 2016 re-
ported that both EASI and local EASI improved significantly in both
groups but there was no difference between the groups, with a
mean of 1.38 in the bleach bath group at one month compared with
2.34 in the placebo group (data extracted from graph using Web-
PlotDigitizer, https://automeris.io/WebPlotDigitizer/). Pooling the
results from these two studies confirmed a non-significantly lower
EASI score at one month in the bleach bath group compared with
the placebo group (MD -2.48; 95% CI -7.36 to 2.40) (Analysis 4.6).
Hon 2016 reported a mean change from baseline in objective SCO-
RAD of -0.50 (SD 10.63) during the bleach bath period compared
with -3.95 (SD 10.54) during the placebo period; the difference be-
tween the groups was not statistically significant (MD 3.45; 95% CI
-1.66 to 8.56) (Analysis 4.7).
(b) Changes in the individual signs of eczema as assessed by a
physician
Wong 2013 reported that "scores for erythema, papulation, licheni-
fication and excoriation showed a significant improvement" but
numerical results were not presented. Shi 2016 reported "no in-
creased erythema or signs of irritation".
(c) Duration of remission and/or prevention of subsequent flares
There were no results given for this outcome.
(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated
Hon 2016 reported a change in isolation rate of S. aureus from 36/40
at baseline to 27/40 during the bleach bath period and 31/40 during
the placebo period. This difference was not statistically significant;
a treatment effect from a paired analysis was not reported.
(e) Change in bacterial counts of S. aureus, i.e. an assessment of
quantity of S. aureus
Holland 1995 reported a significant within-group reduction in me-
dian log10 colony forming units/cm2 from 4.3 (IQR (interquartile
range) 4.2 to 6.8) at baseline to 3.8 (IQR 0.8 to 5.1) at the end of treat-
ment for the Oilatum Plus group and no significant change (from
4.7 (IQR 2.8 to 5.5) to 4.3 (IQR 4.0 to 5.6)) in the Oilatum group; there
was no statistically significant difference between the groups.
For bleach baths, Wong 2013 reported a change in mean colony
forming units/cm2 from 16.8 (SD 15.7) at baseline to 9.7 (SD 12.4)
at one month in the bleach bath group compared with a change
from 7.5 (SD 13.6) to 10.4 (SD 13.6) in the placebo group (MD at
one month -0.70; 95% CI -9.20 to 7.80) (Analysis 4.8). Hon 2016 al-
so reported no significant difference in colony counts, but numeri-
cal results were not presented. Gonzalez 2016 reported that S. au-
reus counts reduced in both groups in both lesional and non-lesion-
al skin; however, results were reported by sample and not by par-
ticipant.
Long-term:
(1) Primary outcome measures
(a) Global degree of improvement in symptoms and/or signs as rated
by patient or medical practitioner
In Wong 2013, 11 of 18 participants reported being "better" or
"much better" in the bleach bath group at two months compared
with nine of 18 in the placebo group (RR 0.78; 95% CI 0.37 to 1.63)
(Analysis 4.9). None of the other studies reported any long-term re-
sults.
(b) Improvement in Quality of Life questionnaires
There were no results given for this outcome in any of the seven
studies.
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(2) Secondary outcome measures
(a) Severe adverse events, i.e. severe enough to require withdrawal of
treatment, including severe skin irritation
Leins 2013 reported no adverse events at 12 weeks.
(b) Minor patient-reported adverse events. This included mild skin
irritation not su?icient to require cessation of treatment.
Leins 2013 reported no adverse events at 12 weeks.
(c) Emergence of antibiotic-resistant micro-organisms
There were no results given for this outcome.
(3) Tertiary outcome measures
(a) Global changes in composite rating scales, using a published
named scale
Leins 2013 reported a significant difference in mean SCORAD at 12
weeks between the bleach bath and emollient groups; however, af-
ter adjustment for baseline imbalance, the difference was no longer
significant. Wong 2013 reported a significant difference in mean
EASI score at two months between the bleach bath and placebo
groups. Numerical results were confirmed on correspondence with
the authors (MD at two months: -12.70; 95% CI -20.06 to -5.34). Pool-
ing results of these two studies resulted in a significant reduction
in severity in the bleach bath compared with the placebo/emollient
group (SMD -1.11; 95% CI -1.68 to -0.53) (Analysis 4.10).
(b) Changes in the individual signs of eczema as assessed by a
physician
There were no results given for this outcome.
(c) Duration of remission and/or prevention of subsequent flares
There were no results given for this outcome.
(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated
Leins 2013 reported that bleach baths 'did not eradicate S. aureus';
no further results were reported.
(e) Change in bacterial counts of S. aureus, i.e. an assessment of
quantity of S. aureus
Wong 2013 reported a change in mean colony forming units/cm2
from 16.8 (SD 15.7) at baseline to 7.8 (SD 11.6) at two months in the
bleach bath group compared with a change from 7.5 (13.6) to 6.2
(10.7) in the placebo group (MD at two months 1.60; 95% CI -5.69 to
8.89) (Analysis 4.11).
8. Antibacterial bath additive plus antibiotic - one study
One study (Huang 2009), a parallel group RCT, compared bleach
and mupirocin versus water and placebo ointment in 31 children
(25 evaluable) with moderate to severe infected eczema, as deter-
mined by IGA. The duration of the condition was not stated. Par-
ticipants were randomised to bleach and mupirocin (n = 15) or wa-
ter and placebo ointment (n = 16). A half cup of 6% bleach (final
concentration 0.005%) or water was added to a full bathtub (40 gal-
lons) of water. The amount of administered bleach solution/water
was adjusted by the family on the basis of the bath tub size and es-
timated height of bath tub water. Participants were instructed to
bathe in the dilute bleach bath or placebo for five to ten minutes
twice weekly. Participants and their household members were in-
structed to apply mupirocin ointment (Centany (OrthoNeutrogena,
Skillman, NJ)) (treatment group) or petrolatum (control group) in-
tranasally twice daily for five consecutive days of each month for
three months. Topical steroids were used as needed.
Short-term:
(1) Primary outcome measures
(a) Global degree of improvement in symptoms and/or signs as rated
by patient or medical practitioner
The study reported significantly lower IGA scores in the treatment
group compared with the placebo at one month (P = 0.024) but nu-
merical results were not reported.
(b) Improvement in Quality of Life questionnaires
There were no results given for this outcome.
(2) Secondary outcome measures
(a) Severe adverse events, i.e. severe enough to require withdrawal of
treatment, including severe skin irritation
No participants withdrew from treatment due to adverse events.
(b) Minor patient-reported adverse events. This included mild skin
irritation not su?icient to require cessation of treatment.
One participant in the treatment group experienced itching and ir-
ritation of the skin.
(c) Emergence of antibiotic-resistant micro-organisms
At one month, one participant (of 11) in the treatment group had
developed MRSA compared with none (of 13) in the placebo group
(RR 3.50; 95% CI 0.16, 78.19) (Analysis 5.1).
(3) Tertiary outcome measures
(a) Global changes in composite rating scales, using a published
named scale
Huang 2009 reported a significantly greater reduction in mean EASI
score at one month in the treatment group compared with the
placebo group (MD -7.90; 95% CI -14.22, -1.58) (Analysis 5.2).
(b) Changes in the individual signs of eczema as assessed by a
physician
There were no results given for this outcome.
(c) Duration of remission and/or prevention of subsequent flares
There were no results given for this outcome.
(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated
At one month, 55% (6/11) in the treatment group had S. aureus iso-
lated compared with 77% (10/13) in the placebo group (RR 0.71;
95% CI 0.38 to 1.31) (Analysis 5.3).
(e) Change in bacterial counts of S. aureus, i.e. an assessment of
quantity of S. aureus
There were no results given for this outcome.
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Long-term:
(1) Primary outcome measures
(a) Global degree of improvement in symptoms and/or signs as rated
by patient or medical practitioner
At three months, 67% (6/9) of participants in the treatment group
showed reductions in IGA scores compared with 15% (2/13) in the
placebo group (RR 4.33; 95% CI 1.12 to 16.82) (Analysis 5.4).
(b) Improvement in Quality of Life questionnaires
There were no results given for this outcome.
(2) Secondary outcome measures
(a) Severe adverse events, i.e. severe enough to require withdrawal of
treatment, including severe skin irritation
There were no results given for this outcome.
(b) Minor patient-reported adverse events. This included mild skin
irritation not su?icient to require cessation of treatment.
There were no results given for this outcome.
(c) Emergence of antibiotic-resistant micro-organisms
At three months, one participant (of 8) in the treatment group had
developed MRSA compared with one (of 13) in the placebo group
(RR 1.63; 95% CI 0.12 to 22.50) (Analysis 5.5).
(3) Tertiary outcome measures
(a) Global changes in composite rating scales, using a published
named scale
Huang 2009 reported a significantly greater reduction in mean EASI
score at three months in the treatment group compared with the
placebo group (MD -12.10; 95% CI -20.18 to -4.02) (Analysis 5.6).
(b) Changes in the individual signs of eczema as assessed by a
physician
There were no results given for this outcome.
(c) Duration of remission and/or prevention of subsequent flares
There were no results given for this outcome.
(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated
At three months, 88% (7/8) in the treatment group had S. aureus
isolated compared with 77% (10/13) in the placebo group (RR 1.14;
95% CI 0.77 to 1.69) (Analysis 5.7).
(e) Change in bacterial counts of S. aureus, i.e. an assessment of
quantity of S. aureus
There were no results given for this outcome.
In summary, the one small study of bleach baths plus antibiotics
suggested possible clinical benefit in infected eczema but with one
case of antibiotic resistance identified.
9. Therapeutic textile - eight studies
Eight studies, with a total of 265 evaluable participants, compared
various treated or impregnated textiles against placebo. Five paral-
lel group RCTs compared clothing impregnated with silver (Gauger
2006; Juenger 2006; Fluhr 2009; Daeschlein 2010; Portela Araujo
2013). Two of the products (Fluhr 2009; Portela Araujo 2013) addi-
tionally included seaweed or algae-based fibres/treatment.
Daeschlein 2010 evaluated 16 children and adults with uninfected
eczema. The severity and duration were not stated. Participants
were randomised to wearing silver-impregnated long vests and
long johns (Juzo Skin Protect Silver ®, Julius Zorn, Aichach, Ger-
many) (n = 7) or the same textiles without silver (Juzo Skin Pro-
tect) (n = 9). These were worn for four weeks continuously, day and
night. The garments were washed every two days and participants
brought used garments to clinic once a week for testing. No infor-
mation was provided on concomitant topical steroid use.
Fluhr 2009 evaluated 37 children and adults with mild to moder-
ate eczema (infective status not specified). Participants who had
a score of ten or more on the Erlangen Atopy Score were included
in the study. The duration of the condition was not stated. Partici-
pants were randomised to wear silver-loaded seaweed-based fibre
(SeaCell® Active) as a long-sleeved t-shirt (n = 19) or placebo (cot-
ton; n = 18) for eight weeks. No information was provided on con-
comitant topical steroid use.
Gauger 2006 evaluated 57 children and adults (of 68 randomised)
with moderate to severe eczema with a SCORAD of 20 or more
(infective status not specified). Duration of the condition was not
stated. Participants were randomised to wear silver-coated tex-
tiles as verum (Padycare ®, consisting of micromesh material, 82%
polyamide, 18% Lycra, with woven silver filaments with a silver con-
tent of 20% in total) as all in one suits for children and long-sleeved
and long-legged clothes for adults (n = 37) or placebo (textiles made
of pure cotton of equal size) (n = 31). Study clothes were worn dai-
ly for two weeks (in the day, like underwear and at night, like pyja-
mas). Topical steroids were used as needed.
Juenger 2006 evaluated 30 children and adults with uninfected
eczema. The severity of the condition in the participants in the
study was not reported. The median duration of the condition in
the intervention group was 20.5 years and 25.5 years in the control
group. Participants were randomised to wearing a long-sleeved un-
dershirt and long underpants with silver thread (n = 10) or identi-
cal garment with polyester thread (n = 10) or prednicarbate 0.25%
ointment (n = 10) for 14 days. Only comparison of silver textile ver-
sus silver-free textile was eligible for this review. Topical steroids
were used as needed.
Portela Araujo 2013 evaluated 18 children (of 19 randomised) with
eczema (infective status not specified). The severity and duration
of the condition were not stated. Participants were randomised to
Skintoskin textiles® (70% cotton, 20% cellulose with algae extracts,
10% silver activated algal cellulose; 6000 ppm, 0.6% silver (n = 12)
or 100% cotton (woven similarly to the trial textile (n = 7) as baby-
grows for babies around one year old and pyjamas and socks for
older participants. These were worn continuously for seven days
following which they were only worn at night (until day 90). Topical
steroids were used as rescue medication only.
Two studies (Koller 2007; Stinco 2008) reported right-and-le$
comparisons of Dermasilk® (sericin-free silk treated with AEGIS
AEM5772/5) compared with untreated silk or cotton. Koller 2007
evaluated 22 children with mild to moderate eczema (infective
status not specified). The duration of the condition was not stat-
ed. Participants were randomised to Dermasilk® (sericin-free silk
treated with AEGIS AEM5772/5) for 12 weeks or simple silk fabric
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(sericin-free silk without AEGIS AEM5772/5) for two weeks followed
by cotton for 10 weeks. Participants were given three different 'arm
tubes'. "For the first 2 wk of the study, parents were advised to dress
one arm of their children with simple silk fabric and the other one
with the Dermasilk® fabric. After 2 wk - throughout the rest of the
study - one arm had to be covered with the cotton and the other
with the Dermasilk® tube." No concomitant topical steroids were
used.
Stinco 2008 evaluated 26 children and adults (of 30 randomised)
with uninfected eczema. The severity and duration of the condi-
tion were not stated. Participants were randomised to wear tubu-
lar sleeves made from knitted fibrin silk bonded with AEGIS AEM
5772/5 (DermaSilk®) or an identical product without the bonded
AEGIS AEM 5772/5. Each participant received four pairs of tubular
sleeves (with different coloured seams) and parents/participants
were asked to dress their arms with the sleeves all night and day,
changing them once a day and washing them with a mild deter-
gent, with the same coloured sleeve always on the same arm. An
assigned emollient was permitted and a gentle, non-irritating skin
cleanser without antiseptics/antimicrobial products was provided.
No topical steroids were used.
One parallel group RCT (Lopes 2015) compared cotton pyjamas
coated with the natural biopolymer chitosan with untreated cotton
in 78 children and adults (69 evaluable) with uninfected eczema.
The severity was not stated. The median duration of eczema in the
intervention group was 18 years and in the control group, 12 years.
Participants were randomised to cotton pyjamas coated with chi-
tosan (ChitoClear CG-800) (n = 43) or uncoated cotton pyjamas (n
= 35). These consisted of long-sleeved top and long pants. Pyjamas
were worn at night for the duration of the study (two-week run-in
period and eight-week intervention period). Topical steroids were
used for rescue medication only.
Short-term:
(1) Primary outcome measures
(a) Global degree of improvement in symptoms and/or signs as rated
by patient or medical practitioner
Juenger 2006 reported no significant difference in the overall dis-
ease control of eczema in the silver textile group compared with the
non-silver textile as assessed by the participant or their carer (RR
2.40; 95% CI 0.91 to 6.36) (Analysis 6.1). There were no data report-
ed for this outcome in any of the other seven studies.
(b) Improvement in Quality of Life questionnaires
Gauger 2006 reported within-group improvements in mean quality
of life using the DIELH at the end of the intervention (two weeks)
from 55.7 to 45.2 for silver textile group and from 53.3 to 44.2 for the
placebo group but no significant difference between the groups.
There were no short-term data reported for this outcome in any of
the other seven studies.
(2) Secondary outcome measures
(a) Severe adverse events, i.e. severe enough to require withdrawal of
treatment, including severe skin irritation
Four studies reported no adverse reactions to silver textiles (Gauger
2006; Portela Araujo 2013) or Dermasilk® (Koller 2007; Stinco 2008).
Lopes 2015 reported that one participant withdrew due to an
eczema flare in the chitosan-coated textile group compared with
no withdrawals in the placebo group (RR 2.45; 95% CI 0.10 to 58.45)
(Analysis 6.2).
(b) Minor patient-reported adverse events. This included mild skin
irritation not su?icient to require cessation of treatment.
Juenger 2006 reported that two out of ten participants in each
group reported dryness of skin (RR 1.00; 95% CI 0.17 to 5.77) (Analy-
sis 6.3).
(c) Emergence of antibiotic-resistant micro-organisms
There were no results given for this outcome.
(3) Tertiary outcome measures
(a) Global changes in composite rating scales, using a published
named scale
Five studies (Gauger 2006; Juenger 2006; Koller 2007; Stinco 2008;
Portela Araujo 2013) reported short-term changes in SCORAD.
Juenger 2006 reported a reduction in the mean SCORAD from base-
line to day 14 from 72.7 to 36.1 in the silver textile group and from
51.5 to 45.9 in the placebo group; the difference between groups
in change in SCORAD was statistically significant using a non-para-
metric U-test, however, the mean values at day 14 were not signifi-
cantly different (mean difference -9.8; 95% CI -27.3 to 7.7) (Analysis
6.4). Gauger 2006 reported a significant within-group reduction in
mean SCORAD from baseline to week two from 47.8 to 34.7 in the
silver textile group and a non-significant reduction from 45.9 to 38.4
in the placebo group; the difference between groups was not statis-
tically significant (standard deviations and CIs were not reported,
precluding pooling). Portela Araujo 2013 also reported a substan-
tial reduction in mean SCORAD from baseline to seven days from
43.8 to 32.5 in the silver/seaweed textile group and from 41.5 to 35.2
in the placebo group (standard deviation and CI were not reported
for the placebo group). Koller 2007 reported a significant difference
at four weeks in both intensity of itching score and subjective score
of SCORAD between the arm treated with Dermasilk and the arm
treated with untreated silk/cotton; the median intensity of itching
score decreased from 9 to 6.5 in the Dermasilk arm and from 9.5 to
8 in the untreated silk/cotton arm and the median subjective score
decreased from 5 to 4 in the Dermasilk arm and increased from 5 to
5.5 in the untreated silk/cotton arm. Stinco 2008 reported a signifi-
cant reduction in mean local SCORAD from baseline to day 28 from
47.35 to 26.32 in the arm treated with Dermasilk and from 46.68 to
35.70 in the placebo group; the difference in mean reduction from
baseline between the groups was statistically significant (mean dif-
ference -10.05; 95% CI -13.60 to -6.50) (Analysis 6.5).
(b) Changes in the individual signs of eczema as assessed by a
physician
There were no results given for this outcome.
(c) Duration of remission and/or prevention of subsequent flares
There were no results given for this outcome.
(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated
There were no results given for this outcome.
(e) Change in bacterial counts of S. aureus, i.e. an assessment of
quantity of S. aureus
Juenger 2006 reported no difference in S. aureus counts at day 14
in the silver textile and placebo groups (MD 0.0 log CFU/cm2; 95% CI
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-0.93 to 0.93) (Analysis 6.6), however, the baseline count in the silver
textile group was considerably higher (3.1 versus 1.8 log CFU/cm2).
Daeschlein 2010 reported lower bacterial counts of S. aureus after
two days in the silver textile group than the placebo group; how-
ever, the difference was not statistically significant (MD 9.90k CFU/
cm2; 95% CI -41.83 to 22.03) (Analysis 6.7) and no baseline counts
were reported.
Long-term:
(1) Primary outcome measures
(a) Global degree of improvement in symptoms and/or signs as rated
by patient or medical practitioner
There were no results given for this outcome in any of the eight
studies.
(b) Improvement in Quality of Life questionnaires
Lopes 2015 reported a significant within-group improvement in
quality of life using the DLQI at the end of the eight-week study pe-
riod for chitosan-coated cotton and a non-significant improvement
for untreated cotton; the difference between the groups was not
statistically significant (MD -0.80; 95% CI -3.32 to 1.72) (Analysis 6.8).
There were no long-term data reported for this outcome in any of
the other seven studies.
(2) Secondary outcome measures
(a) Severe adverse events, i.e. severe enough to require withdrawal of
treatment, including severe skin irritation
There were no results given for this outcome.
(b) Minor patient-reported adverse events. This included mild skin
irritation not su?icient to require cessation of treatment.
There were no results given for this outcome.
(c) Emergence of antibiotic-resistant micro-organisms
There were no results given for this outcome.
(3) Tertiary outcome measures
(a) Global changes in composite rating scales, using a published
named scale
Lopes 2015 reported a significant reduction in mean SCORAD from
baseline to end of treatment (eight weeks) from 44.2 (95% CI 34.5 to
53.9) to 29.4 (21.4 to 37.4) in the chitosan-coated textile group and
from 41.4 (34.3 to 48.6) to 25.7 (18.3 to 33.1) in the placebo group;
the difference between the groups was not statistically significant
(MD 3.70; 95% CI -7.20 to 14.60) (Analysis 6.9). Portela Araujo 2013
reported a significant reduction in mean SCORAD from baseline to
end of treatment (90 days) from 43.8 (SD 12.1) to 24.0 (SD 12.5) in
the silver/seaweed textile group compared with 41.5 (11.6) to 24.2
(12.5) in the placebo group; the difference between the groups was
not statistically significant (MD -0.20; 95% CI -12.05 to 11.65) (Analy-
sis 6.10).
(b) Changes in the individual signs of eczema as assessed by a
physician
There were no results given for this outcome.
(c) Duration of remission and/or prevention of subsequent flares
Lopes 2015 reported a median of 0 flares (IQR 0 to 1) during the
eight-week study period in both the chitosan-coated textile and
placebo groups.
(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated
Lopes 2015 reported no significant difference in the percentage of
participants with S. aureus isolated at the end of treatment (eight
weeks) between the chitosan-coated textile and placebo groups
(RR 1.01; 95% CI 0.69, 1.46) (Analysis 6.11).
(e) Change in bacterial counts of S. aureus, i.e. an assessment of
quantity of S. aureus
Lopes 2015 reported a small increase in mean log10 colony form-
ing units/cm2 of S. aureus between baseline and end of treatment
(eight weeks) from 3.5 (SD 1.4) to 4.0 (SD 1.8) in chitosan-coat-
ed textile group and from 3.3 (1.5) to 3.8 (1.6) in the placebo
group (data extracted from graph using WebPlotDigitizer, https://
automeris.io/WebPlotDigitizer/); neither the within-group changes
from baseline nor the difference between the groups was statisti-
cally significant (MD 0.20; 95% CI -0.65 to 1.05) (Analysis 6.12).
In summary, therapeutic textiles showed no clear benefit in either
infected or uninfected eczema.
9. Protease inhibitor - one study
One study (Foelster Holst 2010), a parallel group RCT, compared a
novel protease inhibitor (SRD441) ointment against placebo in 93
adults with mild to moderate eczema, with an IGA of 2 to 3 and a cur-
rent exacerbation requiring a step up in treatment (infective status
not specified). The duration of the condition was not specified. Par-
ticipants were randomised to receive the study drug SRD441 oint-
ment (mixture of white so$ paraffin and Miglyol 812N, a medium
chain triglyceride, and 1 mg/g SRD441) (n = 45) or the vehicle oint-
ment (white so$ paraffin and Miglyol 812N) (n = 48). The study drug
or vehicle were applied to all affected areas and commonly affect-
ed body areas up to a maximum of 20% BSA for up to 28 days. Un-
medicated emollients and moisturisers were permitted during the
screening period and on all nontreated skin during the treatment
phase. Topical steroids were used as rescue medication only.
Short-term:
(1) Primary outcome measures
(a) Global degree of improvement in symptoms and/or signs as rated
by patient or medical practitioner
The study reported no significant difference in the proportions of
participants with a score of 0 (clear) or 1 (almost clear) on a 6-point
investigator's global assessment scale (RR 0.89; 95% CI 0.29 to 2.71)
(Analysis 7.1).
(b) Improvement in Quality of Life questionnaires
At 28 days, Foelster Holst 2010 reported a decrease in the mean
DLQI of 0.8 points in the protease inhibitor group compared with
3.2 points in the placebo group; the difference was not statistically
significant (standard deviations and CIs were not reported).
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(2) Secondary outcome measures
(a) Severe adverse events, i.e. severe enough to require withdrawal of
treatment, including severe skin irritation
Seven participants in the protease inhibitor group (15.6%) and 11
participants in the placebo group (22.9%) experienced an adverse
event that resulted in discontinuation of the study medication (RR
0.68; 95% CI 0.68, 1.60) (Analysis 7.2). The most frequent adverse
events requiring withdrawal of treatment were application site re-
action (n = 6), application site dryness (n = 4), "atopic dermati-
tis" (despite all participants having this at baseline; hence, we are
not clear what this means), application site pruritus and pruritus
(all, n = 3), and application site irritation, application site swelling,
application site urticaria and pain (all, n = 2). The types of adverse
events were not reported by treatment group.
(b) Minor patient-reported adverse events. This included mild skin
irritation not su?icient to require cessation of treatment.
Twenty participants in the protease inhibitor group (44.4%) and 23
participants in the placebo group (47.9%) experienced minor ad-
verse events (RR 0.93; 95% CI 0.60, 1.44) (Analysis 7.3). Full details
of these adverse events were not reported.
(c) Emergence of antibiotic-resistant micro-organisms
There were no results given for this outcome.
(3) Tertiary outcome measures
(a) Global changes in composite rating scales, using a published
named scale
Foelster Holst 2010 reported a 17.2% decrease from baseline in
SCORAD in the protease inhibitor group compared with 13.9% in
the placebo group; the difference was not statistically significant
(standard deviations and CIs were not reported).
(b) Changes in the individual signs of eczema as assessed by a
physician
There were no results given for this outcome.
(c) Duration of remission and/or prevention of subsequent flares
Foelster Holst 2010 reported no difference in the number and sever-
ity of new exacerbations, but numerical results were not presented.
(d) Change in isolation rate of S. aureus, i.e. isolated or not isolated
There were no results given for this outcome.
(e) Change in bacterial counts of S. aureus, i.e. an assessment of
quantity of S. aureus
There were no results given for this outcome.
Long-term:
There were no long-term outcomes reported.
D I S C U S S I O N
Summary of main results
This review included 41 studies with a total of 1753 participants
analysed. Of the ten types of intervention considered in this review,
we found the most substantial body of evidence for the compari-
son of topical steroids plus topical antibiotics compared with top-
ical steroids alone (see Summary of findings for the main compari-
son). In total, 14 studies addressed this comparison of which only
three reported the first primary outcome, and pooled analysis indi-
cated that the combination group may lead to a slightly increased
proportion with good or excellent global degree of improvement in
symptoms or signs, as rated by the patient or medical practition-
er (follow-up: 6 to 28 days; one of these studies was in clinically in-
fected eczema and the other two studies did not specify; low-quali-
ty evidence). Only one study from this comparison reported the re-
view’s second primary outcome of change from baseline in quality
of life and there is probably little or no difference between groups
(follow-up: 14 days; infected eczema; moderate-quality evidence).
Rates of adverse events requiring withdrawal from treatment were
extremely low in the four studies from this comparison evaluating
this outcome (both groups reported flare of dermatitis, worsening
of the condition, and folliculitis), and consequently there is consid-
erable uncertainty in the effect estimate (follow-up: 6 to 28 days;
studies’ infective status: not stated (one study), uninfected (two
studies), infected (one study); very low-quality evidence). Pooled
analysis of the two studies reporting minor adverse events not re-
quiring withdrawal from treatment showed fewer adverse events,
such as flare of dermatitis, stinging, itch, folliculitis, in the combi-
nation group, but we are uncertain of the validity of this result (fol-
low-up: 14 days; studies’ infective status: not stated and uninfect-
ed; very low-quality evidence). One study in this comparison re-
ported the proportion of strains of S. aureus that were resistant to
the antibiotic used; these were similar between the groups, but we
are not confident in this result (follow-up: three months; infected
eczema; very-low quality of evidence).
Of the four studies comparing oral antibiotics with placebo (Sum-
mary of findings 2), two studies evaluated good or excellent glob-
al improvement and indicated that there may be no difference be-
tween the groups (follow-up: 14 to 28 days; studies’ infective status:
uninfected and mainly infected, low-quality evidence). Only one
study in this comparison reported quality of life and there is prob-
ably little or no difference between the groups (follow-up: 14 days;
infected eczema; moderate-quality evidence). The rates of adverse
events requiring withdrawal from treatment were very low (e.g.
eczema worsening (both groups), loose stools (antibiotic group),
and Henoch-Schönlein purpura (placebo group)) in the four stud-
ies that assessed this outcome in this comparison, resulting in an
extremely imprecise estimate of the treatment effect. Thus, we are
uncertain if there is a difference between groups (follow-up: 14 to
28 days; studies’ infective status: uninfected (two studies), infect-
ed (one study), mainly infected (one study: 28/30 participants); very
low-quality evidence). The only information regarding minor ad-
verse events for this comparison was from one study, which again
showed similar results (low number of events) between the groups.
However, we are uncertain if there is a difference between groups.
Minor adverse events included nausea, vomiting, diarrhoea, and
stomach and joint pains (follow-up: 28 days; infected eczema; very
low-quality evidence). Based on two studies, antibiotic resistance
was found to be similar in both groups, but the evidence was un-
certain (follow-up: 14 days; studies’ infective status: infected and
uninfected; very low-quality evidence).
Of the five studies comparing bleach baths with placebo or bath
emollient (Summary of findings 3), one evaluated the percentage of
participants with good or excellent global improvement and found
there may be no difference between bleach baths or placebo (fol-
low-up: one month; uninfected eczema; low-quality evidence). One
study reported change from baseline in quality of life and found
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that there was probably little or no difference between groups
(bleach baths or placebo) (follow-up: at 28 days; unspecified infec-
tive status; moderate-quality evidence). One study reported just
one dropout due to worsening itch; the numbers of events requir-
ing withdrawal from treatment were very low in the studies with-
in this comparison, and we are uncertain if there is a difference be-
tween bleach baths or placebo (follow-up: two months; uninfect-
ed eczema; very-low quality evidence). Based on one study in this
comparison, some minor adverse events such as burning, stinging,
and dry skin were reported by participants in both groups; there
may be no difference in this outcome between bleach baths and
placebo (follow-up: two months; uninfected eczema; low-quality
evidence). Based on one study, we are uncertain if antibiotic re-
sistance was different between groups (bleach baths and place-
bo) (follow-up: four weeks; unspecified infective eczema; very low-
quality evidence).
Quality of life and antibiotic resistance were the most under-repre-
sented of our core outcomes. Although other outcomes were more
frequently reported, heterogeneity often precluded pooling. Most
studies assessed short-term eczema control, so we are uncertain of
the effects of included treatments in the long term. Although the
included studies assessed iinterventions currently used in clinical
practice, many interventions were assessed by single studies; these
included the following groups: topical steroid plus antibiotic and
antifungal; topical calcineurin inhibitor plus antibiotic; antibacte-
rial soap; antibacterial bath additive plus antibiotic; and protease
inhibitor. Although we found moderate-quality evidence for the as-
sessment of quality of life for our three key comparisons, our oth-
er key outcomes were mainly reported by trials of low or very low
quality.
Antibiotic resistance
Of the 18 studies evaluating antibiotics, only six reported on the
emergence of resistant organisms. These included three studies of
oral antibiotics (Weinberg 1992; Ewing 1998; Francis 2016), three
studies of topical steroids plus topical antibiotics (Lever 1988; Hung
2007; Francis 2016), one study of topical calcineurin inhibitor plus
topical antibiotic (Hung 2007) and one study of bleach bath plus an-
tibiotic (Huang 2009), including two studies each reporting on two
interventions.
In the studies of oral antibiotics, numbers of resistant organisms
to the study drugs were low; however, these were based on small
numbers of participants (Weinberg 1992; Francis 2016). One study
of flucloxacillin reported an increase in MRSA in the treatment
group but did not give numerical results (Ewing 1998).
In the studies of topical steroids or topical calcineurin inhibitor plus
topical fusidic acid, cases of resistance to fusidic acid were report-
ed in 25% to 73% of strains isolated from the intervention groups
(Hung 2007; Francis 2016); however, these were based on small
numbers of participants and, in one of the studies, comparative fig-
ures were not given for the participants that did not receive fusidic
acid. In the one study that also reported rates of fusidic acid resis-
tance in the control group, 20% to 31% of strains were resistant. In
the study of mupirocin, only one participant had a resistant strain
of S. aureus following treatment (Lever 1988); however, as this was
a cross-over trial, it was impossible to produce comparative results
for mupirocin versus placebo.
In the study of bleach bath plus mupirocin (Huang 2009), one partic-
ipant (of 11) developed MRSA in the intervention group compared
with none (of 13) in the control group; however, the numbers were
too small to draw any meaningful conclusions.
Overall completeness and applicability of evidence
Although we identified studies of relevance to our review question,
these were insufficient to address all of the review's objectives. This
review included several different interventions designed to reduce
S. aureus in eczema; however, the studies were generally small and
poorly reported. Furthermore, while a broad range of treatment
categories were included, covering all anti-staphylococcal inter-
ventions currently used in clinical practice, half of these were as-
sessed by single studies:
• four studies of oral antibiotics included a total of 166 partici-
pants;
• five studies of topical antiseptics/antibiotics versus placebo in-
cluded only 99 participants;
• one study of an antibiotic and antifungal combined with a top-
ical steroid compared with topical steroid alone included only
four participants with atopic eczema;
• one study included 26 participants evaluating a topical cal-
cineurin inhibitor plus antibiotic compared with topical cal-
cineurin inhibitor alone;
• one study included 50 participants evaluating antibacterial
soap;
• seven studies of antibacterial bath additives included a total of
164 participants;
• one study of an antibacterial bath additive (bleach) combined
with an antibiotic included 25 participants;
• eight studies, with a total of 265 participants, compared various
treated or impregnated textiles against placebo; and
• one study, with 93 participants, compared a novel protease in-
hibitor (SRD441) ointment against placebo.
The most well-represented treatment group was topical steroids
plus antiseptics/antibiotics versus topical steroids alone, which
was assessed in 14 studies; these studies (34% of the included stud-
ies) contributed over 50% of the review's evaluable participants.
However, even when comparisons included an adequate number
of studies, variation between studies in the specific interventions
and in the outcomes reported precluded any meaningful conclu-
sions regarding their usefulness.
Twenty-one studies were conducted in Western Europe, nine in
North America, seven in the Far East, and four elsewhere in the
world. Environmental factors may influence the severity of the
eczema, bathing behaviour, and tendency to infection. Further-
more, living conditions between different countries influence the
usefulness of the intervention in different populations. For exam-
ple, in Hon 2016, participants did not routinely have bath tubs in
their homes and had to be supplied with portable bathtubs in order
to participate in the trial. In practice, if most of the population do
not have a bath tub, this intervention would be difficult to imple-
ment.
The majority of studies, 19, included both children and adults, 12
only included children, four only included adults and in six stud-
ies, the age of the participants was not reported. Severity of the
eczema, when mentioned, ranged from mild to severe. The method
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of assessing severity was often not described and, when it was, this
ranged from subjective global assessments to objective scoring sys-
tems such as SCORAD.
In clinical practice, patients with clinically obvious, infected
eczema will often be given antibiotic treatment to clear the infec-
tion, leading to an improvement in their eczema. A systematic re-
view found that the pooled prevalence of S. aureus amongst pa-
tients with eczema was 70% for lesional skin, 39% for non-lesion-
al skin, and 62% for nasal colonisation (Totté 2016). The inclusion
criteria of the studies in our review varied widely. Nine studies re-
quired evidence of colonisation or infection, with five requiring mi-
crobiological evidence of S. aureus and another four requiring clini-
cally infected eczema. Fourteen studies excluded participants with
acutely infected eczema, or those requiring oral antibiotics, while
the remainder (19 studies) did not mention this in their inclusion
or exclusion criteria. The differences in inclusion criteria make the
studies difficult to compare and it is difficult to draw conclusions
about the role of clearing S. aureus in clinically infected eczema ver-
sus treating S. aureus in patients without evidence of clinical infec-
tion.
In clinical practice, most people with eczema will use accessory
care such as emollients or specific cleansing products; however,
other aspects of clinical care were not recorded in the included
studies.
Very few trials looked at quality of life, long-term control of eczema,
or antibiotic resistance. Just under half of the studies reported on
the primary outcome, global improvement. Only five studies ad-
dressed quality of life. Twenty-seven studies reported on either se-
vere or minor participant-reported adverse events, or both. Seven
studies looked at microbiological data including sensitivity of or re-
sistant organisms (the secondary outcome emergence of antibiot-
ic-resistant micro-organisms).
Few studies reported the same outcome measures, and outcomes
were assessed using different instruments and at different time
points; therefore, it was impossible to perform pooled analyses for
many interventions.
For three of the key comparisons of oral antibiotic versus place-
bo, topical steroid plus topical antibiotic versus topical steroid, and
bleach bath versus placebo, we were able to pool studies in groups
of up to seven studies for some outcome measures. For the remain-
ing categories, either the studies were not sufficiently similar to
pool or the studies did not report the same outcome measures. For
the initial pooling, we did not take into consideration whether it
was infected or non-infected eczema that was being treated.
Arguably one of the most important outcomes in the treatment of
eczema is long-term control. Only nine studies in our review were
longer than one month’s treatment duration, which was consid-
ered a reasonable time to reflect disease chronicity. The problem
of measuring long-term control has been highlighted as part of the
HOME initiative (Chalmers 2014). Several different methods of mea-
suring long-term control have been employed in RCTs (Barbarot
2016). More recently there have been attempts to validate mea-
sures of long-term control in eczema by assessing “well-controlled
weeks” (Langan 2017).
Antibiotic resistance
Of 18 studies evaluating antibiotics, only six reported on antibiotic
resistance. The numbers of events were too low and the studies of
insufficient duration to establish whether changes were genuine or
to draw any meaningful conclusions.
The concern about the use of antibiotics for eczema leading to de-
velopment of resistant organisms has led clinicians to seek alterna-
tive strategies to decrease S. aureus in eczema. This review includes
five studies of bleach baths and one study in which they were com-
bined with nasal mupirocin. Another strategy to decrease S. aureus
in eczema is the use of endolysin, a trial of which was recently com-
pleted at the time of writing and is yet to report (Totté 2017).
Quality of the evidence
Many of the studies were small, with 37 of the 41 studies including
fewer than 100 participants, and two studies (Hjorth 1985; Polano
1960) provided no data for the outcomes of interest. The quality
of reporting was frequently poor. More than one-quarter of studies
were assessed as having high risk of bias for blinding of participants
and personnel, incomplete outcome data and selective reporting.
For the comparison of topical steroid plus topical antibiotic versus
topical steroid alone, the evidence regarding the global outcome
was judged to be of moderate quality because of the risk of bias in
included studies (lack of blinding and possible selective reporting
in Canpolat 2012; high risk of attrition bias in Gong 2006; possible
selective reporting in Wachs 1976). The evidence regarding change
from baseline in quality of life was judged to be of moderate quality
because of risk of bias (high risk of attrition bias and baseline im-
balance in Francis 2016). The evidence regarding adverse events re-
quiring withdrawal of treatment was judged to be of very low qual-
ity because of risk of bias (high risk of attrition bias and baseline
imbalance in Francis 2016; lack of blinding in Hung 2007; high risk
of attrition bias in Ramsay 1996) and imprecision of the estimate
(downgraded two levels due to the very low numbers of events).
The evidence regarding minor adverse events was also judged to
be of very low quality, this time, because of risk of bias (high risk
of attrition bias in Ramsay 1996), imprecision of the estimate and
heterogeneity of the control group risk (which varied from 3.6% in
Ramsay 1996 to 59.1% in Schuttelaar 2005). The evidence regarding
global change in composite rating scales was judged to be of low
quality because of risk of bias (high risk of attrition bias and base-
line imbalance in Francis 2016; high risk of attrition bias in Gong
2006; lack of blinding in Hung 2007) and heterogeneity in control
group means. The evidence regarding S. aureus isolation rates was
judged to be of moderate quality because of risk of bias (high risk of
attrition bias and baseline imbalance in Francis 2016; lack of blind-
ing in Hung 2007; lack of a washout period and baseline imbalance
in severity in Lever 1988; baseline imbalance in S. aureus colonisa-
tion in Leyden 1977; lack of blinding in Nilsson 1992; possible selec-
tive reporting in Wachs 1976).
For the comparison of oral antibiotics versus placebo, the evidence
regarding the global outcome was judged to be of low quality be-
cause of risk of bias (high risk of attrition bias in both Ewing 1998
and Weinberg 1992) and imprecision of the estimate. The evidence
regarding change from baseline in quality of life and global change
in composite rating scales was judged to be of moderate quali-
ty because of risk of bias (high risk of attrition bias and baseline
imbalance in severity and rates of S. aureus in Francis 2016). The
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evidence regarding adverse events requiring withdrawal of treat-
ment was judged to be of very low quality because of risk of bias
(high risk of attrition bias in Weinberg 1992, Ewing 1998 and Fran-
cis 2016, and baseline imbalance in Francis 2016) and imprecision
of the estimate (downgraded two levels due to the very low num-
ber of events). The evidence regarding S. aureus isolation rates was
judged to be of low quality because of risk of bias (high risk of attri-
tion bias in Weinberg 1992, Ewing 1998 and Francis 2016 and base-
line imbalance in Francis 2016) and imprecision of the estimate.
For the comparison of bleach baths versus placebo, the evidence
regarding global outcome and S. aureus isolation rates was judged
to be of low quality because of risk of bias (likely ineffectiveness of
blinding and baseline imbalance in S. aureus rates in Wong 2013)
and imprecision of the estimate. The evidence regarding change
from baseline in quality of life was judged to be of moderate qual-
ity because of imprecision of the estimate. The evidence regard-
ing adverse events requiring withdrawal of treatment was judged
to be of very low quality because of risk of bias (likely ineffective-
ness of blinding and baseline imbalance in S. aureus rates in Wong
2013) and imprecision of the estimate (downgraded two levels due
to the very low numbers of events). The evidence regarding minor
adverse events was judged to be of low quality because of risk of
bias (likely ineffectiveness of blinding and baseline imbalance in S.
aureus rates in Wong 2013) and imprecision of the estimate. The
evidence regarding global change in composite rating scales was
judged to be of very low quality because of risk of bias (likely in-
effectiveness of blinding in both studies, and baseline imbalance
in severity in Gonzalez 2016 and S. aureus rates in Wong 2013), im-
precision of the estimate and heterogeneity in the control group
means (from 2.3 in Gonzalez 2016 to 25.4 in Wong 2013).
Potential biases in the review process
Our searches identified a number of studies, which at first may
have appeared eligible for the review; however, studies with no
placebo group that compared two anti-staphylococcal interven-
tions were ineligible according to our protocol. Exclusion of such
studies might potentially have resulted in the omission of addition-
al evidence. To include such studies would require more complex
techniques such as network meta-analysis.
The other decision we faced in selection of studies was whether
studies which reported reduction in S. aureus, but used an interven-
tion that was not specifically anti-staphylococcal (e.g. trials of vit-
amin D or probiotics) should be included. We opted not to include
such studies.
We attempted to conduct a comprehensive search for studies, but
the fact that six studies are awaiting classification and have not yet
been incorporated may be a source of potential bias. Several of
these studies appear to have been completed some time ago but
have never been published.
Agreements and disagreements with other studies or
reviews
Other than the previous version of this review, there have been no
other systematic reviews covering all interventions to reduce S. au-
reus in eczema. A systematic review of bleach baths (Chopra 2017)
concluded that "while bleach baths are effective in reducing AD
severity, they do not appear to be more effective than water bath
alone." However, the finding that bleach baths reduce severity was
based on non-randomised, within-group comparisons. The conclu-
sion that bleach baths do not appear more effective than water
alone is consistent with our results. A systematic review of function-
al textiles (Lopes 2013) concluded that recommendation for their
use in treating eczema is weak, with low-quality evidence of effec-
tiveness. This is consistent with our findings.
A recent narrative review summarised the current and future treat-
ment strategies (Hepburn 2017). Potential future treatments for
S. aureus infection include monoclonal antibodies, vaccines, en-
dolysins, vitamin D and probiotics (Hepburn 2017).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
The quality of the evidence included in this review was insufficient
to address the overall set of objectives and provide definitive guid-
ance for clinical practice. Only a limited number of studies were
available to pool in meta-analyses.
We found low-quality evidence that using a topical antibiot-
ic/steroid combination compared with topical steroid alone may be
associated with slight improvement in short-term good or excellent
improvement in symptoms or signs, or both, but there is probably
little or no difference between groups in change from baseline in
quality of life.
Similarly, there is probably little or no difference between oral an-
tibiotics or bleach baths and placebo on quality of life (both short-
term assessment and based on moderate-quality evidence).
When compared to placebo, oral antibiotics or bleach baths may
make no difference to short-term overall good or excellent im-
provement (low-quality evidence).
Low rates of adverse events were reported for all the interventions
considered, but we are uncertain of the effect of our key compar-
isons on adverse effects (whether or not they required withdraw-
al from treatment) as we assessed the quality of the evidence as
very low for all but one adverse event outcome: there is low-quality
evidence that there may be no difference in minor adverse events
(burning/stinging or dry skin) between bleach baths and placebo
(water). Common adverse events included flare of dermatitis, wors-
ening of the condition, folliculitis, stinging, itch and digestive dys-
function.
We are uncertain of the effect of our three key comparisons on an-
timicrobial resistance (all evidence was very low quality), which is
a potential concern with this intervention. Although there was in-
sufficient evidence to determine the effects of antibiotics to treat
infected eczema, this does not preclude their use to treat the infec-
tion itself, which was outside the scope of this review.
The six studies in Studies awaiting classification may alter the con-
clusions of the review, once assessed.
Implications for research
This review highlights the need for further research into the role
of treating S. aureus in eczema. The trials included in this review
were heterogeneous in terms of baseline population, interventions
used, and outcomes. First, there is need to establish valid and re-
peatable criteria for describing clinically infected eczema, perhaps
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using consensus methods supported by reference images or more
objective methods such as colony counts. Whilst there is likely to
be good agreement between clinicians on what grossly infected
eczema is, there is likely to be a lot of variability between clini-
cians in deciding a suitable boundary between clinically infected
and non-infected eczema. Once this is established, there is a need
to clarify whether the study population has clinically infected (or
just colonised) eczema or whether the eczema is clinically uninfect-
ed. Future studies need to assess for the presence or absence of S.
aureus infection at baseline and follow-up visits and for the pres-
ence of resistant organisms. The results of a trial of an anti-staphy-
lococcal intervention may differ depending on whether the eczema
is infected or uninfected at baseline.
In clinical practice, other products such as emollients and washing
products are usually used. Information on this has not been docu-
mented. Collection of this information would provide a more real-
istic view on what is going on in clinical practice.
Many of the trials were small leading to imprecise estimates of
treatment effects; future studies must be adequately powered to
detect clinically meaningful differences in outcomes. Larger trials
will also reduce the risk of chance baseline imbalance. In future tri-
als, attempts should be made to blind the participants and person-
nel, whenever possible; however, for certain interventions, such as
bleach baths, adequate blinding may be very difficult to achieve.
Heterogeneity of outcome measures precluded pooling of data
in many cases. In future studies, the HOME initiative (Chalmers
2014) will help to standardise outcome measures for use in trials of
eczema. As well as objective measures of eczema severity, future
studies of anti-staphylococcal interventions should include mea-
sures of quality of life. Future studies also need to assess whether
any benefit in terms of severity or reduction in flares is sustained
following clearance of S. aureus (for example, following antibiot-
ic treatment) and whether sustained benefit can be achieved by
longer term use of non-antibiotic treatments. Given the time re-
quired to recover from severe flares in eczema, follow-up of sever-
al months would be required. Every effort should be made to max-
imise follow-up of participants, as many studies in our review were
potentially impacted by attrition bias. Studies should report all rel-
evant adverse events.
Many studies were poorly reported and future studies should be
prospectively registered and adhere to CONSORT reporting guide-
lines (Schulz 2010) to ensure complete and transparent reporting
and avoid selective reporting of study results.
In view of the low quality of evidence and lack of information on
quality of life and antibiotic resistance, a larger, definitive trial on
steroid/antibiotic combination treatment is required. With the in-
creased concerns about antibiotic resistance, other strategies to
treat S. aureus infection that do not involve antibiotics should be
further investigated.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Design: parallel group
Total study duration: not stated
Participants Setting not specified but conducted in conjunction with Center for Clinical and Cosmetic Research, Uni-
versity of Miami, USA.




Duration of condition: not stated
Infective status: not stated
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Interventions Application of hypochlorous acid containing solution twice daily or as required for 72 hours versus no
treatment
Category: topical antiseptic/antibiotic
Topical steroids: not stated
Outcomes 1. Participant Global Assessment
2. Investigator Global Assessment
3. Visual Analog Scale itch score
4. Adverse events
5. Incidence of local skin reactions leading to discontinuation
Outcomes were assessed at baseline, 24 hours and 72 hours
Funding Not stated
Notes Only published as abstract
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information provided in abstract
Allocation concealment
(selection bias)





High risk Title stated 'investigator blinded', however impossible to blind intervention
due to no treatment control group
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Minimal results reported in abstract. Only 19/20 participants allocated to inter-




High risk Primary outcomes reported as P values only





Total study duration: not stated
Participants Setting: Secondary care, two centres, USA
Boguniewicz 2001 
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Incl: moderate to severe atopic dermatitis, S. aureus cultured from skin
Excl: overt skin infection
Age: range 6-58 years
Sex: 9 males, 11 females
Duration of condition: not stated
Infective status: uninfected
S. aureus colonisation: 100%
Randomised: 20
Evaluable: 20
Interventions Cefuroxime axetil orally (dose not stated) twice daily vs placebo orally twice daily given for two weeks
each with one week washout in between
Category: oral antibiotics
Topical steroids: all participants
Outcomes 1. Colony counts from two involved areas and inguinal area at the end of each treatment period
Funding Glaxo Wellcome, Inc
Notes Outcomes not clear
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)





Low risk Quote: "Double-blind, placebo-controlled"
Comment: considered low risk despite no evidence of success of blinding
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Unclear risk No trial registration provided
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Methods Design: parallel group
Total study duration: not stated
Participants Setting not specified but conducted in conjunction with Department of Dermatology in Cincinnati and
Portland
Incl: atopic dermatitis (Hanifin and Rajka criteria) of moderate severity (Rajka and Langeland criteria),
Fitzpatrick skin types I-IV
Excl: not stated
Age: mean 34.6 years (range 12-74)
Sex: 15 males, 35 females
Duration of condition: not stated
Infective status: not stated
S. aureus colonisation: 50%
Randomised: 50
Evaluable: not stated
Interventions Bar of soap containing triclocarban 1.5% vs placebo (number in each group not stated)
Whole body to be washed at least daily for 42 days
Category: antibacterial soap
Topical steroids: as needed
Outcomes 1. Change from day 0 to day 14, 28, 42, 49, 56, 63 in self-rating of itching
2. Change from day 0 to day 14, 28, 42, 49, 56, 63 in evaluation scores for extent and severity of dermati-
tis (3 primary attributes combined, 3 secondary attributes combined, all 6 attributes combined, each
attribute individually)
3. Change from day 0 to day 14, 28, 42, 49, 56, 63 in percentage of body surface area (BSA) affected
4. IGA of change from day 0 to day 14, 28, 42, 49, 56, 63 (-5 = severe worsening, 5 = total clearing)
5. Amount of topical steroid used
6. Change from day 0 to day 14, 28, 42, 63 of mean log colony forming units of total organisms and S.
aureus
Funding The Procter & Gamble Company
Notes Participants also used standard moisturiser and 0.025% triamcinolone acetonide cream as required.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)





Low risk Quote: "patients were given either a bar soap (Safeguard®) containing 1.5% tri-
clocarban as the active antimicrobial ingredient or a placebo bar soap identi-
cal to the antimicrobial bar, but without triclocarban".
Breneman 2000 
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Comment: blinding was likely to be effective.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote: "double-blind"




Unclear risk Outcomes presented as means and percentages without sample sizes. One
participant withdrew at day 28 because of worsening dermatitis.
Selective reporting (re-
porting bias)
High risk Participant rating on itching, % with S. aureus isolated and % BSA affected
stated as outcomes, but not reported in results.





Methods Design: parallel group
Total study duration: not stated
Participants Setting: secondary care, single centre, Turkey
Incl: atopic dermatitis (Hanifin and Rajka criteria), mild to moderate severity, infants age 6 months to 2
years, involving 2%-30% of the body
Excl: not stated
Age: hydrocortisone group: mean 13.6 months, hydrocortisone plus mupirocin group: mean 13.3
months
Sex: not stated
Duration of condition: not stated
Infective status: not stated
S. aureus colonisation: 40%
Randomised: 53
Evaluable: 53
Interventions Hydrocortisone plus mupirocin (n = 27) vs hydrocortisone (n = 26) applied twice daily (hydrocortisone
in the morning and evening and mupirocin at noon and night) by parents to areas affected with atopic
dermatitis at least 2 hours before bathing for up to 7 days
Category: topical steroid plus antiseptic/antibiotic
Topical steroids: all participants
Outcomes 1. SCORAD and EASI on day 7 and weeks 2, 4, 8
2. Percentage of BSA affected
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Notes Additional "control" group consisted of infants whose parents did not want to use pharmacological
agents - not included in results of review as not randomised.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)





High risk Quote: "Caregivers, investigators, and clinical staL were blinded to treatment
except parents. Drugs prescribed by a different investigator".
Comment: parents were not blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "clinical follow up dermatologic assessment made by a different clini-
cian".




Low risk All participants included for primary outcome.
Selective reporting (re-
porting bias)
High risk Follow-up was carried out on day 7 and weeks 2, 4 and 8, but the outcomes
were only reported for day 8 and for the end of the study. The outcome of per-
centage of BSA affected was not reported.





Methods Design: parallel group
Total study duration: 7 months
Participants Setting: secondary care, single centre, Germany
Incl: acute atopic dermatitis and written agreement of participants
Excl: acute viral infection (herpes zoster, eczema herpeticum), acute dermal staphylococcal or strepto-
coccal infections (impetigo/erysipelas), UV therapy, topical or systemic corticosteroid treatment, se-
vere general disorders (carcinoma, renal insufficiency, autoimmune disease), pregnancy and age <10
years
Age: intervention group: mean 32 years (range 13-65); control group: mean 27.3 years (range 20-49)
Sex: intervention group: 4 males, 3 females, control group: 5 males, 4 females
Duration of condition: not stated
Infective status: uninfected
S. aureus colonisation: not stated
Daeschlein 2010 
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Randomised: 16
Evaluable: 16
Interventions Silver-impregnated long vests and long johns (Juzo Skin Protect Silver ®, Julius Zorn, Aichach, Ger-
many) (n = 7) vs the same textiles without silver (Juzo Skin Protect) (n = 9)
"Patients wore the textiles (one pair per patient) for 4 weeks continuously day and night without any
special wearing recommendations, with the only request to change and wash the pair every 2 days and
to bring used clothes once a week (every Friday) to the dermatological clinic where they were tested."
Category: therapeutic textile
Topical steroids: not stated
Outcomes 1. Antibacterial reduction during wearing and by washing (weekly)
2. Test for self-reduction by silver textile over 24 hours (from 5 participants from each group)
3. Contamination of conventional underwear by healthy participants
4. Decrease of S. aureus and total bacteria after 2 days of wearing the textiles
5. Bacterial load as amount of total CFU and of S. aureus of the 8 defined test areas from 1. worn silver
textiles and placebo after 2 days of wearing directly after undressing, 2. after washing and 3. separately




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)





Low risk Quote: "Optically and regarding wearing comfort, the two textile types could
not be differentiated". "Double-blind"
Comment: blinding was likely to be effective.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Results reported for all participants.
Selective reporting (re-
porting bias)
Unclear risk Reduction of S. aureus from manual washing was reported, as was the com-
plete elimination of S. aureus. Neither of these were specified in advance.
Other bias Unclear risk Baseline severity and presence of S. aureus not reported
Daeschlein 2010  (Continued)
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Methods Design: parallel group
Total study duration: not stated
Participants Setting: secondary care, single centre, UK
Incl: atopic dermatitis (Hanifin and Rajka criteria) with no sign of bacterial infection, treated with topi-
cal steroids, age 1 to 16 years, regular outpatient attendance
Excl: systemic steroids (past four weeks), systemic or topical antibiotics (past three weeks)
Age: flucloxacillin group: median 7.5 years (range 1.6-15.3), placebo group: median 5.2 years (range
1.1-14.1)
Sex: not stated
Duration of condition: not stated
Infective status: uninfected
S. aureus colonisation: 98%
Randomised: 50
Evaluable: 46
Interventions Flucloxacillin 250 mg four times daily (n = 25) vs placebo (n = 25) for 4 weeks (dose halved for < 10 yrs
old)
Category: oral antibiotic
Topical steroids: as needed
Outcomes 1. Daily family assessment of redness, daytime itch and night-time sleep disturbance on a visual ana-
logue scale of 0-10, number of applications of corticosteroid and/or emollient and evening dose of
trimeprazine tartrate
2. Amount of corticosteroid used at day 14, 28, 42, 84
3. Extent (% BSA) and severity (1 = mild, 5 = severe) of atopic dermatitis at day 14, 28, 42, 84
4. Patient/family and assessor global degree of improvement (1 = much better, 2 = better, 3 = same, 4 =
worse) at day 28, 42, 84
5. Isolation of S. aureus from affected and non-affected skin
6. Mean log S. aureus counts




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Flucloxacillin and placebo capsules were supplied and randomised by
SKB Pharmaceuticals (Mundells, Welwyn Garden City UK)".
Comment: method not described
Allocation concealment
(selection bias)




Low risk Quote: "Double blind", "Placebo was 'taste matched".
Comment: blinding was likely to be successful.
Ewing 1998 
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All outcomes
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Double blind"




High risk Two withdrawals for AEs: one in flucloxacillin and one placebo group; two
participants on flucloxacillin had poor compliance and not included; another
withdrew because they received erythromycin for a chest infection; By visit 5,
37 subjects were analysed, so in total there were 13 withdrawals.
Selective reporting (re-
porting bias)
High risk Data on non-significant differences not shown
Other bias Low risk Well-balanced at baseline for severity (surface area and erythema scores) and




Methods Design: within-patient study (le$/right comparison)
Total study duration: not stated
Participants Setting: secondary care, single centre, Egypt
Incl: inflammatory dermatoses with bilateral, symmetrical lesions of similar aetiology and severity (re-




Duration of condition: mean 14.5 weeks
Infective status: uninfected
S. aureus colonisation: not stated
Randomised: 4 with atopic dermatitis (of 50 total)
Evaluable: 4
Interventions 0.1% halcinonide cream with 0.25% neomycin and 100000u/g nystatin vs 1% hydrocortisone
both applied three times daily for not more than 3 weeks
Category: topical steroid plus antibiotic and antifungal
Topical steroids: all participants




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "according to a code of randomisation by which the test drug was ap-
plied to the lesions on one side whether le$ or right, and the control drug to
those on the opposite side"
Fattah 1976 
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Comment: Method not described
Allocation concealment
(selection bias)





High risk Reported as "double blind", but the creams were different colours.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote: "parallel evaluations were made independently by two physicians".




Low risk Complete data present for atopic dermatitis participants
Selective reporting (re-
porting bias)
Unclear risk No trial registration provided




Methods Design: parallel group
Total study duration: 16 months
Participants Setting: secondary care, Germany
Incl: atopic dermatitis with a score of 10 or more according to the Erlangen Atopy Score, mild to moder-
ate eczema on the volar forearm, no other known dermatological disease, age 12-60 years
Excl: pregnant or lactating women, patients with a history of malignant diseases, systemic medica-
tion for atopic dermatitis 4 weeks prior to the start of the study, any other systemic medication and any
known systemic diseases
Duration of condition: not stated
Infective status: not stated
S. aureus colonisation: 38%
Age: intervention group: mean 25.4 years (range 14-47), control group: mean 25.5 years (range 13-51)
Sex: intervention group: 11 males, 8 females, control group: 9 males, 9 females
Randomised: 37
Evaluable: 37
Interventions Silver-loaded seaweed-based fibre (SeaCell® Active) as long sleeved t-shirt (n = 19) vs placebo (cotton; n
= 18) for 8 weeks
Category: therapeutic textile
Topical steroids: not stated
Outcomes 1. Skin surface pH on volar forearms at 6 and 12 weeks
Fluhr 2009 
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2. TEWL at 6 and 12 weeks
3. Capacity-based skin hydration at 6 and 12 weeks




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)





High risk Quote: "Single-blinded"
Comment: participants and personnel were not both blinded, although un-
clear who was blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk Paper stated "all data sets were complete" but bacterial colonisation was only
reported for 4 and 10 participants in the cotton and silver groups respectively.
Selective reporting (re-
porting bias)
High risk Results reported at 4 and 8 weeks and not at 6 and 12 weeks as stated




Methods Design: parallel group
Total study duration: 15 weeks
Participants Setting: secondary care, 13 centres in Germany (9), Bulgaria (3) and Finland (1)
Incl: "Dermatologist confirmed diagnosis of atopic dermatitis", mild to moderate atopic dermatitis
with IGA of 2-3 at randomisation with affected area(s) of less than or equal to 20% total BSA, current ex-
acerbation requiring "step-up" of standard treatment, over 18 years
Excl: not stated
Age: intervention group: mean 32.87 years (range 18-61), control group: mean 32.88 years (range 19-59)
Sex: intervention group: 14 males, 31 females, control group: 23 males, 25 females
Duration of condition: not stated
Infective status: not stated
Foelster Holst 2010 
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S. aureus colonisation: not stated
Randomised: 93
Evaluable: 93
Interventions Study drug SRD441 ointment (mixture of white so$ paraffin and Miglyol 812N, a medium chain triglyc-
eride, and 1 mg/g SRD441) (n = 45) vs vehicle ointment (white so$ paraffin and Miglyol 812N) (n = 48)
Layer of study drug or vehicle applied to all affected areas and commonly affected body areas up to a
maximum of 20% BSA for up to 28 days
Prohibited medication included systemic and topical steroids, antibiotics, calcineurin inhibitors, pho-
totherapy, skin exfoliation, depilatory cream and moisturisers or emollients containing antibiotics/an-
tiseptics.
Washout period one week for topicals, 8 weeks for phototherapy. Inhaled steroids were allowed as long
as dose stable and < 800 mcg/day. Unmedicated emollients and moisturisers were allowed during the
screening period and on all nontreated skin during the treatment phase.
Category: protease inhibitor
Topical steroids: rescue medication only
Outcomes Primary end point:
1. success defined as a score of 0 (clear) or 1 (almost clear) on the 6-point categorical measure IGA (0 =
clear, 1 = almost clear, 2 = mild, 3 = moderate, 4 = severe, 5 = very severe) at day 21
Secondary endpoints:
2. Time to resolution of primary (presenting) exacerbation, defined as a score of 0 or 1 in IGA
3. IGA score at day 7, 14, 21, 28
4. Change from baseline SCORAD at day 7, 14, 21, 28
5. Change from baseline total pruritus self-assessment (based on the response none/mild/moder-
ate/severe to the question 'How would you describe your pruritus over the last 24 hours?') at day 7, 14,
21, 28
6. No. of subjects requiring rescue medication
7. Change from baseline DLQI at day 7, 14, 21, 28
8. Monitoring of AEs, physical examination, clinical laboratory measures (haematology and clinical
chemistry) and change from baseline in Investigator's Visual Assessment (which records erythema,
oedema and asks the subject about additional symptoms)




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "The random code was generated using a permuted block of size 4,
with subjects randomly assigned to either vehicle ointment or SRD441 oint-
ment (1.0 mg/g) in a 1:1 ratio." "A random number seed value was used to gen-
erate the treatment order and random code within the permuted block algo-
Foelster Holst 2010  (Continued)
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rithm. Random code identifiers were random 4-digit numbers to avoid the bias
associated with sequential numbering of random code."




Low risk Quote: "The final random code block size, random code numbering sequence
and order of treatments within the blocks was blinded from investigators,
study subjects and study staL until the final clinical data base was locked and
approved by the sponsor before breaking the blind and applying the random
code for analysis."





Low risk Quote: "Double blind", "All labelling and packaging for SRD441 and vehicle as-
signments were identical."
Comment: blinding likely to have been successful
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "order of treatments within the blocks was blinded from investigators,
study subjects and study staL until the final clinical data base was locked".
Comment: investigators and study staL remained blinded until the the clinical




Low risk All subjects with missing responses including early dropouts were counted as
non-responders in the analysis on response rates. Nine subjects withdrew in
the treatment group: three had AEs, three treatment failure, two consent with-
drawn, one investigator judgement; 15 subjects in the vehicle group: seven




Unclear risk Outcomes specified very vaguely in trial registration
Other bias Unclear risk Some imbalance in atopic dermatitis intensity (51% moderate versus 60%




Methods Design: parallel group
Total study duration: 17 months
Participants Setting: primary and secondary care, 95 centres (91 primary care, 4 secondary care), United Kingdom
Incl: children (aged 3 months to < 8 years) who had eczema (UK Working Party definition) that was clini-
cally suspected of being infected
Excl: recent use of antibiotics (past week) or potent topical steroids (2 days), suspected eczema her-
peticum, significant comorbid illness, severe infection, allergy to study medication
Age: oral antibiotic group: mean 2.9 years, topical antibiotic group: mean 3.0 years, control group:
mean 3.3 years
Sex: oral antibiotic group: 18 males, 18 females, topical antibiotic group: 17 males, 20 females, control
group: 17 males, 23 females
Duration of condition: not stated
Francis 2016 
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Infective status: clinically infected
S. aureus colonisation: 70%
Randomised: 113
Evaluable: 101
Interventions Oral antibiotic (flucloxacillin four times per day for 7 days, 125 mg in 2.5 mL for children aged 3 months
to 2 years, 250 mg in 5 mL for children aged > 2 years to < 8 years) and topical placebo (n = 36) vs topi-
cal antibiotic (2% fusidic acid cream three times per day for 7 days) and oral placebo (n = 37) vs oral and
topical placebo (n = 40). All treatment groups received topical steroids (clobetasone butyrate 0.05%
cream or ointment for use on trunk/limbs and/or hydrocortisone 1% cream or ointment for use on face,
applied once daily for 14 days) and were encouraged to use emollients (not with antimicrobial agents).
Categories: oral antibiotic (flucloxacillin plus topical placebo vs oral and topical placebos) and
topical steroid plus antiseptic/antibiotic (fusidic acid plus oral placebo vs oral and topical placebos)
Topical steroids: all participants
Outcomes 1. Patient-Orientated Eczema Measure (POEM) at 2 weeks, 4 weeks and 3 months
2. Eczema Area and Severity Index (EASI) at 2 weeks, 4 weeks and 3 months
3. Family impact (Dermatitis Family Impact instrument) at 2 weeks, 4 weeks and 3 months
4. Dermatology-specific quality of life (Infants Dermatology Quality of Life instrument for children aged
3 months to < 4 years/Children's Dermatology Life Quality Index for children aged 4 years to < 8 years)
at 2 weeks, 4 weeks and 3 months
5. Heath utility (Atopic Dermatitis Quality of Life instrument) at 2 weeks, 4 weeks and 3 months
6. Daily symptoms for first 4 weeks (parent assessment of overall severity, itch, sleep disturbance, ooz-
ing or weeping, bleeding, fever and possible AEs on a scale from 0 = normal to 6 = as worse as it could
be)
7. Parental preference for oral or topical treatment at 2 weeks
8. Presence of S. aureus and beta-haemolytic streptococci on the skin and in the mouth and nose at 2
weeks and 3 months and resistance in isolates at each time point
9. AEs
Funding UK National Institute for Health Research
Notes -
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Randomisation was conducted by study pharmacists using pre-pre-
pared allocation lists using block randomisation stratified by site and peni-
cillin allergy status. Random allocation lists were prepared by the study statis-
tician and were block-randomised with randomly chosen balanced block sizes
of 6 or 9."




Low risk Quote: "To ensure allocation concealment, treatment assignment was under-
taken by each pharmacy. As patients were recruited they were assigned the
Francis 2016  (Continued)
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next vacant participant identification number. The randomisation list linked
each unique participant information number to a treatment group ... The phar-
macist selected one or two (for older children) treatment packs for the rele-
vant treatment arm based on the trial pack randomisation list. This was to en-
sure that trial pack identification numbers could not be used to identify treat-
ment allocation."





Low risk Quote: "Study medication packs were identical (with taste- and colour-
matched placebos)."
Comment: blinding was likely to have been successful.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk 12 participants (11%) were withdrawn or lost to follow-up by 2 weeks (prima-
ry end point) with a further three participants lost to follow-up by 4 weeks and




Low risk All stated outcomes from trial registration reported
Other bias High risk Baseline imbalance in severity (mean POEM: oral antibiotic group 14.6, topical
antibiotic group 16.9, control group 13.4; mean EASI: oral antibiotic group 7.3,
topical antibiotic group 9.5, control group 5.8) and presence of S. aureus (oral




Methods Design: parallel group
Total study duration: 10 months
Participants Setting: secondary care, two centres, Germany
Incl: atopic eczema (Hanifin and Rajka criteria), moderate-severe (SCORAD 20 points or more)
Excl: systemic/topical antibiotic treatment 4 weeks prior to the study period
Age: intervention group: median 17.89 years, control group: median 17.26 years
Sex: intervention group: 13 males, 22 females, control group: 6 males, 16 females
Duration of condition: not stated
Infective status: not stated
S. aureus colonisation: not stated
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Interventions Silver-coated textiles as verum (Padycare ®, consisting of micromesh material, 82% polyamide, 18%
Lycra, with woven silver filaments with a silver content of 20% in total) as all in one suits for children
and long-sleeved and long-legged clothes for adults (n = 37) vs placebo (textiles made of pure cotton of
equal size) (n = 31)
Participants were instructed to wear the study clothes daily directly on the skin over a two-week peri-
od. It was recommended to wear them during the day like underwear and at night like a pyjama. Wash-
ing and cleaning behaviours were continued as usual. The textiles could only be washed at 30°C.
Category: therapeutic textile
Topical steroids: as needed
Outcomes 1. SCORAD at week 1 and 2
2. Functionality and wearing comfort at week 1 and 2 by self-report questionnaire
3. Daily self-reported pruritus intensity during day and night
4. Daily self-reported sleep loss and frequency of waking up
5. Daily self-reported wearing comfort of the study textiles during day and night
6. Symptoms recorded on a 10-point scale
7. Additional topical or systemic treatments (except emollients)
8. Side effects




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)





Unclear risk Although stated to be "double blind", the fact that some participants were re-
ported to have dropped out "due to ... assignment to the placebo group" im-
plied that participants knew which study textiles they were wearing.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Participants were not allowed to wear study textiles during their consultation,
so investigator didn't recognise them, however it was likely that participants




High risk 11 dropouts (16.2%), of which nine were from the placebo group
Selective reporting (re-
porting bias)
High risk Functionality and wearing comfort only reported at 7 days; selective report-
ing of results from the questionnaires; the conclusions and abstract empha-
Gauger 2006  (Continued)
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sised the significant (but not randomised) difference within the silver group
over time and not the non-significant difference from placebo.





Methods Design: parallel group
Total study duration: 10 months
Participants Setting: secondary care, four centres, China
Incl: atopic dermatitis (Hanifin and Rajka criteria) or eczema (results for atopic dermatitis reported sep-
arately)
Excl: severe fungal infection, other skin diseases which might disturb the diagnosis and treatment, oth-
er severe systemic infection, pregnancy, lactation, diseases affecting immune function e.g. diabetes
mellitus, AIDS, autoimmune disease, tumours, and severe heart, liver, kidney, mental diseases, treat-
ment with systemic corticosteroids, immunosuppressive agents last four weeks, allergy to drugs in the
study, or in another study in the last four weeks
Age (all recruited participants): range 2 to 65
Sex (all recruited participants): 177 males, 150 females
Duration of condition: not stated
Infective status: not stated
S. aureus colonisation: 60%
Randomised: 337 total
Evaluable: 119 with atopic dermatitis (of 327 total)
Interventions Hydrocortisone butyrate ointment and mupirocin ointment (n = 58) vs hydrocortisone butyrate oint-
ment and vehicle ointment (n = 61) applied once daily (with 2 to 3 hours between products) for 28 days
Category: topical steroid plus antiseptic/antibiotic
Topical steroids: all participants
Outcomes 1. EASI (Eczema Area and Severity Index) score at day 7, 14, 28
2. Bacterial cultures from most severe lesion and non-lesional skin at day 7, 14, 28
3. Assessment of therapeutic effect at day 28 scored as excellent, good, fair, poor




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)
Unclear risk Not stated
Gong 2006 
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Low risk Quote: "Precautions being taken to preserve the 'blinding' of both patients
and observers. All drugs were packaged to maintain randomisation and blind-
ing. Mupirocin ointment and vehicle were identical in appearance and packag-
ing."
Comment: blinding was ensured.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Precautions being taken to preserve the 'blinding' of both patients
and observers. All drugs were packaged to maintain randomisation and blind-
ing. Mupirocin ointment and vehicle were identical in appearance and packag-
ing."




High risk 10 dropouts. Reported analyses appearrf to be per protocol only.
Selective reporting (re-
porting bias)
High risk Assessment of therapeutic effect only reported at day 28, whereas it was prob-
ably measured at day 7 and 14 as well. Positive rates of bacteria only reported
at day 7, but measured at day 14 and 28 as well.
Other bias High risk Performed subgroup analysis at end of study which were not part of the prede-
termined outcomes. Well-balanced at baseline for severity (EASI) but presence




Methods Design: parallel group
Total study duration: not stated
Participants Setting: secondary care, three centres, US
Incl: moderate-severe atopic dermatitis (modified Hanifin and Rajka criteria (Eichenfield 2003)), age 3
months to 5 years
Excl: concurrent inflammatory skin disorders, currently using or had used systemic/topical antibiotics,
corticosteroids or calcineurin inhibitors for atopic dermatitis in the prior 2 weeks, overt infection
Age: intervention group: mean 22 months (range 4.5-60), control group: mean 5.4 months (range 3-14)
Sex: intervention group: 4 males, 5 females, control group: 7 males, 2 females
Duration of condition: not stated
Infective status: uninfected
S. aureus colonisation: 57%
Randomised: 21
Evaluable: 18
Interventions Bleach bath (bottle of bleach to be diluted with bath water 2 x /week to achieve a 0.005% sodium
hypochlorite concentration) plus topical corticosteroid (n = 10) vs placebo (bottle of water) plus topical
corticosteroid (n = 11)
Category: antibacterial bath additive
Topical steroids: all participants
Gonzalez 2016 
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Outcomes 1. Bacterial densities by high throughput DNA sequencing and quantitative PCR for total bacteria,
Streptococcus, Staphylococcus, S. aureus, Corynebacterium, Propionibacterium (all outcomes reported
at week 0 and week 4)
Bacterial diversity scores
Microbial community composition
Relative abundance of major phyla
Area under the curve plots of differentiating taxa and differentiating genera with more than 1% abun-
dance
All participants with atopic dermatitis had 4 clinical sites swabbed including the worst affected area,




4. Local EASI at worst lesion
5. Patient-reported treatment use
Funding "Dr Gonzalez was supported in part by a gi$ from the Bohnert Foundation"..."Supported in part by UH2
AR057506 and New York University Clinical and Translational Science Awards grant UL1 TR000038 from




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Treatment randomisation was done by 2 independent nonclinical
staL members. One person made 12 sealed envelopes containing the word
"bleach" and 12 identical sealed envelopes containing the word "water,"
which were then shuffled and numbered sequentially. The envelopes were
opened in number order and plain white bottles were filled with the corre-
sponding ingredient, bleach or water, and then labelled with the correspond-
ing number."




Low risk Quote: "Treatment randomisation was done by 2 independent nonclinical
staL members. One person made 12 sealed envelopes containing the word
"bleach" and 12 identical sealed envelopes containing the word "water,"
which were then shuffled and numbered sequentially. The envelopes were
opened in number order and plain white bottles were filled with the corre-
sponding ingredient, bleach or water, and then labelled with the correspond-
ing number."





High risk Bleach and water were put into plain white sequentially numbered bottles,
however it is likely that the participants would have smelled the bleach.
Gonzalez 2016  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote: "Investigators, data analysts, and sequencers were blinded to treat-
ment until unblinding was necessary for comparative data analysis after the
experiment ended."
Comment: Low risk for objective microbiological assessments; Unclear for IGA





Unclear risk 3 out of 21 participants with atopic dermatitis didn't complete the study be-
cause they moved out of the state or did not return for examination. When




Unclear risk No trial registration provided
Other bias High risk Groups were well-balanced at baseline for colonisation density of S. aureus






Total study duration: not stated
Participants Setting: secondary care, single centre, UK
Incl: atopic eczema displaying features of recurrent infection and/or frequent exacerbations, attending
paediatric dermatology clinic, > six months old
Excl: systemic or topical antibiotics or systemic steroids within two weeks of study
Age: mean 4.5 years (range 1 to 9)
Sex: 9 males, 17 females
Duration of condition: 19 participants onset at age < 1 year
Infective status: mixed
S. aureus colonisation: not stated
Randomised: 30
Evaluable: 26
Interventions Oilatum Plus vs Oilatum
15 mL in an 8-inch bath of water, soak for 10 to 15 minutes daily for 4 weeks
Category: antibacterial bath additive
Topical steroids: as needed
Outcomes 1. Area affected, severity of signs and symptoms and total score (based on Costa 1989) at weeks 2 and 4
2. Global Impression Scale (not ill at all, borderline ill, mildly ill, moderately ill, severely ill, extremely ill)
at weeks 2 and 4
3. Global Change Scale (much worse, minimally worse, no change, minimally improved, much im-
proved, very much improved) at weeks 2 and 4
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Notes -
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "The order in which the 2 preparations were used was determined by a
computer generated random code."
Comment: randomisation method was sufficient.
Allocation concealment
(selection bias)





Unclear risk Quote: "Double-blind"
Comment: but no further information given
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote: "Double-blind"




Unclear risk Four participants dropped out: two for unrelated reasons, one side effect of
Oilatum plus and one because of deterioration of eczema while using the Oila-
tum emollient. Three participants did not adhere to the washout period, so
"the data generated during the second treatment phase by the patient with no
washout was excluded from the analysis."
Selective reporting (re-
porting bias)
High risk Subjective outcomes only reported as 'not significant' and results not shown.
Other bias High risk Statistical comparisons only reported as significant differences from baseline





Methods Design: within-patient study (le$/right comparison)
Total study duration: unknown
Participants Setting: secondary care, single centre, Japan
Incl: mild to moderate atopic dermatitis with similar eczema in bilateral elbow fossae
Excl: Skin infection showing pus on exudate
Age: 12 to 29
Sex: 3 males, 12 females





Interventions Povidone iodine 10% vs unspecified placebo
Hizawa 1998 
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Applied twice daily for one week
Category: topical antiseptic/antibiotic
Topical steroids: not stated
Outcomes 1. Physicians' and patients' assessments of symptoms rated on visual analogue scale (0-100)
2. Patients' assessment of itch rated on visual analogue scale (0-100)
3. Colony counts of S. aureus from elbow lesions
Funding Unknown
Notes Paper kindly reviewed by Dr Yukihiro Ohya and risk of bias kindly completed by Prof Masaki Futamura
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Drawing lots"
Comment: no further information given
Allocation concealment
(selection bias)





High risk The intervention treatment was applied on participant’s right or le$ side, and
no treatment on the opposite side. Participants would know the intervention
side.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Unclear risk Doctor evaluation was analysed with the data from 15 participants (all partic-
ipants). However patient evaluation was analysed with data from 13 partici-
pants. Authors did not mention it, but was shown on a figure.
Selective reporting (re-
porting bias)
Unclear risk Trial not prospectively registered
Other bias High risk Statistical comparisons only reported as significant differences from baseline
within groups and not between groups. Groups appeared balanced at baseline





Methods Design: within-patient study (le$/right comparison)
Total study duration: not stated
Participants Setting: secondary care, three centres, Denmark
Incl: patients presenting to a dermatology clinic with fairly symmetrically located, steroid-responding
dermatoses (results for atopic dermatitis reported separately)
Excl: age < 2 years, pregnancy
Age (all recruited participants): 26 children, median 9 years (range 1-15), and 55 adults, median age 23
years (range 16-78)
Hjorth 1985 
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Sex (all recruited participants): 26 males, 55 females
Duration of condition: not reported
Infective status: not stated
S. aureus colonisation: not stated
Randomised: 60 with atopic dermatitis (of 81 total)
Evaluable: 60
Interventions 0.1% betamethasone 17-valerate (Betnovate) plus 2% microcrystalline fusidic acid (Fucibet) vs 0.1%
betamethasone 17-valerate
Applied twice daily for seven days
Category: topical steroid plus antiseptic/antibiotic
Topical steroids: all participants
Outcomes 1. Global degree of improvement (cleared, improved, unchanged, worse) at 1 week
2. Change from baseline in symptom score at 1 week
3. Investigator preference for treatment at 1 week
4. AEs
5. Sensitivity to fusidic acid
6. Isolation rate of S. aureus




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)





Low risk Quote: "The test preparations were supplied in tubes of identically looking
cream containing either 0.1% betamethasone 17-valerate or a combination of
this with 2% microcrystalline fusidic acid".
Comment: low risk of performance bias
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote: "Double-blind"




Low risk No dropouts
Selective reporting (re-
porting bias)
High risk Only P values shown for clinical scores, no details given
Hjorth 1985  (Continued)
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Methods Design: parallel group
Total study duration: not stated
Participants Setting: secondary care, single centre, UK
Incl: moderate or severe atopic eczema with S. aureus present on skin
Excl: use of bath emollients, antiseptic bath additives or medicated soaps in past 2 weeks, systemic or
topical antibacterials or oral steroids in past month
Age: mean 17.3 years (range 4-34)
Sex: 6 males, 9 females
Duration of condition: not stated
Infective status: not stated
S. aureus colonisation: 100%
Randomised: 15
Evaluable: 15
Interventions Oilatum Plus (containing triclosan and benzalkonium chloride) (n = 7) vs Oilatum (n = 8)
15 mL in 8 inches of water from 10 to15 min soak daily for 4 weeks
Category: antibacterial bath additive
Topical steroids: not stated
Outcomes 1. Clinical score from summation of symptom score and area of lesions (based on Staughton 1984)
2. Colonisation density of Micrococcaceae and S. aureus (William & Kligman scrub method) on non-le-




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)





Unclear risk Quote: "Double-blind"
Comment: unclear who was blinded and how it was achieved
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote: "Double-blind"
Comment: unclear who was blinded and how it was achieved
Holland 1995 
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High risk Quote: "those patients receiving Oilatum Emollient decreased from eight to
five and eight to three on the third and fourth visits, possibly indicating their
dissatisfaction with the treatment. This did not occur with patients receiving
the more effective Oilatum Plus treatment."
Comment: high attrition rates
Selective reporting (re-
porting bias)
High risk Results for clinical score only reported as P values
Other bias Low risk Well-balanced at baseline for severity (non-standard clinical score) and coloni-





Total study duration: 24 months
Participants Setting: secondary care, single centre, Hong Kong
Incl: atopic dermatitis (Hanifin and Rajka criteria), moderate-severe (by SCORAD), previous S. aureus
colonisation
Excl: current or recent use (within past 4 weeks) of oral antibiotics, intercurrent illness for two weeks
prior to study, coexisting skin diseases
Age: mean 12.1 years (range 4-18)
Sex: 23 males, 17 females
Duration of condition: not stated
Infective status: unspecified
S. aureus colonisation: 90%
Randomised: 40
Evaluable: 40
Interventions Bleach bath (0.005% sodium hypochlorite) vs placebo (water). Participants were instructed to bathe for
10 minutes 2-3 times per week. Four weeks treatment period, four weeks washout, four weeks cross-
over treatment
Category: antibacterial bath additive
Topical steroids: rescue medication only
Outcomes 1. Change from baseline in presence of S. aureus at right antecubital fossa and most severely infected
or eczematous lesion at end of each treatment period
2. Change from baseline in SCORAD and objective SCORAD at end of each treatment period
3. S. aureus antimicrobial resistance patterns
4. Change from baseline in skin hydration and TEWL at end of each treatment period
5. Change from baseline in blood markers (white blood cell, eosinophil, total IgE and specific IgE
against staphylococcal enterotoxin A and staphylococcal enterotoxin B) at end of each treatment peri-
od
6. Change from baseline in topical steroid usage during each treatment period
7. Change from baseline in Children Dermatology Life Quality Index (CDLQI) at end of each treatment
period
Hon 2016 
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8. Global acceptability of treatment
9. AEs
Funding The Chinese University of Hong Kong
Notes -
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Patients were assigned randomly through computerized randomisa-
tion (sealed envelope using numbers) generated by a research staL (not in-
volved in the clinical management and patient assessment), to the treatment
or placebo study arm".
Comment: method was unlikely to introduce selection bias.
Allocation concealment
(selection bias)
Low risk Quote: "Patients were assigned randomly through computerized randomisa-
tion (sealed envelope using numbers) generated by a research staL (not in-
volved in the clinical management and patient assessment), to the treatment
or placebo study arm".





Low risk Quote: "Bleach and water with patient identification numbers were dispensed
in identical opaque bottles with the same brand-name labels. Investigators
were blinded to the contents of the bottles. Dispensing of these items sequen-
tially, according to patient identification numbers will be performed by a re-
search assistant in a separate room from the principal investigator who as-
sesses the patients. Neither patients nor clinicians knew the patients’ assigned
study arm. These bottles were brown plastic bottles and the selected dilution
was pretested by the pharmacist so that the colour and odour was similar.
However, patients and/or family members might differentiate the pure bleach
container from the water container on the basis of odour and were instructed
at the beginning not to disclose their suspicions to the investigators. Bathing
in the dilute bleach baths was not associated with any odour of bleach, and in-
vestigators were not able to distinguish study arms during examinations."
Comment: blinding was achieved.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk One participant did not complete global acceptability of treatment. Blood




High risk Colony counts and resistance only reported as non-significant. All other out-
comes reported in full




Methods Design: parallel group
Huang 2009 
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Total study duration: 24 months
Participants Setting: secondary care, single centre, US
Incl: moderate-severe atopic dermatitis as determined with the IGA, signs of bacterial skin infection
(weeping, crusting and/or pustules)
Excl: current/recent use/within the past 8 weeks of topical or oral antibiotic preparations and allergy to
cephalosporins or mupirocin
Age: intervention group: mean 8.0 years (range 2.1-17.3), control group: mean 6.3 years (range 0.7-15.7)
Sex: intervention group: 7 males, 8 females, control group: 8 males, 8 females
Duration of condition: not stated
Infective status: clinically infected
S. aureus colonisation: 87%
Randomised: 31
Evaluable: 25
Interventions Bleach and mupirocin (n = 15) vs water and placebo ointment (n = 16). 0.5 cup of 6% bleach (final con-
centration 0.005%) or water in a full bathtub (40 gallons) of water. Amount of administered bleach so-
lution/water adjusted by the family on the basis of the bath tub size and estimated height of bath tub
water. Participants were instructed to bathe in the dilute bleach bath or placebo for 5-10 minutes twice
weekly. Participants and their household members were instructed to apply mupirocin ointment (Cen-
tany (OrthoNeutrogena, Skillman, NJ)) (treatment group) or petrolatum (control group) intranasally for
twice daily for five consecutive days of each month. Continued for 3 months
Category: antibacterial bath additive plus antibiotic
Topical steroids: as needed
Outcomes 1. EASI at 1 and 3 months
2. Proportion of BSA affected at 1 and 3 months
3. IGA score (clear = 0, almost clear = 1, mild = 2, moderate = 3, severe = 4, very severe = 5) at 1 month
and 3 months
4. Before intervention qualitative bacterial cultures of the nares and the worst overtly infected lesions
were obtained. At 1-3 months after initiation of treatment, swabs of the nares and the most severely in-
fected eczematous lesions were obtained again. Antibiotic discs tested resistance to amoxicillin, amox-
icillin-clavulanate, oxacillin, cephalosporin, trimethoprim-sulphamethoxazole, erythromycin, clar-
ithromycin, mupirocin.
5. AEs
Funding Society for Pediatric Dermatology; Centany ointment, placebo ointment and partial funding for bacteri-
al cultures were provided by OrthoNeutrogena.
Notes -
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Patients were assigned randomly, through block randomisation gen-
erated by the statistician, to the treatment or placebo study arm."
Huang 2009  (Continued)
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Comment: randomisation method unlikely to introduce selection bias.
Allocation concealment
(selection bias)
Low risk Quote: "Investigators were blinded to the contents of the bottles and jars and
dispensed these items sequentially, according to patient identification num-
bers."





High risk Quote: "Mupirocin and petrolatum ointment were dispensed in identical white
jars, labelled with the patient identification numbers... Bleach and water with
patient identification numbers were dispensed in identical bleach bottles with
the same brand name labels... Neither patients nor clinicians knew the pa-
tients' assigned study arm. However, patients and/or family members were
able to differentiate the pure bleach container from the water container on the
basis of odor and were instructed at the beginning not to disclose their suspi-
cions to the investigators."
Comment: unlikely that blinding was achieved
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote: "patients and/or family members were able to differentiate the pure
bleach container from the water container on the basis of odor and were in-
structed at the beginning not to disclose their suspicions to the investigators.
Bathing in the dilute bleach baths was not associated with an odor of bleach,
and investigators were not able to distinguish study arms during examina-
tions."




High risk ITT analysis, but six participants in treatment group and three in placebo
group either lost to follow-up or withdrew consent
Selective reporting (re-
porting bias)
High risk Primary outcome measures in trial registration changed following completion
of the trial.
Other bias High risk Groups were well-balanced at baseline for presence of S. aureus but there was





Methods Design: parallel group (2 x 2 factorial)
Total study duration: 1 year
Participants Setting: secondary care, single centre, Taiwan
Incl: atopic dermatitis (Hanifin and Rajka criteria), moderate to severe at the time of entry (Rajka and
Langeland criteria)
Excl: systemic or topical antibiotics, systemic or topical steroid use within 4 weeks, overt secondary in-
fection requiring oral antibiotic treatment
Age: steroid group: mean 17.4 years, steroid + fusidic acid group: mean 12.9 years, tacrolimus group:
mean 15.4 years, tacrolimus + fusidic acid: mean 16.9 years
Sex: steroid group: 4 males, 11 females, steroid + fusidic acid group: 8 males, 7 females, tacrolimus
group: 8 males, 7 females, tacrolimus + fusidic acid group: 6 males, 9 females
Hung 2007 
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Duration of condition: not stated
Infective status: uninfected
S. aureus colonisation: 75%
Randomised: 60
Evaluable: 54
Interventions 0.05% fluticasone propionate cream (Cutivate) (n = 15) vs 0.05% fluticasone propionate cream with
2% fusidic acid cream (Fucidin) (n = 15) vs 0.03% tacrolimus ointment (Protopic) (n = 15) vs 0.03%
tacrolimus ointment with 2% fusidic acid cream (n = 15) applied twice daily for 8 weeks. Fusidic acid
cream was applied first followed by fluticasone or tacrolimus 20 minutes later without occlusive dress-
ings. Oral antihistamine was given to all participants.
Categories: topical steroid plus antibiotic (steroid plus fusidic acid vs steroid) and topical calcineurin in-
hibitor plus antibiotic (tacrolimus plus fusidic acid vs tacrolimus)
Topical steroids: all participants (steroid plus fusidic acid vs steroid)/none (tacrolimus plus fusidic acid
vs tacrolimus)
Outcomes 1. SCORAD at 2 and 8 weeks
2. Local clinical severity of atopic dermatitis at 2 and 8 weeks, evaluated using modified local SCORAD
of 6 intensity items (1. erythema/darkening, 2. oedema/papulation, 3. oozing/crusts, 4. excoriation, 5.
lichenification/prurigo and 6. local dryness) graded on a 4 point scale (0 = absent, 1 = mild, 2 = moder-
ate, 3 = severe) to give a total score from 0-18
3. Proportion of BSA affected at 2 and 8 weeks
4. Pruritus and sleep loss score at 2 and 8 weeks






Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)





High risk Participants not blinded
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Clinical assessment not blinded so high risk, but bacteriology studies blinded
so low risk - hence unclear overall
Hung 2007  (Continued)
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Unclear risk 54/60 participants completed the study; two participants receiving tacrolimus
with fusidic acid dropped out of the treatment protocol because of intolerance
to a burning sensation. Two participants receiving tacrolimus only and anoth-
er two receiving fluticasone only dropped out of the treatment protocol be-




High risk Local SCORAD only reported at baseline
Other bias Low risk Well-balanced at baseline for severity (SCORAD) and presence and colonisa-




Methods Design: parallel group
Total study duration: 8 months
Participants Setting: single centre, Germany
Incl: "acute" atopic dermatitis, age > 2 years
Excl: acute viral infection, acute "staphyloderma", other skin disease that could influence evaluation,
UV treatment, topical or systemic immunosuppressive or immunomodulating treatment, topical or
systemic antibiotics, severe generalised disease, pregnancy, female not on contraception, allergy to sil-
ver
Age: silver textile group: median 21 years, silver-free textile group: median 25.5 years
Sex: silver textile group: 6 males, 4 females, silver-free textile group: 3 males, 7 females
Duration of condition: silver textile group: 20.5 years, silver-free textile group: 25.5 years
Infective status: uninfected
S. aureus colonisation: not stated
Randomised: 30
Evaluable: 30
Interventions Long-sleeved undershirt and long underpants with silver thread (n = 10) vs identical garment with poly-
ester thread (n = 10) vs prednicarbate 0.25% ointment (n = 10) for 14 days (only comparison of silver
textile versus silver-free textile eligible for this review)
Category: therapeutic textile
Topical steroids: as needed
Outcomes 1. Patient/carer global rating of "overall disease control" at day 14 on scale from 0 (controlled) to 3 (not
controlled)
2. Change from baseline SCORAD at day 3, 7, 14
3. Patient/carer rating of severity of pruritus at day 3, 7, 14 on scale from 0 (no itching/scratching) to 3
(bothersome itching/scratching that interfered with sleep)
3. Colonisation density of bacteria at day 14
4. AEs (patient/carer-reported)
Funding Julius Zorn GmbH
Notes Participants were allowed to use as much prednicarbate ointment as they wished; those in the silver
textile group used almost as much as those in the prednicarbate group whereas those in the non-silver
group barely used any.
Juenger 2006 
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Did not provide adequate data for primary outcomes for this review. Outcomes beyond 14 days not in-
cluded as participants in all three groups wore silver textile garments from day 15-28
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "The 30 study patients were assigned to one of three groups on the ba-
sis of a randomisation list...generated by an independent biometrician before
recruiting".
Comment: low risk of selection bias
Allocation concealment
(selection bias)





High risk Quote: "Silver and silver-free garments (each set consisting of one long-armed
undershirt and one pair of long underpants) were identical with respect to ap-
pearance and wearing comfort."
Comment: Silver and silver-free garments were similar, however the steroid
group had no garment and there was no indication that clinicians were blind-
ed.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Quote: "All patients randomised and enrolled in the study completed the en-
tire course of the study; there were no drop outs."
Comment: low risk of attrition bias due to no dropouts
Selective reporting (re-
porting bias)
Unclear risk No trial registration provided
Other bias High risk Large baseline imbalance in severity (mean SCORAD: silver textile group 72.7,




Methods Design: within-patient study (le$/right comparison)
Total study duration: 3 months
Participants Design: secondary care, single centre, Austria
Incl: children with mild to moderate atopic dermatitis (Hanifin and Rajka criteria)
Excl: topical or systemic anti-inflammatory agents
Age: mean 8.1 years (range 5-12)
Sex: 11 males, 11 females
Duration of condition: not stated
Infective status: not stated
Koller 2007 
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S. aureus colonisation: not stated
Randomised: 22
Evaluable: 22
Interventions Dermasilk® (sericin-free silk treated with AEGIS AEM5772/5) for 12 weeks vs simple silk fabric (sericin-
free silk without AEGIS AEM5772/5) for 2 weeks followed by cotton for 10 weeks
Participants received 3 different 'arm tubes'. "For the first 2 wk of the study, parents were advised to
dress one arm of their children with simple silk fabric and the other one with the Dermasilk® fabric. Af-
ter 2 wk - throughout the rest of the study - one arm had to be covered with the cotton and the other
with the Dermasilk® tube."
Category: therapeutic textile
Topical steroids: none
Outcomes 1. Intensity score and subjective symptom score from SCORAD at week 2, 4, 8, 12
Funding Menzl GesmbH provided cotton, silk and Dermasilk®.
Notes -
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "The patients were randomised by age group and by disease severity."
Comment: randomisation method was not described.
Allocation concealment
(selection bias)





High risk No indication that parents or investigators were blinded, other than for out-
come assessment
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote: "The investigator performing the clinical examination did not know
which arm had been covered by Dermasilk®. Clinical evaluations were carried
out by the same medical blinded doctor."





Low risk All participants accounted for
Selective reporting (re-
porting bias)
Unclear risk No trial registration provided
Other bias Unclear risk Well-balanced at baseline for severity (SCORAD intensity and subjective
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Methods Design: parallel group
Total study duration: not stated
Participants Setting: secondary care, six centres, Germany
Incl: atopic eczema suggestive of heavy S. aureus colonisation with > 106 CFU/cm2
Excl: age < 12 (though < 18 subsequently excluded from analysis), infection requiring antibiotics, other
severe disease, pregnant, antibiotics last 48 h
Age: not stated
Sex: 54 males, 89 females (not reported for final 117 eligible participants)
Duration of condition: not stated
Infective status: not stated
S. aureus colonisation: 100%
Randomised: unclear (180 "enrolled and diagnosed as cases of atopic eczema" but implied not all of
these met inclusion criteria and 143 "recruited")
Evaluable: unclear (numbers included varied from 81 to 114 across outcome measures; 26 randomised
participants appeared to have been excluded - 18 that did not meet the microbiological inclusion crite-
rion and eight aged less than 18 years)
Interventions Prednicarbate 0.25% cream plus didecyldimethylammonium chloride 0.25% vs prednicarbate 0.25%
cream applied twice daily for 5 days
Category: topical steroid plus antiseptic/antibiotic
Topical steroids: all participants
Outcomes 1. Clinician assessments of efficacy, aesthetic acceptability and tolerability at day 6 (ratings were made
on a scale from 1 = excellent to 4 = poor, but results reported only as % "efficacious" with no indication
of cut-point used)
2. Clinical score (10 clinical parameters rated from 1 = none to 5 = very severe) at day 6, 20, 34
3. Colonisation density of S. aureus at day 6 and 34 and number exceeding 106 CFU/cm2





Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)





Low risk Quote: "Double-blind" identical preparation. "The preparations were supplied
in a blind coded fashion."
Comment: blinding was likely to have been successful.
Korting 1994 
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Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk Very large number of post-randomisation exclusions/loss to follow-up. Rea-
sons not reported by treatment group
Selective reporting (re-
porting bias)
Unclear risk No trial registration provided
Other bias High risk Inclusion criteria changed after recruitment to exclude participants aged < 18
years. Well-balanced at baseline for severity (non-standard clinical score) and




Methods Design: parallel group
Total study duration: not stated
Participants Setting: secondary care, single centre, Australia
Incl: Patients aged between 6 months and 18 years with moderate to severe atopic eczema (SCORAD >




Duration of condition: not stated
Infective status: not stated
S. aureus colonisation: not stated
Randomised: 19
Evaluable: 19
Interventions Bleach bath (sodium hypochlorite 0.005%) three times per week vs bath emollient (bath oil containing
liquid paraffin 95% volume per volume). All participants received a course of oral antibiotics.
Category: antibacterial bath additive
Topical steroids: not stated
Outcomes 1. SCORAD at 4 and 12 weeks
2. eradication of S. aureus at 4 and 12 weeks
3. use of systemic antibiotics at 4 and 12 weeks
4. tolerability of bleach baths at 4 and 12 weeks
Funding Royal Children's Hospital, Melbourne
Leins 2013 
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Notes Only published as abstract. Copy of conference poster obtained from corresponding author
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No information provided in conference poster
Allocation concealment
(selection bias)





High risk 'Single blinded'
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk "Eczema severity was measured using the SCORAD index by a dermatology





Unclear risk Conference poster was based on 19 participants that completed follow-up. It
was unclear whether these were all the participants randomised. The trial reg-
istration indicated a total sample size of 74 participants. Correspondence with
the author indicated that the conference poster reported 'pilot data'.
Selective reporting (re-
porting bias)
Unclear risk Only results from the 12-week follow-up were reported. The trial registration
indicated additional follow-up at 24 weeks.





Total study duration: not stated
Participants Setting: secondary care, single centre, Italy
Incl: children with atopic dermatitis (Hanifin and Rajka criteria)
Excl: systemic treatment in the previous 2 weeks, presence of malignancy, presence or recurrence of
skin infection or other dermatoses/inability to cooperate
Age: mean 4.2 years (range 6 months-14 years)
Sex: 24 males, 14 females
Duration of condition: not stated
Infective status: uninfected
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Interventions During the first week: no use of topical or systemic drug; then from day 8 onwards: intervention 1% ery-
thromycin (Sigma-Aldrich S.r.l., Milano) in white Vaseline on whole skin surface twice daily from day 8
to day 21 and Vaseline from day 22 to 35 vs Vaseline from day 8 to 21 on whole skin surface twice daily
and erythromycin from day 22 to 35
Category: topical antiseptic/antibiotic
Topical steroids: none
Outcomes 1. SCORAD at day 8, 21, 35
2. Bacterial colonisation of lesional/non-lesional skin by culture at day 35
3. Safety and tolerability: all participants patch tested at the beginning and end
Funding Not stated
Notes Dr Nadia Terrazzini assisted with data extraction.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Correspondence with authors:
"This is the method we used to generate the two groups stratified for sex and
age:
1. Age and sex of patients were recorded in a word excel sheet in which patients
were anonymized
2. Patients were ordered by age
3. Four classes were identified by age range:
I: 0.5 to 3 years
II: 4 to 7 years
III: 8 to 11 years
IV: 12 to 14 years.
1. Two subclasses were identified by sex in each age class: male and female
2. Each subject in the sex subclass was sequentially enumerated (1…2…3…
4…)
3. Pare [even] numbers were assigned to group B and spare [odd] numbers were
assigned to group A."
Further correspondence clarified: "I confirm that subjects were randomly dis-
tributed before enumeration."
Comment: The patients were randomised into two groups stratified by sex and
age: the method was unlikely to introduce selection bias.
Allocation concealment
(selection bias)





Low risk Correspondence with authors: "Patients and SCORAD evaluator were blind."
Comment: blinding was done.
Lembo 2011  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Correspondence with authors: "Patients and SCORAD evaluator were blind."




High risk Only 50% of participants completed the study.
Selective reporting (re-
porting bias)
Unclear risk No trial registration provided






Total study duration: not stated
Participants Setting: secondary care, single centre, UK
Incl: atopic dermatitis, age > 2 years
Excl: potent topical steroids, topical or systemic antibiotics during past 4 weeks
Age: mupirocin/placebo group: mean 22.4 years (range 2-52), placebo/mupirocin group: mean 20.4
years (range 2 -56)
Sex: mupirocin/placebo group: 12 males, 12 females, placebo/mupirocin group: 12 males, 9 females
Duration of condition: not stated
Infective status: not stated
S. aureus colonisation: 89%
Randomised: 49
Evaluable: 45
Interventions 2% mupirocin ointment followed by placebo (polyethylene glycol ointment) or vice-versa applied once
daily for two weeks. All participants received 0.05% clobetasol butyrate ointment applied twice daily
during the two-week pre-trial period and once daily while using mupirocin/placebo.
Category: topical steroid plus antiseptic/antibiotic
Topical steroids: all participants
Outcomes 1. Clinical severity score (six features assessed at 16 body sites on a scale of 0-3) at end of each 2-week
treatment
2. Percentage BSA affected at end of each 2-week treatment period
3. Participants' subjective assessment of itch, sleep disturbance and appearance of skin on a 5-point
scale (much better, better, same, worse, much worse) during each 2-week treatment period
3. Isolation rates of S. aureus at worst affected site and control site at end of each 2-week treatment pe-
riod
4. Emergence of resistant organisms
5. AEs
Funding Beecham Pharmaceutical Co supplied mupirocin and placebo and assisted with statistical analysis.
Notes -
Lever 1988 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Patients were randomly allocated to receive placebo first or mupirocin
first".
Comment: randomisation method was not described.
Allocation concealment
(selection bias)





Unclear risk No mention of appearance of formulations
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Observers were blind as to the topical preparation used and the bacte-
riological findings".
"Bacteriological results were scored blind by the same bacteriologist".




Unclear risk Four participants dropped out.
Selective reporting (re-
porting bias)
Unclear risk No trial registration provided
Other bias High risk No washout period between treatments. Well-balanced at baseline for pres-





Methods Design: parallel group
Total study duration: not stated
Participants Setting: secondary care, single centre, USA
Incl: unclear ("typical but rather severe atopic dermatitis")
Excl: use of antibacterial soaps or receipt of antibiotic therapy in previous month
Age: not stated ("mainly children")
Sex: not stated
Duration of condition: not stated
Infective status: not stated
S. aureus colonisation: 100%
Randomised: 36
Evaluable: 36
Interventions Fluocinolone acetonide plus 0.5% neomycin sulphate (Neo-Synalar) cream (n = 15) vs fluocinolone ace-
tonide (Synalar) cream (n = 21) applied twice daily for one week
Category: topical steroid plus antiseptic/antibiotic
Leyden 1977 
Interventions to reduce Staphylococcus aureus in the management of eczema (Review)









Cochrane Database of Systematic Reviews
Topical steroids: all participants
Outcomes 1. Improvement in pruritus, erythema, lichenification, oozing and crusting, scaling (scored 0-3, then
graded % reduction in total score from baseline as 75% or greater = excellent, 50-75% = good, 25-50% =
fair, 0-25% = poor) at 1 week
2. Change in isolation rate of S. aureus at 1 week
3. Change in bacterial counts of S. aureus at 1 week
Funding Not stated
Notes Two studies were reported in this paper. Only study I was included as study II did not have proper con-
trols.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "36 patients were randomly assigned".
Comment: randomisation method was not described.
Allocation concealment
(selection bias)





Unclear risk Quote: "Double-blind"
Comment: but method not stated
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote: "Double-blind"




Low risk All participants accounted for
Selective reporting (re-
porting bias)
Unclear risk Not all information for the different clinical parameters reported but not clear
as to what extent this biased the results. No trial registration provided
Other bias High risk Baseline imbalance in colonisation density of S. aureus (mean 420,000/cm2




Methods Design: parallel group
Total study duration: 7 months
Participants Setting: secondary care, single centre, Portugal
Incl: atopic dermatitis; age older than 12 years
Excl: severe skin disease other than atopic dermatitis; secondary infections; major systemic diseases;
women who were pregnant; subjects unable to comply with study and follow-up procedures
Age: intervention group: median 23 years, control group: median 26 years
Sex: intervention group: 20 males, 23 females, control group: 14 males, 21 females
Duration of condition: intervention group: median 18 years, control group: median 12 years
Lopes 2015 
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Infective status: uninfected
S. aureus colonisation: 61%
Randomised: 78
Evaluable: 69
Interventions Cotton pyjamas coated with chitosan (ChitoClear CG-800) (n = 43) vs uncoated cotton pyjamas (n = 35).
Pyjamas consisted of long-sleeved top and long pants to be worn at night for the duration of the study
(2-week run-in period and 8-week intervention period)
Category: therapeutic textile
Topical steroids: rescue medication only
Outcomes 1. Mean relative and absolute change in SCORAD at 8 weeks
2. Number of participants with a minimal clinically important difference in SCORAD at 8 weeks
3. Mean change in DLQI (or CDLQI if aged less than 16 years) at 8 weeks
4. Changes in daily pruritus and sleep loss scores at 8 weeks
5. Need for rescue medication
6. Number of flares
7. Number of totally controlled weeks and well controlled weeks
8. Number and severity of AEs




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Subjects were randomly assigned ... through computer-generated ran-
dom numbers."
Comment: randomisation method unlikely to introduce selection bias
Allocation concealment
(selection bias)
Low risk Quote: "The randomisation was performed by an independent researcher; the
randomisation table and intervention codes were kept by the independent re-
searcher in an opaque sealed envelope up to completion of data analysis. A
study nurse established phone contact with the independent researcher, who
informed the nurse which treatment package was to be assigned to which pa-
tient."





Low risk Quote: "Both pyjamas were made of 100% organic cotton, without dyes or
preservatives and were visually indistinguishable from each other."
Comment: blinding likely achieved
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk No indication that blinding was inadequate
Lopes 2015  (Continued)
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Unclear risk Approx 10% were lost to follow-up, reasons were unclear.
Selective reporting (re-
porting bias)
High risk The trial registration listed a number of immunological serum markers that
were not reported. Quality of life was a co-primary outcome in the trial regis-
tration but listed as a secondary outcome in the paper. Additional outcomes of
totally controlled weeks and well-controlled weeks were included in the paper
but not in the trial registration.





Methods Design: within-patient study (le$/right comparison)
Total study duration: not stated
Participants Setting: single centre, Japan
Incl: volunteers with atopic dermatitis of mild to moderate severity on their arms
Excl: none stated
Age: mean 29.8 years
Sex: 7 males, 10 females
Duration of condition: not stated
Infective status: not stated
S. aureus colonisation: not stated
Randomised: 17
Evaluable: 17
Interventions FX cream (0.2% farnesol + 5% xylitol) vs placebo cream (identical in appearance) for 7 days. Frequency
not stated
Category: topical antiseptic/antibiotic
Topical steroids: not stated
Outcomes 1. Scores of dryness, scaling, excoriation, redness and papules at day 7 (scoring system not described)
2. Colonisation density of S. aureus (stamp bottle method) and ratio of S. aureus to total number of aer-
obic skin microflora at day 7




Bias Authors' judgement Support for judgement
Masako 2005b 
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Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)





Low risk Quote: "no difference between [FX cream and placebo cream] in colour or tex-
ture"
Comment: blinding likely achieved
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Evaluation of skin microflora was performed by a single biologist who
was blinded to care allocation".




Low risk All participants accounted for
Selective reporting (re-
porting bias)
High risk Incomplete reporting of clinical outcomes (dryness and scaling reported as
significance only; excoriation, redness and papules not reported)





Methods Design: parallel group
Total study duration: not stated
Participants Setting: secondary care, single centre, Sweden
Incl: moderate-severe atopic dermatitis (Hanifin and Rajka criteria)
Excl: topical or oral antibiotics or topical corticosteroids in previous 2 weeks, skin infection requiring
oral antibiotics
Age (for all participants, including 40 with mild-moderate atopic dermatitis): median 13 years (range
2-58)
Sex (for all participants): 30 males, 40 females
Duration of condition: not stated
Infective status: uninfected
S. aureus colonisation: 93%
Randomised: 30
Evaluable: 28
Interventions Betamethasone plus neomycin cream applied to all affected areas except face twice daily for one week
then once daily for one week (n = 15 evaluable) vs clobetasol cream applied twice daily on days 1, 2, 3,
4, 8, 9, 12 and 14 (n = 13 evaluable)
Category: topical steroid plus antiseptic/antibiotic
Topical steroids: all participants
Outcomes 1. Patients' daily subjective assessment of total severity of symptoms (0 = no symptoms to 8 = very se-
vere symptoms)
Nilsson 1992 
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2. Severity score for most severe lesion (7 clinical features graded 0 = none, 1 = mild, 2 = moderate, 3 =
severe) at 1 and 2 weeks
3. Isolation of S. aureus from most severe lesion at 1 and 2 weeks
4. Density of S. aureus from most severe lesion at 1 and 2 weeks
Funding Not stated
Notes A second study was also reported (clobetasone butyrate 0.05% vs alclometasone dipropionate 0.05%
cream for mild-moderate atopic dermatitis), which was not eligible for the review.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Allocated at random"
Comment: method not stated
Allocation concealment
(selection bias)





High risk Different regimens used for steroid alone/steroid plus antibiotic combination
Blinding of outcome as-
sessment (detection bias) 
All outcomes





Unclear risk No information on why four participants were "not evaluable"
Selective reporting (re-
porting bias)
Unclear risk No trial registration provided
Other bias Low risk Well-balanced at baseline for severity (non-standard clinical score) and pres-




Methods Design: cross-over (four arms, four periods)
Total study duration: not stated
Participants Setting: secondary care, single centre, The Netherlands
Incl: atopic dermatitis ("neurodermatitis") of long standing without apparent secondary infection, hav-






S. aureus colonisation: not stated
Polano 1960 
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Randomised: 24
Evaluable: 14
Interventions Metiderm (0.5% prednisolone plus 0.5% neomycin) vs 0.5% prednisolone vs 1% hydrocortisone vs
petrolatum base (used in all other ointments). Applied for one week (or until ointment was used up).
Frequency not stated
Category: topical steroid plus antiseptic/antibiotic
Topical steroids: all participants
Outcomes 1. Severity score (lichenification, redness, weeping, crusting, apparent secondary infection scored from
0 = absent to 5 = maximum development) at end of each treatment
Funding Hydrocortisone and prednisolone supplied by N.V. Organon; Metiderm was supplied by Pharbil (agent
of Schering Corp).
Notes Outcomes were pooled without giving primary data, thus not fulfilling outcome measures.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Each of the 24 possible sequences was written down on a filing card.
For any patient to be treated for the first time, the junior author chose a card at
random."
Comment: unclear if this method would introduce selection bias
Allocation concealment
(selection bias)
High risk Quote: "Each of the 24 possible sequences was written down on a filing card.
For any patient to be treated for the first time, the junior author chose a card at
random."





Unclear risk Ointments dispensed in identical tubes, labels removed by junior author. No
information on similarity of ointments
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk Only 14 participants completed
Selective reporting (re-
porting bias)
Unclear risk No trial registration provided
Other bias High risk No washout between treatments. Impossible to assess balance as more com-
binations of treatment order than participants. Unclear whether statistical
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Methods Design: parallel group
Total study duration: 27 months
Participants Setting: secondary care, single centre, Portugal
Incl: atopic dermatitis (Hanifin and Rajka criteria), age < 16 years, presence of active lesions
Excl: presence of other skin diseases, history of hypersensitivity to silver, use of antibiotics and/or an-
ti-inflammatories in the 2 weeks prior to, or during, the study
Age: mean 7 years
Sex: 11 males, 7 females
Duration of condition: not stated
Infective status: not stated
S. aureus colonisation: not stated
Randomised: 19
Evaluable: 18
Interventions Skintoskin textiles® (70% cotton, 20% cellulose with algae extracts, 10% silver activated algal cellulose;
6000 ppm, 0.6% silver (n = 12) vs 100% cotton (woven similarly to the trial textile (n = 7) as babygrows
for babies around one year old and pyjamas and socks for older participants worn continuously for 7
days, after that only at night (until day 90)
Category: therapeutic textile
Topical steroids: rescue medication only
Outcomes 1. SCORAD at day 7, 90
2. Intensity of itching (0-10 on a visual analogue scale) at day 7, 90




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)





Low risk Quote: "The clothes were indistinguishable by look and feel".
Comment: likely that blinding was achieved
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote: "Clothes made with the fiber under study and the placebo were provid-
ed by the manufacturer and randomly distributed by a different element from
that who made the clinical assessment".
Portela Araujo 2013 
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Low risk One participant in the treatment group didn't complete the study.
Selective reporting (re-
porting bias)
Unclear risk No trial registration provided





Methods Design: parallel group
Total study duration: not stated
Participants Setting: secondary care, number of centres unclear, Canada
Incl: mild - moderate atopic dermatitis, amenable to treatment with topical steroid, age > 3 years




Duration of condition: not stated
Infective status: not stated
S. aureus colonisation: 36%-53% across groups
Randomised: 186
Evaluable: 174 (154 completed study)
Interventions Fusidic acid 2% plus 1% hydrocortisone cream (n = 91 evaluable) vs 1% hydrocortisone cream (n = 83
evaluable) for 2 weeks. Frequency not stated
Category: topical steroids plus antiseptic/antibiotic
Topical steroids: all participants
Outcomes 1. Severity score (erythema, scaling, oedema, discharge, crusting graded 0 = absent, 1 = mild, 2 = mod-
erate, 3 = severe) in all participants and those with pathogens at 1 and 2 weeks
2. Extent of lesions (localised, limited or generalised) at 1 and 2 weeks
3. Patients' and investigators' assessments of overall severity (0 = nil, 1 = minimal, 2 = mild, 3 = moder-
ately severe) at 1 and 2 weeks
4. Overall clinical response (excellent = reduction in severity score by 75% or more, good = reduction by
50-74%, fair = reduction by 25-49%, poor = reduction by < 25%) at 1 and 2 weeks
5. Treatment failure, defined as < 50% reduction in severity score by end of treatment or withdrawal





Interventions to reduce Staphylococcus aureus in the management of eczema (Review)









Cochrane Database of Systematic Reviews
Notes Reported two studies. Study II (comparing topical 2% fusidic acid vs 2% fusidic acid plus 1% hydrocor-
tisone) excluded. Unclear if pathogens were S. aureus
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)





Unclear risk Quote: "Double-blind"
Comment: but no details given
Blinding of outcome as-










Unclear risk No trial registration provided




Methods Design: within-patient study (le$/right comparison)
Total study duration: not stated
Participants Setting: secondary care, single centre, Germany
Incl: symmetrical subacute atopic dermatitis, SCORAD < 80, age 12-59 years
Excl: infectious disease, severe underlying clinical disease, cancer, poor health, dependence on alco-
hol/drugs, pregnancy, breast feeding, other study within 4 weeks, use of oral steroids in past 2 weeks or
topical steroids in past 1 week, hypersensitivity to hypericum or any of the cream ingredients, current
treatment with psychotropic, anti-inflammatory, antibiotic, immunomodulatory drugs.
Age: mean 30.4 years (SD 12.9)
Sex: 10 males, 8 females
Duration of condition: not stated
Infective status: not stated
S. aureus colonisation: 94%
Randomised: 21
Evaluable: 18
Interventions Hyperforin 1.5% cream vs placebo (identical vehicle with added chromogenic substances to colour the
vehicle for the purpose of blinding). Applied twice daily for four weeks
Category: topical antiseptic/antibiotics
Schempp 2003 
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Topical steroids: none
Outcomes 1. Modified SCORAD (excluding subjective score) at day 7, 14, 28
2. Colonisation with S. aureus (number of CFU) at day 28
3. Patient-assessed tolerance and cosmetic acceptability at day 7, 14, 28
4. AEs
Funding Lichtwer Pharma AG
Notes -
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)





Unclear risk Quote: "Double blind"
Comment: Low risk for participants as identical vehicle in placebo coloured to
blind treatment; unclear risk for personnel
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote: "Double blind"




Unclear risk 3/21 not included in analysis as they withdrew - in all cases there was acute
episode of atopic dermatitis which led to withdrawal from the study.
Selective reporting (re-
porting bias)
Unclear risk No trial registration provided
Other bias Low risk Well-balanced at baseline for severity (SCORAD) and presence and colonisa-




Methods Design: parallel groups
Total study duration: not stated
Participants Setting: secondary care, single centre, The Netherlands
Incl: atopic eczema (modified Hanifin and Rajka criteria), SCORAD 25 or more, > 18 years old
Excl: clinical infection, visible pustular lesions, investigational drugs, nonsteroidal immunosuppres-
sants, phototherapy, systemic steroids or topical/systemic antibiotics past four weeks, topical ultrapo-
tent steroids or tar past seven days, known hypersensitivity to drug, pregnant, breast feeding
Age: tetracycline + triamcinolone: mean 36.8 years, triamcinolone: mean 31.1 years
Sex: tetracycline + triamcinolone: 8 males, 14 females, triamcinolone: 5 males, 17 females
Duration of condition: not stated
Schuttelaar 2005 
Interventions to reduce Staphylococcus aureus in the management of eczema (Review)









Cochrane Database of Systematic Reviews
Infective status: uninfected
S. aureus colonisation: 91%
Randomised: 44
Evaluable: 44
Interventions 3% tetracycline + 0.1% triamcinolone acetonide in oculentum simplex FNA (n = 22) vs 0.1% triamci-
nolone acetonide in oculentum simplex FNA (n = 22). Applied all over body twice daily for two weeks
Category: topical steroid plus antiseptic/antibiotic
Topical steroids: all participants
Outcomes 1. Modified SCORAD (excluding subjective score) and Six Area, Six Sign Atopic Dermatitis (SASSAD)
score at weeks 2, 4, 8





Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "computer generated in blocks of four. The list was produced and
stored by the clinical trials pharmacist."
Comment: randomisation method unlikely to introduce selection bias.
Allocation concealment
(selection bias)
Low risk Quote: "The list was produced and stored by the clinical trials pharmacist."





Low risk Quote: "Participants and assessor were blinded to group assignment during
collection of data." "Colorant chinoline yellow CI 47005 (0.2%) and AZO rubine
red E122 (0.000375%) were used to achieve adequate blinding by making the
two ointments exactly similar in appearance."
Comment: blinding was likely to have been successful.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk No dropouts for primary outcome (week 2)
Selective reporting (re-
porting bias)
Unclear risk No trial registration provided
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Methods Design: within-patient study (le$/right comparison)
Total study duration: 2 years
Participants Setting: secondary care, single centre, US
Incl: atopic dermatitis
Excl: none specified
Age: mean 26.3 years (range 12-45)
Sex: 5 males, 5 females
Duration of condition: not stated
Infective status: not stated
S. aureus colonisation: not stated
Randomised: 10
Evaluable: 10
Interventions Bleach bath (sodium hypochlorite 0.005%) vs placebo (tap water). Each arm was immersed for 10 min-
utes.
Category: antibacterial bath additive
Topical steroids: none
Outcomes 1. Skin hydration at 0, 15, 30 and 60 minutes post-immersion
2. TEWL at 0, 15, 30 and 60 minutes post-immersion
3. pH at 0, 15, 30 and 60 minutes post-immersion
4. Skin discomfort including itching and burning or pain during the 10-minute immersion and through-




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not stated
Allocation concealment
(selection bias)
Low risk Quote: "The randomisation was performed prior to recruitment by the study
coordinator, and stored in sealed envelopes that were not opened until the pa-
tient was recruited by the investigators."





High risk Quote: "Participants remained blinded to the water or dilute hypochlorite im-
mersion."
Comment: participants and investigators are likely to have been able to distin-
guish bleach from water by smell.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Skin hydration, TEWL and pH are objective measures.
Shi 2016 
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Low risk All participants accounted for
Selective reporting (re-
porting bias)
Unclear risk All outcomes reported but trial registration indicated a second intervention
(multiple moisturisers) not reported in the paper




Methods Design: within-patient study (le$/right comparison)
Total study duration: 8 months
Participants Setting: secondary care, single centre, Italy
Incl: atopic dermatitis (Hanifin and Rajka criteria), patients presenting with eczematous lesions located
on the arms and without any signs of infection
Excl: acute infections, neurological or psychiatric disorders, autoimmune disease and immune defects
Age: mean 14.2 years (range 3-31)
Sex: 15 males, 15 females
Duration of condition: not stated
Infective status: uninfected
S. aureus colonisation: not stated
Randomised: 30
Evaluable: 26
Interventions Tubular sleeves made from knitted fibrin silk bonded with AEGIS AEM 5772/5 (DermaSilk®) vs an identi-
cal product without the bonded AEGIS AEM 5772/5
Each participant was given 4 pairs of tubular sleeves (with seams of different colours) and parents/par-
ticipants were asked to dress their arms with the sleeves all night and day, changing them once a day
and washing them with a mild detergent. The parents/participants were asked to use the same colour
sleeve always on the same arm and not to cross them over. Only moisturising treatment with an as-
signed emollient was permitted. A gentle, non-irritating skin cleanser without antiseptics/antimicrobial
products was provided.
Washout phases for current treatment were 1 week for topical corticosteroids/antibiotics on the body
areas to be treated with the silk, 2 weeks for systemic corticosteroids/antibiotics, 1 week for topical
antimycotics, 4 weeks for topical calcineurin inhibitors and 8 weeks for systemic immunosuppressant




Outcomes 1. Local SCORAD (adapted for arm only) at days 7, 14, 21, 28
2. Parent/participant assessment of pruritus measured with a VAS (between 0 and 10) at days 7, 14, 21,
28
Stinco 2008 
Interventions to reduce Staphylococcus aureus in the management of eczema (Review)









Cochrane Database of Systematic Reviews
3. AEs
Funding Garments were provided by Alpretec
Notes -
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "The choice of which arm to dress with the red- or green-coded sleeve
was randomised and labeled on the basis of a computer-generated random-
ization schedule".
Comment: randomisation method unlikely to introduce selection bias
Allocation concealment
(selection bias)
Low risk Quote: "Each pair consisted of a sleeve with a red seam and one with a green
seam. One of these colours indicated that the sleeve had been treated with
AEGIS AEM 5772/5 but neither the authors, parents nor participants knew
which one hade been coated. This information was known only to the manu-
facturer and sealed in an envelope."





Low risk As above, blinding was likely to have been successful.
Blinding of outcome as-
sessment (detection bias) 
All outcomes








Unclear risk No trial registration provided





Methods Design: parallel group
Total study duration: not stated
Participants Setting: Secondary care, single centre, Singapore
Incl: atopic dermatitis (Hanifin and Rajka criteria), mild to moderate severity (SCORAD)
Excl: severe atopic dermatitis, recent hospitalisation, recent/current use of systemic antibiotics, sys-
temic steroids, potent or very potent topical steroids or phototherapy in the past 1 month, known con-
tact allergy to any of the ingredients, uncooperative patients and pregnant women
Age: intervention group: mean 17.8 years, control group: mean 18.1 years
Tan 2009 
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Sex: intervention group: 19 males, 11 females, control group: 20 males, 10 females
Duration of condition: intervention group: median 12 years, control group: median 9 years
Infective status: not stated
S. aureus colonisation: not stated
Randomised: 60
Evaluable: 60
Interventions Emollient containing 1% triclosan (n = 30) vs vehicle alone (n = 30) applied twice daily to whole body for
27 days.
Washout period of one week. All participants were provided with 0.0025% betamethasone valerate
cream for the first 27 days and asked to apply a thin layer of the corticosteroid cream over the eczema-
tous areas for the first 27 days followed by either study cream or vehicle on the whole body. Following
this, participants who still had persistent eczema were allowed to continue use of the steroid if neces-
sary. Participants were provided with emulsifying ointment as cleansers and instructed not to use any
systemics or topical antibiotics, antibacterial soap or antibacterial shampoo.
Category: topical steroid plus antiseptic/antibiotic
Topical steroids: all participants
Outcomes 1. SCORAD at days 14, 27 and 41
2. Amount of topical steroid used to day 41
3. AEs
Funding Hygieia Healthcare Ltd
Notes -
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: "Patients were assigned to one of two treatment groups using a com-
puter-generated randomisation list, stratified according to disease severity".
Comment: randomisation method unlikely to introduce selection bias
Allocation concealment
(selection bias)





Low risk Quote "All study personnel and physicians remained blinded to allocation of
treatment until completion of the data analysis. Both the study cream and ve-
hicle were odourless, of the same appearance and consistency and provided in
identical bottles."
Comment: blinding was likely to have been successful.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Quote "All study personnel and physicians remained blinded to allocation of
treatment until completion of the data analysis. Both the study cream and ve-
hicle were odourless, of the same appearance and consistency and provided in
identical bottles."
Comment: blinding was maintained until analysis.
Tan 2009  (Continued)
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Unclear risk No trial registration provided
Other bias Unclear risk Well-balanced at baseline for severity (SCORAD) but presence of S. aureus not




Methods Design: parallel group
Total study duration: not stated
Participants Setting: Secondary care, single centre, USA
Incl: clinically infected, moderate to severe atopic dermatitis
Excl: pregnant, age < 1 year, renal disease, symptoms requiring oral antibiotics or steroids
Age: not stated
Sex: not stated
Duration of condition: not stated
Infective status: clinically infected
S. aureus colonisation: 79%
Randomised: 83
Evaluable: 79
Interventions Betamethasone valerate (Betnovate) plus gentamicin cream (n = 25 evaluable) vs betamethasone
valerate cream (n = 27 evaluable) vs gentamicin cream (n = 27). Applied three times daily for 22 days.
Only the comparison of betamethasone valerate plus gentamicin vs betamethasone valerate was eligi-
ble for the review.
Category: topical steroids plus antiseptic/antibiotic
Topical steroids: all participants
Outcomes 1. Physician graded global assessment of severity (from 0 = complete absence to 10 = very severe -
worst case ever seen) at days 4, 8, 15, 22
2. Degree of inflammation and infection (graded 0-10) at days 4, 8, 15, 22
3. Severity of individual signs and symptoms (erythema, pustules, crusting, exudate, vesiculation,
lichenification; graded 0-10) at days 4, 8, 15, 22
4. Results of treatment and overall evaluation rated Poor (< 25% improvement, or worsening), Fair
(25-49% improvement), Good (50-74% improvement) or Excellent (75% or greater improvement) at
days 4, 8, 15, 22
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "Patients under the care of an individual investigator were randomly
assigned so that five were to receive [each treatment]".
Comment: randomisation method not fully described
Allocation concealment
(selection bias)





Unclear risk Quote: "precautions being observed to preserve the 'blinding' of both patients
and therapists"
Comment: unclear if blinding was achieved
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Quote: "precautions being observed to preserve the 'blinding' of both patients
and therapists"




Unclear risk Four dropouts, treatment groups not stated
Selective reporting (re-
porting bias)
High risk Results for individual signs and symptoms not reported; all results only report-
ed at the beginning and end of treatment and not intermediate assessments
Other bias Low risk Well-balanced at baseline for severity (nonstandard clinical score) and pres-




Methods Design: parallel group
Total study duration: not stated
Participants Setting: secondary care, South Africa
Incl: S. aureus super-infected atopic dermatitis (Hanifin and Rajka criteria)
Excl: cefadroxil resistant organisms, "concomitant medications that could have affected the variables
being measured"
Age: cefadroxil: mean 4.1 years, placebo: mean 4.4 years
Sex: cefadroxil: 7 males, 6 females, placebo: 7 males, 10 females
Duration of condition: cefadroxil: mean 3.2 years, placebo: mean 2.6 years
Infective status: mixed (28/30 clinically infected)
S. aureus colonisation: 100%
Randomised: 33
Evaluable: 30
Interventions Cefadroxil 50 mg/kg/day in 2 equal doses (n = 16) vs placebo (n = 17) for 2 weeks
Category: oral antibiotic
Topical steroids: not stated
Outcomes 1. Patient- and physician-rated global evaluations of improvement at 2 weeks
2. Hanifin/Rajka activity scale at 2 weeks
Weinberg 1992 
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3. Severity of individual signs and symptom (pruritus, erythema, peeling, lichenification, induration, ul-
ceration) at 2 weeks
4. Positive bacterial cultures, sensitivity and clinical superinfection at 2 weeks
5. Total serum IgE, IgA, IgG, IgM at 2 weeks
6. AEs
Funding Not stated (one author was an employee of Bristol-Myers Squibb (Pty) Ltd)
Notes -
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "The patients were randomised".
Comment: unclear if randomisation method was adequate
Allocation concealment
(selection bias)





Unclear risk Quote: "double-blind", "placebo-controlled"
Comment: unclear if blinding was achieved and what method was used
Blinding of outcome as-
sessment (detection bias) 
All outcomes




High risk Three withdrawn from cefadroxil group because of side effects, severe non-
compliance and presence of a resistant organism
Selective reporting (re-
porting bias)
High risk Results not shown for lichenification, induration or ulceration (reported as
"not significant"). Within-group improvements reported in clinical parameters,
not between groups.





Methods Design: parallel group
Total study duration: not stated
Participants Setting: secondary care, single centre, Malaysia
Incl: atopic dermatitis (Hanifin and Rajka criteria), moderate to severe (Rajka and Langeland criteria)
Excl: known sensitivity to sodium hypochlorite (bleach), eczema herpeticum or other cutaneous infec-
tions, systemic antibiotics or systemic steroids at the time of recruitment, those on other antiseptic
baths, pregnant/lactating
Wong 2013 
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Age: 2-30 years
Sex: bleach bath group: 4 males, 14 females, placebo group: 7 males, 11 females
Duration of condition: not stated
Infective status: uninfected
S. aureus colonisation: 94%
Randomised: 42
Evaluable: 36
Interventions Bleach bath (100 mL of sodium hypochlorite (bleach) in 100 L of water, equivalent to approximately
half a bathtub full, diluting the sodium hypochlorite to concentration of 0.005%) (n = 21) vs placebo
(100 mL of distilled water in 100 L of water) (n = 21).
For children < 12 years old 50 mL was added to a quarter tub of water.
Instructed to soak from the neck down in the diluted baths for 10 minutes twice a week for 2 months.
After each bath, participants rinsed oL with normal tap water. Maintained on a stable regimen of top-
ical anti-inflammatory and emollient therapy. No new topical/systemic treatment was introduced be-
fore and during the study period. Aqueous cream as soap substitute.
Category: antibacterial bath additive
Topical steroids: as needed
Outcomes 1. EASI score (overall and for each body region) at weeks 2, 4 and 8
2. Physicians' assessment of severity of specific signs and symptoms (erythema, oedema/indura-
tion/papulation, excoriation, lichenification) on a 4-point scale (from "absent" to "severe") at weeks 2,
4 and 8
3. Participants' assessment of overall response (from "much worse" to "much better") and intensity of
itch (visual analogue scale from 1 to 10) at weeks 2, 4 and 8
4. Quantitative bacterial cultures and S. aureus density at weeks 4 and 8
5. AEs
Funding Dermatological Society of Malaysia
Notes Correspondence with author confirmed additional details about the study and risk of bias.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Correspondence with author: "Patients were randomly assigned through com-
puter generated simple randomised numbers to the treatment or placebo
study arms".
Comment: randomisation method unlikely to introduce selection bias
Allocation concealment
(selection bias)
Low risk Correspondence with author: "[Dr S Wong] had no access to the allocation se-
quence. The study pharmacist dispensed either bleach or placebo (distilled
water) according to the computer generated numbers. [Dr S Wong] did not
know which treatment the patient received either at the start or on follow-up."
Comment: allocation was concealed.
Wong 2013  (Continued)
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High risk Although double-blind, it is possible that the participant could smell the
bleach and identify which treatment group he or she was in.
Blinding of outcome as-
sessment (detection bias) 
All outcomes




Low risk Three participants withdrew in treatment arm - one lost to follow-up, one non-
compliant, one withdrew consent and three participants withdrew in placebo
arm - one lost to follow-up, one non-compliant, one worsening itch
Selective reporting (re-
porting bias)
Unclear risk No trial registration provided. In paper nothing reported for week 2 or total
numbers positive and negative for S. aureus. Authors have provided this infor-
mation via email.
Other bias High risk Well-balanced at baseline for severity (EASI) but imbalance in colonisation
density of S. aureus (mean log CFU/cm2: bleach bath group 16.8 SD 15.7, place-
bo group 7.5, SD 13.6 - data supplied by author)
Wong 2013  (Continued)
AE: adverse event
AIDS: acquired immune deficiency syndrome
BSA: body surface area
CDLQI: Children's Dermatology Life Quality Index
CFU: colony forming units
DLQI: Dermatology Life Quality Index
DNA: deoxyribonucleic acid
EASI: Eczema Area & Severity Index
Excl: exclusion criteria






PCR: polymerase chain reaction
POEM: Patient Oriented Eczema Measure
SASSAD: Six Area, Six Sign Atopic Dermatitis
SCORAD: SCORing Atopic Dermatitis
TEWL: transepidermal water loss
UV: ultra-violet
VAS: visual analogue scale
Vs: versus
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Alangari 2017 Not randomised
Ariyoshi 1973 Not atopic dermatitis
Berardesca 2009 Topical gluco-oligosaccharide and collagen tripeptide F, not an anti-staphylococcal intervention
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Study Reason for exclusion
Bergstrom 2009 Review article, not a randomised controlled trial
Bianchi 2014 Emollient containing bacterial extract, not an anti-staphylococcal intervention
Bjornberg 1975 Not randomised or controlled
Breneman 1990 No separate results for atopic dermatitis
Carpenter 1973 Studied "common dermatoses", no separate results for atopic dermatitis
Clark 1974 Not specifically atopic dermatitis. Not randomised
Craig 2010 Commentary on another paper, not a randomised controlled trial
Davis 1968 Studied "inflammatory and infective dermatoses", no separate results for atopic dermatitis
Drago 2011 Probiotic, not an anti-staphylococcal intervention
Drago 2012 Probiotic, not an anti-staphylococcal intervention
Dunstan 2011 Studied Mycobacteria vaccae, not an antistaphylococcal intervention
Eaglstein 1977 Studied "secondarily infected dermatitis" with no further description of atopic dermatitis
Gauger 2003 Open-label, controlled le$/right comparison. Not randomised
Girolomoni 2016 Review article, not a randomised controlled trial
GP Medical Research 1967 Compared anti-staphylococcal - steroid combination with addition of antifungal, no appropriate
control
Gratton 1987 Not atopic dermatitis
Gueniche 2008 Study involving Vitreoscilla filiformis, not an anti-staphylococcal intervention
Gueniche 2009 Study involving Vitreoscilla filiformis, not an anti-staphylococcal intervention
Hoey 2006 Phototherapy, not an anti-staphylococcal intervention
Ishibashi 1993 No separate results for atopic dermatitis
Kimata 1998 Not randomised
Kotrajaras 1971 Not atopic dermatitis. Not randomised
La Colla 2009 Correspondence relating to another study using Vitreoscilla filiformis, not an anti-staphylococcal in-
tervention
Leung 2008 Chinese herbal medicine, not an anti-staphylococcal intervention. Not randomised
Leung 2009 Pimecrolimus cream, not an anti-staphylococcal intervention
Lloyd 1969 No separate results for atopic dermatitis
Masako 2005a In vitro study
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Study Reason for exclusion
Meenan 1988 Compared two anti-staphylococcal - steroid combinations, no appropriate control
Mora 2004 Topical suspension of bacterial antigens, not an anti-staphylococcal intervention
Nielsen 1979 No separate results for atopic dermatitis. Not randomised
Parish 1987 Not atopic dermatitis
Pratap 2013 Not specifically atopic dermatitis. Correspondence with Dr Mariam Philip on 30 December 2014
confirmed this:
"The study was on infected eczema. In our study there were only very few cases of atopic dermati-
tis."
Prescott 2005 Probiotics, not an anti-staphylococcal intervention
Ravenscroft 2003 Compared two anti-staphylococcal agents, no appropriate control
Remitz 2001 No control, and not randomised
Rist 2002 Compared two anti-staphylococcal agents, no appropriate control
Salo 1988 Compared two preparations of the same anti-staphylococcal agent, no appropriate control
Sandström Falk 2006 Not randomised
Sasai-Takedatsu 1997 Treatment arbitrarily divided by a referee physician, not appropriately randomised
Schempp 2010 Review article, not a randomised controlled trial
Schultz Larsen 2007 Compared two anti-staphylococcal agents, no appropriate control
Senti 2006 Not randomised
Stalder 1992 Compared two anti-staphylococcal agents, no appropriate control
Takahama 1992 Not specifically atopic dermatitis
Thaci 1999 Compared two anti-staphylococcal agents, no appropriate control
Theodoridis 1979 Studied "eczematous dermatitis" with no further description of atopic dermatitis
Thum 2013 Study on resistance patterns, not a randomised controlled trial
Udompataikul 2015 Compared vitamin D against placebo - not primarily an anti-staphylococcal intervention
Van der Bijl 1966 Not atopic dermatitis. Not randomised
Verallo-Rowell 2008 Compared coconut and virgin olive oils, both interventions suggested to have anti-staphylococcal
properties, no appropriate control
Weitgasser 1983 Compared two different anti-staphylococcal - steroid combinations, no appropriate control. No
separate results for atopic dermatitis
Whitefield 1998 In vitro study and case series using antimicrobial lotion, not a randomised controlled trial
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Study Reason for exclusion
Wilkinson JD 1985 Compared two different steroid - antibiotic combinations, no appropriate control. No separate re-
sults for atopic dermatitis
Wilkinson RD 1980 Compared three steroid - antibiotic combinations, no appropriate control. No separate results for
atopic dermatitis
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Parallel groups RCT
Participants Patients aged 18 to 50 years, currently suffering from atopic dermatitis with a primary diagnosis of
atopic dermatitis at least 12 weeks prior to inclusion into the study, with a SCORAD between 20 and
50 (i.e. mild to moderate atopic dermatitis), diagnosed with disseminated symmetric dermatitis
and with colonisation of lesional skin with S. aureus
Interventions rHuB[beta]D2 cream versus placebo cream
Outcomes Safety and tolerability, change in local SCORAD) at end of treatment (day 14), change in S. aureus
colonization rate at end of treatment, change in the colonization rate of any bacteria at end of
treatment, symptomatic relief using a Likert scale




Methods Within patient (le$/right) RCT
Participants Patients aged 6 month to 50 years, first atopic dermatitis diagnosis at least 4 weeks prior to study
entry, actual clinically manifested atopic dermatitis, disseminated symmetric eczemas of the
limbs, ESCORAD (SCORAD of extremities) between 5 and 12, Staphylococcus superinfection
Interventions Triclosan cream versus placebo
Outcomes Changes in ESCORAD from baseline to day 14, changes in logarithm of staphylococcus-bacteria
count from baseline to day 7 and 14, changes in ESCORAD from baseline to day 7, changes in sin-
gle-ESCORAD of erythema, oedema/papulation, oozing/crusting, excoriation, lichenification from
baseline to day 7 and 14, clinical and microbiological response rates for day 7 and 14, evaluation of
skin parameters on a numeric scale by the investigator and the subject, side effects, tolerance and
efficacy evaluation on a numeric scale from 1-6 by the investigator and the patient, compliance.




Methods Within patient RCT
Participants Patients aged 18 years or older, manifest atopic eczema (Hanifin and Rajka criteria), two compara-
ble lesional areas of 20 - 50 cm2 with a distance of at least 5 cm, clinical condition of atopic eczema
EudraCT 2008-005890-37 
Interventions to reduce Staphylococcus aureus in the management of eczema (Review)









Cochrane Database of Systematic Reviews
mild to moderate (meeting Hanifin and Rajka's criteria), TEWL in the lesional areas at least 12 g/
m2h, TEWL value differences ≤ 30 % are allowed between both lesional areas
Interventions K201 cream [Lactic acid (5 %), Propylene glycol (20 %), Urea (5 %)] versus placebo
Outcomes Barrier impairment (TEWL measurements), clinical skin condition (corneometric measurements
and clinical assessments) and bacterial colonization of S. aureus over a four-week treatment peri-
od.




Methods Parallel groups RCT
Participants Adults aged 18 to 70 years with localised atopic dermatitis (e.g. flexural eczema in a more or less
symmetrical distribution on arms) where two individual lesions each covering an area between
10-200 cm2 and where each individual lesion has an investigators global assessment score between
1-3, additional localised lesion of area between 10-200 cm2 and where the individual lesion has an
investigators global assessment score between 1-3, total localised disease not exceeding 20% body
surface area, and colonisation of lesions with S. aureus
Interventions ATx201 (topical antibiotic) versus placebo
Outcomes Treatment related adverse events, investigators global assessment score, treatment success (100-
fold reduction in S. aureus colony count), local dermal tolerability




Methods Parallel groups RCT
Participants Children aged 6 months to 7 years with atopic dermatitis (Hanifin and Rajka or Williams 1994 crite-
ria) with affected BSA 15-70% and SCORAD 25-70
Interventions Broncho-Vaxom 1 capsule (3.5 mg) per day versus placebo
Outcomes Number of atopic dermatitis flares over 9 months of treatment, changes in SCORAD over 9 months
of treatment, area of eczema involvement, amount of corticosteroids used




Methods Parallel groups RCT
Participants Patients aged 18 years or older, atopic dermatitis of moderate and severe severity (EASI score of 7.1
to 50), topical corticosteroid use
Interventions Staphefekt SA.100 cream (Gladskin) versus placebo
Totté 2017 
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Outcomes Number of days/week corticosteroid use over 12 weeks, mean grams/week topical corticosteroid
use at 12 and 20 weeks, proportion of patients with atopic dermatitis who indicate to have used
less corticosteroids at week 2 and 12 as compared to baseline and at week 20 as compared to the
12 week treatment period, change in EASI from baseline to week 2, 6, 12 and 20, change in POEM
from baseline to week 2, 6, 12 and 20, change in IGA from baseline to week 2, 6 and 12 and week
20, change in Pruritus Numerical Rating Scale from baseline to week 2, 6, 12 and week 20, mean
time to flare from baseline through week 12 and from week 12 through week 20, number of flares
through week 12, change in Skindex-29 score from baseline to week 12 and week 20, proportion
of patients with a reduction of S. aureus from baseline to measurement 1 (0.5 hour after baseline)
as determined by semi quantitative culture, proportion of patients with a > 1 log reduction of S.
aureus from the lowest measurement (visit 1 or visit 2a) to week 2 and week 12 as determined by
qPCR, change in relative abundance of bacteria from baseline to weeks 2, 12 and 20, incidence of
(serious) adverse device events
Notes Recruitment completed (February 2018)
Totté 2017  (Continued)
BSA: body surface area
EASI: Eczema Area & Severity Index
ESCORAD: SCORing Atopic Dermatitis of the Extremities
IGA: Investigator Global Assessment
POEM: Patient Oriented Eczema Measure
qPCR: quantitative polymerase chain reaction
RCT: randomised clinical trial
SCORAD: SCORing Atopic Dermatitis
TEWL: transepidermal water loss
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title A multicentre study evaluating the efficacy of combining topical antibiotic/steroid/moisturizer
therapy compared to an active comparator in the treatment of severe atopic dermatitis: a random-
ized, clinical trial
Methods Parallel group RCT
Participants Children aged 2-9 years with atopic dermatitis (UK Working Party Criteria), baseline SCORAD score
of 50 or above (severe atopic dermatitis), not on systemic antibiotics, qualifying for second-line
treatment agents for atopic dermatitis (systemic or phototherapy)
Interventions Antibiotic and steroid combination (Supiroban 2% cream and fluocinolone acetonide) versus
steroid alone
Outcomes Change in SCORAD from baseline to weeks 4, 8 and 12, frequency of atopic dermatitis relapse
episodes, change in IDQoL index from baseline to weeks 4, 8 and 12
Starting date March 2017 (anticipated)




IDQoL: Infants' Dermatitis Quality of Life
RCT: randomised clinical trial
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SCORAD: SCORing Atopic Dermatitis
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Oral antibiotic vs placebo





Statistical method Effect size
1 Global outcome (good or excellent) at
end of treatment
2 75 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.18, 3.50]
2 Change from baseline in IDQoL at end of
treatment
1   Mean Difference (Random, 95% CI) Totals not selected
3 Change from baseline in CDLQI at end of
treatment
1   Mean Difference (Random, 95% CI) Totals not selected
4 Adverse events requiring withdrawal
from treatment
4 199 Risk Ratio (M-H, Random, 95% CI) 1.43 [0.28, 7.36]
5 Change from baseline in POEM at end of
treatment
1   Mean Difference (Random, 95% CI) Totals not selected
6 Change from baseline in EASI at end of
treatment
1   Mean Difference (Random, 95% CI) Totals not selected
7 Mean erythema scores as assessed by a
physician at end of treatment
1   Mean Difference (IV, Random, 95% CI) Totals not selected
8 Number of people with erythema at end
of treatment
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
9 Presence of clinically apparent infection
at end of treatment
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
10 Number of patients in whom S. aureus
was isolated at end of treatment
3 144 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.46, 1.26]
11 Change from baseline in isolation rate
of S. aureus at end of treatment
1   Mean Difference (IV, Random, 95% CI) Totals not selected
12 Mean log of S. aureus counts from le-
sional skin at end of treatment
1   Mean Difference (IV, Random, 95% CI) Totals not selected
13 Change from baseline in IDQoL at 3
months
1   Mean Difference (Random, 95% CI) Totals not selected
14 Change from baseline in CDLQI at 3
months
1   Mean Difference (Random, 95% CI) Totals not selected
15 Change from baseline in POEM at 3
months
1   Mean Difference (Random, 95% CI) Totals not selected
16 Change from baseline in isolation rate
of S. aureus at 3 months
1   Mean Difference (IV, Random, 95% CI) Totals not selected
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Statistical method Effect size
17 Mean erythema scores as assessed by
physician 56 days post-treatment
1   Mean Difference (IV, Random, 95% CI) Totals not selected
 
 
Analysis 1.1.   Comparison 1 Oral antibiotic vs placebo, Outcome
1 Global outcome (good or excellent) at end of treatment.
Study or subgroup Oral antibiotic Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Ewing 1998 6/22 17/24 48.49% 0.39[0.19,0.8]
Weinberg 1992 10/12 9/17 51.51% 1.57[0.94,2.63]
   
Total (95% CI) 34 41 100% 0.8[0.18,3.5]
Total events: 16 (Oral antibiotic), 26 (Placebo)  
Heterogeneity: Tau2=1.04; Chi2=11.05, df=1(P=0); I2=90.95%  
Test for overall effect: Z=0.3(P=0.76)  
Favours placebo 100.1 50.2 20.5 1 Favours oral antibiotic
 
 
Analysis 1.2.   Comparison 1 Oral antibiotic vs placebo,
Outcome 2 Change from baseline in IDQoL at end of treatment.
Study or subgroup Flucloxacillin Placebo Mean Dif-
ference
Mean Difference Mean Difference
  N N (SE) IV, Random, 95% CI IV, Random, 95% CI
Francis 2016 25 20 0.1 (0.107) 0.11[-0.1,0.32]
Favours flucloxacillin 0.50.25-0.5 -0.25 0 Favours placebo
 
 
Analysis 1.3.   Comparison 1 Oral antibiotic vs placebo,
Outcome 3 Change from baseline in CDLQI at end of treatment.
Study or subgroup Flucloxacillin Placebo Mean Dif-
ference
Mean Difference Mean Difference
  N N (SE) IV, Random, 95% CI IV, Random, 95% CI
Francis 2016 9 14 0.4 (0.301) 0.43[-0.16,1.02]
Favours flucloxacillin 21-2 -1 0 Favours placebo
 
 
Analysis 1.4.   Comparison 1 Oral antibiotic vs placebo, Outcome
4 Adverse events requiring withdrawal from treatment.
Study or subgroup Oral antibiotic Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Boguniewicz 2001 0/20 0/20   Not estimable
Favours oral antibiotic 1000.01 100.1 1 Favours placebo
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Study or subgroup Oral antibiotic Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Ewing 1998 1/25 1/25 36.52% 1[0.07,15.12]
Francis 2016 1/36 1/40 36.01% 1.11[0.07,17.12]
Weinberg 1992 1/16 0/17 27.47% 3.18[0.14,72.75]
   
Total (95% CI) 97 102 100% 1.43[0.28,7.36]
Total events: 3 (Oral antibiotic), 2 (Placebo)  
Heterogeneity: Tau2=0; Chi2=0.35, df=2(P=0.84); I2=0%  
Test for overall effect: Z=0.42(P=0.67)  
Favours oral antibiotic 1000.01 100.1 1 Favours placebo
 
 
Analysis 1.5.   Comparison 1 Oral antibiotic vs placebo,
Outcome 5 Change from baseline in POEM at end of treatment.
Study or subgroup Flucloxacillin Placebo Mean Dif-
ference
Mean Difference Mean Difference
  N N (SE) IV, Random, 95% CI IV, Random, 95% CI
Francis 2016 34 36 1.5 (1.467) 1.52[-1.36,4.4]
Favours flucloxacillin 52.5-5 -2.5 0 Favours placebo
 
 
Analysis 1.6.   Comparison 1 Oral antibiotic vs placebo, Outcome 6 Change from baseline in EASI at end of treatment.
Study or subgroup Flucloxacillin Placebo Mean Dif-
ference
Mean Difference Mean Difference
  N N (SE) IV, Random, 95% CI IV, Random, 95% CI
Francis 2016 34 34 0.2 (0.163) 0.2[-0.12,0.52]
Favours flucloxacillin 10.5-1 -0.5 0 Favours placebo
 
 
Analysis 1.7.   Comparison 1 Oral antibiotic vs placebo, Outcome 7
Mean erythema scores as assessed by a physician at end of treatment.
Study or subgroup Flucloxacillin Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Ewing 1998 22 2.1 (0.8) 24 1.7 (0.6) 0.4[-0.03,0.83]
Favours Flucloxacill 10.5-1 -0.5 0 Favours placebo
 
 
Analysis 1.8.   Comparison 1 Oral antibiotic vs placebo, Outcome
8 Number of people with erythema at end of treatment.
Study or subgroup Cefadroxil Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Weinberg 1992 5/13 7/17 0.93[0.38,2.28]
Favours cefadroxil 50.2 20.5 1 Favours placebo
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Analysis 1.9.   Comparison 1 Oral antibiotic vs placebo, Outcome
9 Presence of clinically apparent infection at end of treatment.
Study or subgroup Cefadroxil Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Weinberg 1992 0/13 9/15 0.06[0,0.94]
Favours cefadroxil 10000.001 100.1 1 Favours placebo
 
 
Analysis 1.10.   Comparison 1 Oral antibiotic vs placebo, Outcome 10
Number of patients in whom S. aureus was isolated at end of treatment.
Study or subgroup Oral antibiotic Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Ewing 1998 15/22 22/24 43.68% 0.74[0.55,1.01]
Francis 2016 18/34 15/34 34.95% 1.2[0.73,1.97]
Weinberg 1992 4/13 14/17 21.36% 0.37[0.16,0.87]
   
Total (95% CI) 69 75 100% 0.76[0.46,1.26]
Total events: 37 (Oral antibiotic), 51 (Placebo)  
Heterogeneity: Tau2=0.13; Chi2=5.92, df=2(P=0.05); I2=66.22%  
Test for overall effect: Z=1.06(P=0.29)  
Favours oral antibiotic 100.1 50.2 20.5 1 Favours placebo
 
 
Analysis 1.11.   Comparison 1 Oral antibiotic vs placebo, Outcome 11
Change from baseline in isolation rate of S. aureus at end of treatment.
Study or subgroup Oral antibiotic Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Francis 2016 34 -30.4 (63.1) 34 -15.9 (69.2) -14.5[-45.98,16.98]
Favours oral antibiotic 10050-100 -50 0 Favours placebo
 
 
Analysis 1.12.   Comparison 1 Oral antibiotic vs placebo, Outcome 12
Mean log of S. aureus counts from lesional skin at end of treatment.
Study or subgroup Flucloxacillin Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Ewing 1998 21 3.6 (3.3) 19 5 (2.1) -1.4[-3.09,0.29]
Favours flucloxacillin 52.5-5 -2.5 0 Favours placebo
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Analysis 1.13.   Comparison 1 Oral antibiotic vs placebo, Outcome 13 Change from baseline in IDQoL at 3 months.
Study or subgroup Fluxcloxacillin Placebo Mean Dif-
ference
Mean Difference Mean Difference
  N N (SE) IV, Random, 95% CI IV, Random, 95% CI
Francis 2016 18 16 -0.2 (0.117) -0.21[-0.44,0.02]
Favours flucloxacillin 10.5-1 -0.5 0 Favours placebo
 
 
Analysis 1.14.   Comparison 1 Oral antibiotic vs placebo, Outcome 14 Change from baseline in CDLQI at 3 months.
Study or subgroup Flucloxacillin Placebo Mean Dif-
ference
Mean Difference Mean Difference
  N N (SE) IV, Random, 95% CI IV, Random, 95% CI
Francis 2016 6 8 -0.1 (0.426) -0.14[-0.97,0.69]
Favours flucloxacillin 10.5-1 -0.5 0 Favours placebo
 
 
Analysis 1.15.   Comparison 1 Oral antibiotic vs placebo, Outcome 15 Change from baseline in POEM at 3 months.
Study or subgroup Flucloxacllin Placebo Mean Dif-
ference
Mean Difference Mean Difference
  N N (SE) IV, Random, 95% CI IV, Random, 95% CI
Francis 2016 28 25 -0.2 (1.485) -0.21[-3.12,2.7]
Favours flucloxacillin 42-4 -2 0 Favours placebo
 
 
Analysis 1.16.   Comparison 1 Oral antibiotic vs placebo, Outcome
16 Change from baseline in isolation rate of S. aureus at 3 months.
Study or subgroup Oral antibiotic Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Francis 2016 26 -52.6 (56.1) 25 -20 (64.8) -32.6[-65.92,0.72]
Favours oral antibiotic 10050-100 -50 0 Favours placebo
 
 
Analysis 1.17.   Comparison 1 Oral antibiotic vs placebo, Outcome 17
Mean erythema scores as assessed by physician 56 days post-treatment.
Study or subgroup Flucloxacillin Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Ewing 1998 19 1.9 (0.9) 18 2 (0.6) -0.1[-0.59,0.39]
Favours flucloxacill 10.5-1 -0.5 0 Favours placebo
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Comparison 2.   Topical steroid plus topical antibiotic vs topical steroid





Statistical method Effect size
1 Global outcome (good or excellent) at
end of treatment
3 224 Risk Ratio (M-H, Random, 95% CI) 1.10 [1.00, 1.21]
2 Global outcome (mean self-assessment
score) at end of treatment
1   Mean Difference (IV, Random, 95% CI) Totals not selected
3 Change from baseline in IDQoL at end of
treatment
1   Mean Difference (Random, 95% CI) Totals not selected
4 Change from baseline in CDLQI at end of
treatment
1   Mean Difference (Random, 95% CI) Totals not selected
5 Adverse events requiring withdrawal
from treatment
4 325 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.21, 7.25]
6 Minor adverse events not requiring
withdrawal from treatment
2 218 Risk Ratio (M-H, Random, 95% CI) 0.30 [0.12, 0.78]
7 Change from baseline in EASI at end of
treatment
1   Mean Difference (Random, 95% CI) Totals not selected
8 Change from baseline in POEM at end of
treatment
1   Mean Difference (Random, 95% CI) Totals not selected
9 Mean value of composite rating scale at
end of treatment
4 256 Std. Mean Difference (IV, Random,
95% CI)
-0.00 [-0.33, 0.33]
10 No of patients in whom S. aureus was
isolated at end of treatment
7 298 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.27, 0.84]
11 Change from baseline in isolation rate
of S. aureus at end of treatment
1   Mean Difference (IV, Random, 95% CI) Totals not selected
12 Change from baseline in IDQoL at 3
months
1   Mean Difference (Random, 95% CI) Totals not selected
13 Change from baseline in CDLQI at 3
months
1   Mean Difference (Random, 95% CI) Totals not selected
14 Change from baseline in POEM at 3
months
1   Mean Difference (Random, 95% CI) Totals not selected
15 Change from baseline in isolation rate
of S. aureus at 3 months
1   Mean Difference (IV, Random, 95% CI) Totals not selected
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Analysis 2.1.   Comparison 2 Topical steroid plus topical antibiotic vs topical
steroid, Outcome 1 Global outcome (good or excellent) at end of treatment.
Study or subgroup Steroid
+antibiotic
Steroid alone Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Canpolat 2012 20/27 17/26 7.2% 1.13[0.79,1.62]
Gong 2006 55/58 54/61 78.22% 1.07[0.96,1.19]
Wachs 1976 23/25 20/27 14.58% 1.24[0.97,1.6]
   
Total (95% CI) 110 114 100% 1.1[1,1.21]
Total events: 98 (Steroid+antibiotic), 91 (Steroid alone)  
Heterogeneity: Tau2=0; Chi2=1.3, df=2(P=0.52); I2=0%  
Test for overall effect: Z=1.93(P=0.05)  
Favours steroid alone 20.5 1.50.7 1 Favours combination
 
 
Analysis 2.2.   Comparison 2 Topical steroid plus topical antibiotic vs topical steroid,
Outcome 2 Global outcome (mean self-assessment score) at end of treatment.
Study or subgroup Steroid+antibiotic Steroid alone Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Nilsson 1992 15 1.7 (1.6) 13 0.5 (0.9) 1.2[0.25,2.15]
Favours combination 42-4 -2 0 Favours steroid
 
 
Analysis 2.3.   Comparison 2 Topical steroid plus topical antibiotic vs topical
steroid, Outcome 3 Change from baseline in IDQoL at end of treatment.




Mean Difference Mean Difference
  N N (SE) IV, Random, 95% CI IV, Random, 95% CI
Francis 2016 22 20 0.2 (0.11) 0.18[-0.04,0.4]
Favours antibiotic 10.5-1 -0.5 0 Favours placebo
 
 
Analysis 2.4.   Comparison 2 Topical steroid plus topical antibiotic vs topical
steroid, Outcome 4 Change from baseline in CDLQI at end of treatment.




Mean Difference Mean Difference
  N N (SE) IV, Random, 95% CI IV, Random, 95% CI
Francis 2016 9 14 0.7 (0.296) 0.7[0.12,1.28]
Favours antibiotic 10.5-1 -0.5 0 Favours placebo
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Analysis 2.5.   Comparison 2 Topical steroid plus topical antibiotic vs topical
steroid, Outcome 5 Adverse events requiring withdrawal from treatment.
Study or subgroup Steroid
+antibiotic
Steroid alone Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Francis 2016 5/37 1/40 37.46% 5.41[0.66,44.14]
Hung 2007 0/15 0/15   Not estimable
Ramsay 1996 1/91 3/83 34.84% 0.3[0.03,2.87]
Schuttelaar 2005 1/22 1/22 27.7% 1[0.07,15]
   
Total (95% CI) 165 160 100% 1.24[0.21,7.25]
Total events: 7 (Steroid+antibiotic), 5 (Steroid alone)  
Heterogeneity: Tau2=1.01; Chi2=3.43, df=2(P=0.18); I2=41.68%  
Test for overall effect: Z=0.24(P=0.81)  
Favours combination 500.02 100.1 1 Favours steroid
 
 
Analysis 2.6.   Comparison 2 Topical steroid plus topical antibiotic vs topical
steroid, Outcome 6 Minor adverse events not requiring withdrawal from treatment.
Study or subgroup Steroid
+antibiotic
Steroid alone Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Ramsay 1996 2/91 3/83 28.27% 0.61[0.1,3.55]
Schuttelaar 2005 3/22 13/22 71.73% 0.23[0.08,0.7]
   
Total (95% CI) 113 105 100% 0.3[0.12,0.78]
Total events: 5 (Steroid+antibiotic), 16 (Steroid alone)  
Heterogeneity: Tau2=0; Chi2=0.83, df=1(P=0.36); I2=0%  
Test for overall effect: Z=2.49(P=0.01)  
Favours combination 100.1 50.2 20.5 1 Favours steroid
 
 
Analysis 2.7.   Comparison 2 Topical steroid plus topical antibiotic vs topical
steroid, Outcome 7 Change from baseline in EASI at end of treatment.




Mean Difference Mean Difference
  N N (SE) IV, Random, 95% CI IV, Random, 95% CI
Francis 2016 31 34 0.4 (0.168) 0.42[0.09,0.75]
Favours antibiotic 10.5-1 -0.5 0 Favours placebo
 
 
Analysis 2.8.   Comparison 2 Topical steroid plus topical antibiotic vs topical
steroid, Outcome 8 Change from baseline in POEM at end of treatment.




Mean Difference Mean Difference
  N N (SE) IV, Random, 95% CI IV, Random, 95% CI
Francis 2016 31 36 1.5 (1.551) 1.49[-1.55,4.53]
Favours antibiotic 52.5-5 -2.5 0 Favours placebo
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Analysis 2.9.   Comparison 2 Topical steroid plus topical antibiotic vs topical
steroid, Outcome 9 Mean value of composite rating scale at end of treatment.
Study or subgroup Steroid+antibiotic Steroid alone Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Francis 2016 31 4.9 (5.7) 34 2.5 (5.6) 26.74% 0.42[-0.07,0.91]
Gong 2006 58 1.4 (2.3) 61 2.5 (5.2) 36.81% -0.27[-0.63,0.1]
Hung 2007 15 24.7 (16.5) 13 25.4 (15.9) 15.24% -0.04[-0.78,0.7]
Schuttelaar 2005 22 18.1 (13.9) 22 18.8 (13.1) 21.21% -0.05[-0.64,0.54]
   
Total *** 126   130   100% -0[-0.33,0.33]
Heterogeneity: Tau2=0.04; Chi2=4.87, df=3(P=0.18); I2=38.37%  
Test for overall effect: Z=0.01(P=0.99)  
Favours combination 10.5-1 -0.5 0 Favours steroid
 
 
Analysis 2.10.   Comparison 2 Topical steroid plus topical antibiotic vs topical steroid,
Outcome 10 No of patients in whom S. aureus was isolated at end of treatment.
Study or subgroup Steroid
+antibiotic
Steroid alone Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Francis 2016 11/31 16/34 26.99% 0.75[0.42,1.37]
Hung 2007 3/15 5/13 13.7% 0.52[0.15,1.77]
Lever 1988 1/24 14/21 6.92% 0.06[0.01,0.44]
Leyden 1977 3/15 13/21 16.22% 0.32[0.11,0.94]
Nilsson 1992 0/15 0/13   Not estimable
Schuttelaar 2005 6/22 15/22 23.17% 0.4[0.19,0.84]
Wachs 1976 4/25 4/27 12.99% 1.08[0.3,3.86]
   
Total (95% CI) 147 151 100% 0.48[0.27,0.84]
Total events: 28 (Steroid+antibiotic), 67 (Steroid alone)  
Heterogeneity: Tau2=0.22; Chi2=9.35, df=5(P=0.1); I2=46.51%  
Test for overall effect: Z=2.58(P=0.01)  
Favours combination 2000.005 100.1 1 Favours steroid
 
 
Analysis 2.11.   Comparison 2 Topical steroid plus topical antibiotic vs topical steroid,
Outcome 11 Change from baseline in isolation rate of S. aureus at end of treatment.
Study or subgroup Topical antibiotic Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Francis 2016 31 -31.2 (67) 34 -15.9 (69.2) -15.3[-48.43,17.83]
Favours antibiotic 10050-100 -50 0 Favours placebo
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Analysis 2.12.   Comparison 2 Topical steroid plus topical antibiotic vs
topical steroid, Outcome 12 Change from baseline in IDQoL at 3 months.




Mean Difference Mean Difference
  N N (SE) IV, Random, 95% CI IV, Random, 95% CI
Francis 2016 15 16 -0.1 (0.122) -0.07[-0.31,0.17]
Favours antibiotic 10.5-1 -0.5 0 Favours placebo
 
 
Analysis 2.13.   Comparison 2 Topical steroid plus topical antibiotic vs
topical steroid, Outcome 13 Change from baseline in CDLQI at 3 months.




Mean Difference Mean Difference
  N N (SE) IV, Random, 95% CI IV, Random, 95% CI
Francis 2016 6 8 -0.1 (0.423) -0.13[-0.96,0.7]
Favours antibiotic 10.5-1 -0.5 0 Favours placebo
 
 
Analysis 2.14.   Comparison 2 Topical steroid plus topical antibiotic vs
topical steroid, Outcome 14 Change from baseline in POEM at 3 months.




Mean Difference Mean Difference
  N N (SE) IV, Random, 95% CI IV, Random, 95% CI
Francis 2016 21 25 -1.1 (1.628) -1.13[-4.32,2.06]
Favours antibiotic 52.5-5 -2.5 0 Favours placebo
 
 
Analysis 2.15.   Comparison 2 Topical steroid plus topical antibiotic vs topical
steroid, Outcome 15 Change from baseline in isolation rate of S. aureus at 3 months.
Study or subgroup Topical antibiotic Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Francis 2016 21 -28.6 (62.4) 25 -20 (64.8) -8.6[-45.44,28.24]
Favours antibiotic 10050-100 -50 0 Favours placebo
 
 
Comparison 3.   Topical calcineurin inhibitor plus antibiotic vs topical calcineurin inhibitor





Statistical method Effect size
1 Adverse events requiring withdrawal
from treatment
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Mean SCORAD at end of treatment 1   Mean Difference (IV, Random, 95% CI) Totals not selected
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Statistical method Effect size
3 No of patients in whom S. aureus was
isolated at end of treatment
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 3.1.   Comparison 3 Topical calcineurin inhibitor plus antibiotic vs topical
calcineurin inhibitor, Outcome 1 Adverse events requiring withdrawal from treatment.
Study or subgroup Tacrolimus+antibiotic Tacrolimus alone Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Hung 2007 2/15 0/15 5[0.26,96.13]
Favours combination 1000.01 100.1 1 Favours tacrolimus
 
 
Analysis 3.2.   Comparison 3 Topical calcineurin inhibitor plus antibiotic vs
topical calcineurin inhibitor, Outcome 2 Mean SCORAD at end of treatment.
Study or subgroup Tacrolimus+antibiotic Tacrolimus alone Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Hung 2007 13 31.5 (17.6) 13 32.9 (19.4) -1.41[-15.64,12.82]
Favours combination 2010-20 -10 0 Favours tacrolimus
 
 
Analysis 3.3.   Comparison 3 Topical calcineurin inhibitor plus antibiotic vs topical calcineurin
inhibitor, Outcome 3 No of patients in whom S. aureus was isolated at end of treatment.
Study or subgroup Tacrolimus+antibiotic Tacrolimus alone Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Hung 2007 2/13 7/13 0.29[0.07,1.13]
Favours combination 200.05 50.2 1 Favours tacrolimus
 
 
Comparison 4.   Bleach bath vs placebo or bath emollient





Statistical method Effect size
1 Global outcome (good or excellent)
at 1 month
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Global outcome (mean IGA score) at
4 weeks
1   Mean Difference (IV, Random, 95% CI) Totals not selected
3 Change from baseline in CDLQI at
end of treatment
1   Mean Difference (Random, 95% CI) Totals not selected
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Statistical method Effect size
4 Adverse events requiring withdraw-
al from treatment
2   Risk Ratio (M-H, Random, 95% CI) Totals not selected
5 Minor adverse events not requiring
withdrawal from treatment
3   Risk Ratio (M-H, Random, 95% CI) Totals not selected
6 Mean EASI score at 1 month 2 54 Mean Difference (IV, Random, 95% CI) -2.48 [-7.36, 2.40]
7 Change from baseline in objective
SCORAD at end of treatment
1   Mean Difference (Random, 95% CI) Totals not selected
8 Mean S. aureus counts from lesional
skin at 1 month
1   Mean Difference (IV, Random, 95% CI) Totals not selected
9 Global outcome (not good or excel-
lent) at 2 months
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
10 Mean value of composite rating
scale at 2-3 months
2 55 Std. Mean Difference (IV, Random, 95%
CI)
-1.11 [-1.68, -0.53]
11 Mean S. aureus counts from lesion-
al skin at 2 months
1   Mean Difference (IV, Random, 95% CI) Totals not selected
 
 
Analysis 4.1.   Comparison 4 Bleach bath vs placebo or bath
emollient, Outcome 1 Global outcome (good or excellent) at 1 month.
Study or subgroup Bleach bath Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Wong 2013 7/18 9/18 0.78[0.37,1.63]
Favours placebo 50.2 20.5 1 Favours bleach bath
 
 
Analysis 4.2.   Comparison 4 Bleach bath vs placebo or bath
emollient, Outcome 2 Global outcome (mean IGA score) at 4 weeks.
Study or subgroup Bleach bath Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Gonzalez 2016 9 0.5 (1.6) 9 1.1 (1) -0.54[-1.79,0.71]
Favours bleach bath 21-2 -1 0 Favours placebo
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Analysis 4.3.   Comparison 4 Bleach bath vs placebo or bath emollient,
Outcome 3 Change from baseline in CDLQI at end of treatment.
Study or subgroup Bleach bath Placebo Mean Dif-
ference
Mean Difference Mean Difference
  N N (SE) IV, Random, 95% CI IV, Random, 95% CI
Hon 2016 40 40 0.9 (1.133) 0.9[-1.32,3.12]
Favours bleach bath 42-4 -2 0 Favours placebo
 
 
Analysis 4.4.   Comparison 4 Bleach bath vs placebo or bath emollient,
Outcome 4 Adverse events requiring withdrawal from treatment.
Study or subgroup Bleach bath Placebo/emollient Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Leins 2013 0/8 0/11 Not estimable
Wong 2013 0/21 1/21 0.33[0.01,7.74]




Analysis 4.5.   Comparison 4 Bleach bath vs placebo or bath emollient,
Outcome 5 Minor adverse events not requiring withdrawal from treatment.
Study or subgroup Bleach bath Placebo/emollient Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Leins 2013 0/8 0/11 Not estimable
Shi 2016 0/10 0/10 Not estimable
Wong 2013 5/18 5/18 1[0.35,2.87]




Analysis 4.6.   Comparison 4 Bleach bath vs placebo or bath emollient, Outcome 6 Mean EASI score at 1 month.
Study or subgroup Bleach bath Placebo Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Gonzalez 2016 9 1.4 (6.3) 9 2.3 (6.9) 64.17% -0.96[-7.05,5.13]
Wong 2013 18 20.2 (11.8) 18 25.4 (13.1) 35.83% -5.2[-13.34,2.94]
   
Total *** 27   27   100% -2.48[-7.36,2.4]
Heterogeneity: Tau2=0; Chi2=0.67, df=1(P=0.41); I2=0%  
Test for overall effect: Z=1(P=0.32)  
Favours bleach bath 105-10 -5 0 Favours placebo
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Analysis 4.7.   Comparison 4 Bleach bath vs placebo or bath emollient,
Outcome 7 Change from baseline in objective SCORAD at end of treatment.
Study or subgroup Bleach bath Placebo Mean Dif-
ference
Mean Difference Mean Difference
  N N (SE) IV, Random, 95% CI IV, Random, 95% CI
Hon 2016 40 40 3.5 (2.605) 3.45[-1.66,8.56]
Favours bleach bath 105-10 -5 0 Favours placebo
 
 
Analysis 4.8.   Comparison 4 Bleach bath vs placebo or bath emollient,
Outcome 8 Mean S. aureus counts from lesional skin at 1 month.
Study or subgroup Bleach bath Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Wong 2013 18 9.7 (12.4) 18 10.4 (13.6) -0.7[-9.2,7.8]
Favours bleach bath 105-10 -5 0 Favours placebo
 
 
Analysis 4.9.   Comparison 4 Bleach bath vs placebo or bath emollient,
Outcome 9 Global outcome (not good or excellent) at 2 months.
Study or subgroup Bleach bath Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Wong 2013 7/18 9/18 0.78[0.37,1.63]
Favours bleach bath 20.5 1.50.7 1 Favours placebo
 
 
Analysis 4.10.   Comparison 4 Bleach bath vs placebo or bath emollient,
Outcome 10 Mean value of composite rating scale at 2-3 months.
Study or subgroup Bleach bath Placebo/emollient Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Leins 2013 8 15 (13.7) 11 32 (15.2) 33.6% -1.11[-2.11,-0.12]
Wong 2013 18 13.1 (7.8) 18 25.8 (13.9) 66.4% -1.1[-1.81,-0.39]
   
Total *** 26   29   100% -1.11[-1.68,-0.53]
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.99); I2=0%  
Test for overall effect: Z=3.76(P=0)  
Favours bleach bath 21-2 -1 0 Favours placebo/emollient
 
 
Analysis 4.11.   Comparison 4 Bleach bath vs placebo or bath emollient,
Outcome 11 Mean S. aureus counts from lesional skin at 2 months.
Study or subgroup Bleach bath Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Wong 2013 18 7.8 (11.6) 18 6.2 (10.7) 1.6[-5.69,8.89]
Favours bleach bath 105-10 -5 0 Favours placebo
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Comparison 5.   Bleach bath plus antibiotic vs placebo





Statistical method Effect size
1 Number of patients in whom MRSA was
isolated at 1 month
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Change from baseline in EASI at 1
month
1   Mean Difference (IV, Random, 95% CI) Totals not selected
3 Number of patients in whom S. aureus
was isolated at 1 month
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 Number of patients with a reduction in
IGA at 3 months
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
5 Number of patients in whom MRSA was
isolated at 3 months
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
6 Change from baseline in EASI at 3
months
1   Mean Difference (IV, Random, 95% CI) Totals not selected
7 Number of patients in whom S. aureus
was isolated at 3 months
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 5.1.   Comparison 5 Bleach bath plus antibiotic vs placebo,
Outcome 1 Number of patients in whom MRSA was isolated at 1 month.
Study or subgroup Bleach bath + antibiotic Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Huang 2009 1/11 0/13 3.5[0.16,78.19]
Favours Bleach bath + antibiotic 1000.01 100.1 1 Favours placebo
 
 
Analysis 5.2.   Comparison 5 Bleach bath plus antibiotic vs
placebo, Outcome 2 Change from baseline in EASI at 1 month.
Study or subgroup Bleach bath + antibiotic Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Huang 2009 11 -10.4 (9.3) 14 -2.5 (6) -7.9[-14.22,-1.58]
Favours Bleach bath + antibiotic 105-10 -5 0 Favours placebo
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Analysis 5.3.   Comparison 5 Bleach bath plus antibiotic vs placebo,
Outcome 3 Number of patients in whom S. aureus was isolated at 1 month.
Study or subgroup Bleach bath + antibiotic Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Huang 2009 6/11 10/13 0.71[0.38,1.31]
Favours Bleach bath + antibiotic 20.5 1.50.7 1 Favours placebo
 
 
Analysis 5.4.   Comparison 5 Bleach bath plus antibiotic vs placebo,
Outcome 4 Number of patients with a reduction in IGA at 3 months.
Study or subgroup Bleach bath + antibiotic Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Huang 2009 6/9 2/13 4.33[1.12,16.82]
Favours placebo 1000.01 100.1 1 Favours combination
 
 
Analysis 5.5.   Comparison 5 Bleach bath plus antibiotic vs placebo,
Outcome 5 Number of patients in whom MRSA was isolated at 3 months.
Study or subgroup Bleach bath + antibiotic Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Huang 2009 1/8 1/13 1.63[0.12,22.5]
Favours Bleach bath + antibiotic 1000.01 100.1 1 Favours placebo
 
 
Analysis 5.6.   Comparison 5 Bleach bath plus antibiotic vs
placebo, Outcome 6 Change from baseline in EASI at 3 months.
Study or subgroup Bleach bath + antibiotic Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Huang 2009 9 -15.3 (11.4) 13 -3.2 (5.8) -12.1[-20.18,-4.02]
Favours Bleach bath + antibiotic 2010-20 -10 0 Favours placebo
 
 
Analysis 5.7.   Comparison 5 Bleach bath plus antibiotic vs placebo,
Outcome 7 Number of patients in whom S. aureus was isolated at 3 months.
Study or subgroup Bleach bath + antibiotic Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Huang 2009 7/8 10/13 1.14[0.77,1.69]
Favours Bleach bath + antibiotic 1000.01 100.1 1 Favours placebo
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Comparison 6.   Therapeutic textile vs placebo





Statistical method Effect size
1 Number of patients in complete re-
mission or well under control at end
of study
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Adverse events requiring withdraw-
al from treatment
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Minor adverse events not requiring
withdrawal from treatment
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
4 Mean SCORAD at end of treatment 1   Mean Difference (IV, Random, 95% CI) Totals not selected
5 Change from baseline in local SCO-
RAD at end of treatment
1   Mean Difference (Random, 95% CI) Totals not selected
6 Mean log of S. aureus counts from
lesional skin at end of treatment
1   Mean Difference (IV, Random, 95% CI) Totals not selected
7 Mean S. aureus counts (thousands)
from lesional skin at end of treatment
1   Mean Difference (IV, Random, 95% CI) Totals not selected
8 Mean DLQI at 8 weeks 1   Mean Difference (IV, Random, 95% CI) Totals not selected
9 Mean SCORAD at 8 weeks 1   Mean Difference (IV, Random, 95% CI) Totals not selected
10 Mean SCORAD at 90 days 1   Mean Difference (IV, Random, 95% CI) Totals not selected
11 No of patients in whom S. aureus
was isolated at 8 weeks
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
12 Mean log of S. aureus counts at 8
weeks
1   Mean Difference (IV, Random, 95% CI) Totals not selected
 
 
Analysis 6.1.   Comparison 6 Therapeutic textile vs placebo, Outcome 1 Number
of patients in complete remission or well under control at end of study.
Study or subgroup Silver textile Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Juenger 2006 8/10 3/9 2.4[0.91,6.36]
Favours placebo 100.1 50.2 20.5 1 Favours silver textile
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Analysis 6.2.   Comparison 6 Therapeutic textile vs placebo,
Outcome 2 Adverse events requiring withdrawal from treatment.
Study or subgroup Chitosan-coated textile Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Lopes 2015 1/43 0/35 2.45[0.1,58.45]
Favours chitosan 500.02 100.1 1 Favours placebo
 
 
Analysis 6.3.   Comparison 6 Therapeutic textile vs placebo, Outcome
3 Minor adverse events not requiring withdrawal from treatment.
Study or subgroup Silver textile Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Juenger 2006 2/10 2/10 1[0.17,5.77]
Favours silver textile 100.1 50.2 20.5 1 Favours placebo
 
 
Analysis 6.4.   Comparison 6 Therapeutic textile vs placebo, Outcome 4 Mean SCORAD at end of treatment.
Study or subgroup Silver textile Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Juenger 2006 10 36.1 (21.1) 10 45.9 (18.7) -9.8[-27.27,7.67]
Favours silver textile 2010-20 -10 0 Favours placebo
 
 
Analysis 6.5.   Comparison 6 Therapeutic textile vs placebo, Outcome
5 Change from baseline in local SCORAD at end of treatment.
Study or subgroup Dermasilk Placebo Mean Dif-
ference
Mean Difference Mean Difference
  N N (SE) IV, Random, 95% CI IV, Random, 95% CI
Stinco 2008 26 26 -10 (1.81) -10.05[-13.6,-6.5]
Favours Dermasilk 2010-20 -10 0 Favours placebo
 
 
Analysis 6.6.   Comparison 6 Therapeutic textile vs placebo, Outcome
6 Mean log of S. aureus counts from lesional skin at end of treatment.
Study or subgroup Silver textile Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Juenger 2006 10 2.1 (0.9) 10 2.1 (1.2) 0[-0.93,0.93]
Favours silver textile 10.5-1 -0.5 0 Favours placebo
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Analysis 6.7.   Comparison 6 Therapeutic textile vs placebo, Outcome 7
Mean S. aureus counts (thousands) from lesional skin at end of treatment.
Study or subgroup Silver textile Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Daeschlein 2010 11 13.7 (6.9) 8 23.6 (45.7) -9.9[-41.83,22.03]
Favours silver textile 5025-50 -25 0 Favours placebo
 
 
Analysis 6.8.   Comparison 6 Therapeutic textile vs placebo, Outcome 8 Mean DLQI at 8 weeks.
Study or subgroup Chitosan-coated textile Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Lopes 2015 37 4.8 (4.3) 32 5.6 (6.1) -0.8[-3.32,1.72]
Favours chitosan 52.5-5 -2.5 0 Favours placebo
 
 
Analysis 6.9.   Comparison 6 Therapeutic textile vs placebo, Outcome 9 Mean SCORAD at 8 weeks.
Study or subgroup Chitosan-coated textile Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Lopes 2015 37 29.4 (24.8) 32 25.7 (21.4) 3.7[-7.2,14.6]
Favours chitosan 105-10 -5 0 Favours placebo
 
 
Analysis 6.10.   Comparison 6 Therapeutic textile vs placebo, Outcome 10 Mean SCORAD at 90 days.
Study or subgroup Silver/seaweed textile Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Portela Araujo 2013 11 24 (12.5) 7 24.2 (12.5) -0.2[-12.05,11.65]
Favours silver/seaweed 2010-20 -10 0 Favours placebo
 
 
Analysis 6.11.   Comparison 6 Therapeutic textile vs placebo, Outcome
11 No of patients in whom S. aureus was isolated at 8 weeks.
Study or subgroup Chitosan-coated textile Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Lopes 2015 22/34 18/28 1.01[0.69,1.46]
Favours chitosan 20.5 1.50.7 1 Favours placebo
 
 
Analysis 6.12.   Comparison 6 Therapeutic textile vs placebo, Outcome 12 Mean log of S. aureus counts at 8 weeks.
Study or subgroup Chitosan-coated textile Placebo Mean Difference Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI Random, 95% CI
Lopes 2015 34 4 (1.8) 28 3.8 (1.6) 0.2[-0.65,1.05]
Favours chitosan 21-2 -1 0 Favours placebo
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Comparison 7.   Protease inhibitor vs placebo





Statistical method Effect size
1 Global outcome (good or excellent) 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
2 Adverse events requiring withdrawal
from treatment
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
3 Adverse events not requiring with-
drawal from treatment
1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
 
 
Analysis 7.1.   Comparison 7 Protease inhibitor vs placebo, Outcome 1 Global outcome (good or excellent).
Study or subgroup Protease inhibitor Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Foelster Holst 2010 5/45 6/48 0.89[0.29,2.71]




Analysis 7.2.   Comparison 7 Protease inhibitor vs placebo,
Outcome 2 Adverse events requiring withdrawal from treatment.
Study or subgroup Protease inhibitor Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Foelster Holst 2010 7/45 11/48 0.68[0.29,1.6]
Favours protease inhibito 50.2 20.5 1 Favours placebo
 
 
Analysis 7.3.   Comparison 7 Protease inhibitor vs placebo, Outcome
3 Adverse events not requiring withdrawal from treatment.
Study or subgroup Protease inhibitor Placebo Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
Foelster Holst 2010 20/45 23/48 0.93[0.6,1.44]
Favours protease inhibito 20.5 1.50.7 1 Favours placebo
 
 
A D D I T I O N A L   T A B L E S
 
Study ID Information requested Response
Canpolat 2012 10th April 2015 No response
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Dear Professor Canpolat
We are currently updating the Cochrane systematic review of Interventions to re-
duce Staphylococcus aureus in the management of atopic eczema. Your recent
article ‘Hydrocortisone acetate alone or combined with mupirocin for atopic der-
matitis in infants under two years of age – a randomized double blind pilot tri-
al’ (Eur Rev Med Pharmacol Sci 2012; 16:1989-93) will be included in the updated
review.
We would be grateful if you could answer a few questions for clarification:
1. Could you describe the method used to generate the allocation sequence in
the trial?
2. Could you describe the method used, if any, to conceal the allocation se-
quence?
3. The abstract indicates that efficacy evaluation was made at ‘day 7 and weeks 2,
4 and 8’ however the results are only reported for ‘day 8’. Could you please clarify
and provide any outcome data for additional time points that are available?
I look forward to hearing from you.
Kind regards
Dr Susannah George
Specialty Registrar in Dermatology
Eastbourne District General Hospital
Fluhr 2009 11th April 2015
Dear Dr Fluhr
We are currently updating the Cochrane systematic review of Interventions to re-
duce Staphylococcus aureus in the management of atopic eczema. Your article
‘Silver-loaded seaweed-based cellulosic fiber improves epidermal skin physiol-
ogy in atopic dermatitis: safety assessment, mode of action and controlled, ran-
domized single-blinded exploratory in vivo study’ (Exp Dermatol 2009; 19:e9-15)
will be included in the updated review.
We would be grateful if you could answer a few questions for clarification:
1. Could you describe the method used to generate the allocation sequence for
the randomised in vivo study?
2. Could you describe the method used, if any, to conceal the allocation se-
quence?
3. You have indicated that the study was single-blinded. Could you clarify who
was and was not blinded (the participants, investigators, wider study team, those
assessing the outcomes)?
4. Could you clarify how and when the outcomes were assessed and who made
the assessment?
5. Did you record any clinical assessment of the severity of atopic dermatitis or of
quality of life?
6. Could you provide the values for the mean and standard error of the mean for
the S. aureus colonisation changes reported in Figure 2a?
I look forward to hearing from you.
No response
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Kind regards
Dr Susannah George
Specialty Registrar in Dermatology
Eastbourne District General Hospital
Gauger 2006 11th April 2015
Dear Dr Gauger
We are currently updating the Cochrane systematic review of Interventions to
reduce Staphylococcus aureus in the management of atopic eczema. Your ar-
ticle ‘Efficacy and functionality of silver-coated textiles in patients with atopic
eczema’ (JEADV 2006; 18:534-41) will be included in the updated review.
We would be grateful if you could answer a few questions for clarification:
1. Could you describe the method used to generate the allocation sequence for
the trial?
2. Could you describe the method used, if any, to conceal the allocation se-
quence?
3. You have indicated that the study was double-blind. However, the Results state
that ‘Nine of the 11 dropouts were from the placebo group, due to either systemic
antibiotics or assignment to the placebo group by the patient.’ This appears to
imply that patients in the placebo group were aware of their assignment. Could
you clarify who was and was not blinded (the participants, investigators, wider
study team, those assessing the outcomes) and how long this was maintained?
4. Could you supply the full results for the responses to the questionnaire (Table
2) at 1 week and at the end of the study in terms of the number of participants in
each group giving each response?
5. Could you supply the standard deviations at each time point for the general
SCORAD (fig. 1), eczema extent in the SCORAD (fig. 2), subjective symptoms in
SCORAD (fig. 3) and impairment of quality of life (fig. 4)?
I look forward to hearing from you.
Kind regards
Dr Susannah George
Specialty Registrar in Dermatology
Eastbourne District General Hospital
No response
Hung 2007 18th April 2015
Dear Dr Chiang
We are currently updating the Cochrane systematic review of Interventions to re-
duce Staphylococcus aureus in the management of atopic eczema. Your article
by Hung et al, ‘Staphylococcus colonization in atopic dermatitis treated with flu-
ticasone or tacrolimus with or without antibiotics’ (Ann Allergy Asthma Immunol
2007; 98:51-6) will be included in the updated review.
We would be grateful if you could answer a few questions for clarification:
1. Could you describe the method used to generate the allocation sequence for
the trial?
No response
Table 1.   Correspondence with authors  (Continued)
Interventions to reduce Staphylococcus aureus in the management of eczema (Review)









Cochrane Database of Systematic Reviews
2. Could you describe the method used, if any, to conceal the allocation se-
quence?
3. Could you supply the full results for the outcomes reported in Figure 1 and Fig-
ure 2 (e.g. means and standard deviations or standard errors at each time point)?
4. Could you supply the full results for each group at each time point for the other
outcomes not reported in the paper – modified local SCORAD, colonisation densi-
ty of S. aureus, antibiotic resistance?
I look forward to hearing from you.
Kind regards
Dr Susannah George
Specialty Registrar in Dermatology
Eastbourne District General Hospital
Koller 2007 18th April 2015
Dear Dr Koller
We are currently updating the Cochrane systematic review of Interventions to re-
duce Staphylococcus aureus in the management of atopic eczema. Your article
‘Action of a silk fabric treated with AEGISTM in children with atopic dermatitis: a
3-month trial’ (Pediatr Allergy Immunol 2009; 18:335-8) will be included in the up-
dated review.
We would be grateful if you could answer a few questions for clarification:
1. Could you describe the method used to generate the allocation sequence for
the trial?
2. Could you describe the method used, if any, to conceal the allocation se-
quence?
3. Did you give any instructions on washing and drying the tubes?
4. Did you calculate a total for the modified SCORAD?
I look forward to hearing from you.
Kind regards
Dr Susannah George
Specialty Registrar in Dermatology
Eastbourne District General Hospital
No response
Leins 2013 13th October 2015
Dear Liz Leins,
We are currently updating the Cochrane systematic review of Interventions to re-
duce Staphylococcus aureus in the management of atopic eczema. Our search-
es identified your trial on Bleach Baths for Eczema as possibly relevant for the
Cochrane Systematic Review and we would be very grateful if you could send us
further details of the study and any results.
Many thanks for your help.
Kind regards,
Susannah George
Specialty Registrar in Dermatology
18th October 2015
Hi Susannah,
The final results are un-
published so I can’t send
you those, however our




pilot data (although our fi-
nal results are the same).
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Lembo 2011 10th April 2015
Dear Dr Lembo
We are currently updating the Cochrane systematic review of Interventions to re-
duce Staphylococcus aureus in the management of atopic eczema. Your recent
article ‘L’eritromicina topica nella terapia della dermatite atopica’ (Ann Ital Der-
matol Allergol 2011; 65:3) will be included in the updated review.
We would be grateful if you could answer a few questions for clarification:
1. You have indicated that the patients were randomised into the two groups
stratified by age and sex. Could you describe the method used to generate the al-
location sequence within each stratum?
2. Could you describe the method used, if any, to conceal the allocation se-
quence?
3. You have indicated that the study was double-blind. Could you clarify who was
and was not blinded (the participants, investigators, wider study team, those as-
sessing the outcomes)?
I look forward to hearing from you.
Kind regards
Dr Susannah George
Specialty Registrar in Dermatology
Eastbourne District General Hospital
30th April 2015
Dear Dr. George.
Sorry for writing you so
late but it has been a very
busy period. We are hap-
py about your intention to
include our paper in your
updated review.
This is the method we
used to generate the two
groups stratified for sex
and age:
1. Age and sex of patients
were recorded in a word
excel sheet in which pa-
tients were anonymised
2. Patients were ordered
by age
3. Four classes were iden-
tified by age range:
I: 0.5 to 3 years
II: 4 to 7 years
III: 8 to 11 years
IV: 12 to 14 years.
1. Two subclasses were
identified by sex in each
age class: male and fe-
male




3. Pare numbers were as-
signed to group B and
spare numbers were as-
signed to group A.




Leyden 1977 15th February 2017
Dear Professor Leyden
16th February 2017
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I am a consultant dermatologist in the UK and I am currently updating the
Cochrane systematic review on antistaphylococcal interventions in atopic der-
matitis. Your paper on steroid-antibiotic combinations from 1977 is included in
the review and I am having some difficulty interpreting the detail of the results to
include them in the review.
For the comparison of Synalar vs Neo-Synalar, you reported clinical responses of
30% excellent, 40% good and 30% fair for Synalar and 70% excellent, 20% good
and 10% fair for Neo-Synalar. However, these exact percentages do not seem
possible based on the reported sample sizes of 21 and 15, respectively. I realise
this study was a long time ago, however I wondered if you would be able to clarify
whether the percentages reported were based on a smaller subset of patients, or
whether they have been approximated/rounded oL to multiples of 10%.





Brighton and Sussex University Hospitals NHS Trust






We are currently updating the Cochrane systematic review of Interventions to re-
duce Staphylococcus aureus in the management of atopic eczema. Your recent
article ‘A proposal for the use of new silver-seaweed-cotton fibers in the treat-
ment of atopic dermatitis’ (Cutan Ocul Toxicol 2013; 32:268-74) will be included
in the updated review.
We would be grateful if you could answer a few questions for clarification:
1. Could you describe the method used to generate the allocation sequence for
the trial?
2. Could you describe the method used, if any, to conceal the allocation se-
quence?
3. Could you describe the reason why one patient in the intervention group did
not complete the study? At what point did they drop out?
4. In your study, were patients given only one set of clothes to wear continuously
for the first seven days? How often were they expected to wash the clothing? Do
you have any data as to whether the patients did or did not wear the clothing as
instructed?
I look forward to hearing from you.
Kind regards
Dr Susannah George
Specialty Registrar in Dermatology
Eastbourne District General Hospital
No response
Wong 2013 12th April 2015 13th April 2015
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Dear Dr Wong
We are currently updating the Cochrane systematic review of Interventions to re-
duce Staphylococcus aureus in the management of atopic eczema. Your recent
article ‘Efficacy and safety of sodium hypochlorite (bleach) baths in patients with
moderate to severe atopic dermatitis in Malaysia’ (J Dermatol 2013; 40:874-80)
will be included in the updated review.
We would be grateful if you could answer a few questions for clarification:
1. Could you describe the method used to generate the allocation sequence for
the trial?
2. Could you describe the method used, if any, to conceal the allocation se-
quence?
3. You have indicated that the study was double-blind. However, previous studies
of bleach baths have reported that the intervention was obvious due to the smell
of bleach. Did you make any attempt to address this in your study, and did you
have any evidence that the participants were genuinely blinded to their treat-
ment allocation? More generally, could you clarify who was and was not blinded
(the participants, investigators, wider study team, those assessing the outcomes)
and how long this was maintained?
4. Could you supply the full results for the bacteriological assessments (means
and standard deviations in CFU/cm2 at baseline and follow-up)?
5. Could you supply the mean and standard deviation for each group at each time
point for EASI (Figure 3), BSA affected (Figure 5) and itch scores (Figure 7)?
I look forward to hearing from you.
Kind regards
Dr Susannah George
Specialty Registrar in Dermatology
Eastbourne District General Hospital
Dear Dr George,
Thank you for your email. I
will try and answer all your
questions as accurately as
possible.
1.Could you describe the







the treatment or placebo
study arms.
2. Could you describe the
method used, if any, to
conceal the allocation se-
quence?
I had no access to the al-
location sequence. the
pharmacist helping in this
study, dispensed either
bleach or placebo (dis-
tilled water) according to
the computer generated
numbers. So I didn't know
which the patient got, and
on all the subsequent fol-
low-up, the patient was
assessed by me without
knowledge of what treat-
ment they were given.
3. You have indicated
that the study was dou-
ble-blind. However, pre-
vious studies of bleach
baths have reported that
the intervention was ob-
vious due to the smell of
bleach. Did you make any
attempt to address this in
your study, and did you
have any evidence that the
participants were genuine-
ly blinded to their treat-
ment allocation? More
generally, could you clar-
ify who was and was not
blinded (the participants,
investigators, wider study
team, those assessing the
outcomes) and how long
this was maintained?
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Both treatment and place-
bo were placed in iden-
tical bottles. yes, the pa-
tient may have been able
to smell the bleach. but
nothing else was done to




medication was not. This
was maintained through-
out the study period.
4. Could you supply the
full results for the bacte-
riological assessments
(means and standard devi-
ations in CFU/cm2 at base-
line and follow-up)?
- see excel sheet attached
5. Could you supply the
mean and standard devia-
tion for each group at each
time point for EASI (Figure
3), BSA affected (Figure 5)
and itch scores (Figure 7)?
- see excel sheet attached
I hope the above answers
your questions. Please do
not hesitate to contact me
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A P P E N D I C E S
Appendix 1. CENTRAL (Cochrane Library) search strategy
#1 MeSH descriptor: [Staphylococcus aureus] explode all trees
#2 MeSH descriptor: [Staphylococcal Skin Infections] explode all trees
#3 MeSH descriptor: [Staphylococcus] explode all trees
#4 staphylococc*:ti,ab,kw
#5 {or #1-#4}
#6 MeSH descriptor: [Eczema] explode all trees
#7 MeSH descriptor: [Dermatitis, Atopic] explode all trees
#8 MeSH descriptor: [Neurodermatitis] explode all trees
#9 MeSH descriptor: [Dermatitis] explode all trees
#10 eczema or dermatitis or neurodermatitis:ti,ab,kw
#11 besnier$ prurigo:ti,ab,kw
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#12 {or #6-#11}
#13 #5 and #12
Appendix 2. MEDLINE (Ovid) search strategy
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. clinical trials as topic.sh.
6. randomly.ab.
7. trial.ti.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. exp animals/ not humans.sh.
10. 8 not 9
11. exp Eczema/ or eczema.mp.
12. exp Dermatitis, Atopic/
13. neurodermatitis.mp. or exp Neurodermatitis/
14. exp Dermatitis/ or dermatitis.mp.
15. Besnier$ Prurigo.mp.
16. or/11-15
17. exp staphylococcus/ or exp staphylococcus aureus/
18. staphylococc$.ti,ab.
19. exp Staphylococcal Skin Infections/
20. or/17-19
21. 10 and 16 and 20
[Lines 1-10: Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity- and precision-maximizing
version (2008 revision)]
Appendix 3. Embase (Ovid) search strategy
1. exp staphylococcal skin infection/




6. eczema.mp. or exp ECZEMA/
7. exp DERMATITIS/ or dermatitis.mp.
8. exp atopic dermatitis/






15. (crossover$ or cross over$).tw.
16. placebo$.tw.
17. (doubl$ adj blind$).tw.
18. allocat$.tw.
19. trial.ti.
20. randomized controlled trial.sh.
21. random$.tw.
22. or/12-21
23. exp animal/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
24. human/ or normal human/
25. 23 and 24
26. 23 not 25
27. 22 not 26
28. 5 and 11 and 27
Appendix 4. LILACS search strategy
In LILACS we searched using the Controlled clinical trials topic-specific query filter and the following terms:
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(dermatitis or eczema or neurodermatitis or besnier$ or eccema) and (staphylococc$ or estafilococo)
W H A T ' S   N E W
 
Date Event Description
15 October 2019 New search has been performed A new search led to the addition of 20 new included studies, and
we updated the review in line with MECIR standards.
15 October 2019 New citation required but conclusions
have not changed
Update completed. We incorporated GRADE into this update of
the review.
 
H I S T O R Y
Protocol first published: Issue 1, 2002
Review first published: Issue 3, 2008
 
Date Event Description
14 March 2008 Amended Converted to new review format.
 
C O N T R I B U T I O N S   O F   A U T H O R S
SG was the contact person with the editorial base, SG co-ordinated contributions from the co-authors, and wrote the final dra$ of the
review.
SG, SK, DH screened papers against eligibility criteria.
SG obtained data on ongoing and unpublished studies.
SG, SK, DH appraised the quality of papers.
SG, SK, DH extracted data for the review and sought additional information about papers.
SG, DH entered data into RevMan.
SG, DH analysed and interpreted data.
SG, DH worked on the methods sections.
SG drafted the clinical sections of the background and responded to the clinical comments of the referees.
DH responded to the methodology and statistics comments of the referees.
AR was the consumer co-author and checked the review for readability and clarity, as well as ensuring outcomes were relevant to con-
sumers.
AB, FBH, JR, HW performed the original review and provided advice on inclusion of studies and interpretation of data.
SG is the guarantor of the update.
Disclaimer
This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Skin Group.
The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Pro-
gramme, NIHR, NHS or the Department of Health.
D E C L A R A T I O N S   O F   I N T E R E S T
Susannah MC George: none known.
Sanja Karanovic: none known.
David A Harrison: none known.
Anjna Rani: none known.
Andrew J Birnie has received payment from Leo Pharma and Almirall for delivering lectures on skin cancer and sun damage. Almirall has
covered meeting registration fee, plus travel and accommodation, for the American Academy of Dermatology meeting in March 2017.
Fiona J Bath-Hextall: none known.
Jane C Ravenscroft: none known.
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Hywel C Williams: I am director of the NIHR HTA Programme. HTA is part of the NIHR which also supports the NIHR systematic reviews
programme from which this work is funded. I was also a co-applicant on a relevant clinical trial (SCIN trial) that is not yet published that
sought to prevent hand eczema in nurses, funded by the National Institute of Health Research Health Technology Assessment Programme
S O U R C E S   O F   S U P P O R T
Internal sources
• Queens Medical Centre NHS Trust, UK.
External sources
• The National Institute for Health Research (NIHR), UK.
The NIHR, UK, is the largest single funder of the Cochrane Skin Group
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We have changed the title of this review to 'Interventions to reduce Staphylococcus aureus in the management of eczema'. In the original
protocol, it was 'Interventions to reduce Staphylococcus aureus for atopic eczema'. The wording 'in the management of' was added in
response to a comment from an external referee. The word 'atopic' was removed in the subsequent update to meet current terminology.
Under 'Objectives' we changed the text from 'To assess the efficacy and possible adverse effects of interventions to reduce S. aureus for
treating atopic eczema' to 'To assess the effects of interventions to reduce S. aureus for treating eczema', in line with updated guidance
from the Cochrane Handbook for Systematic Reviews of Interventions.
Under 'Types of interventions' in the review text, we adjusted the categories of types of interventions to cover all relevant interventions
identified by the searches. We also clarified the rationale (as originally intended) for which comparators were considered valid for each
intervention and included placebo and untreated textiles in the list of potential comparators.
Under 'Types of outcome measures', we have omitted the secondary outcome listed in the protocol: 'we will report on skin irritation
separately as it is a common occurrence' from the review. We have explained this in the Methods section under 'Data extraction and
management'. We have also explained the definitions of short-term benefit and long-term benefit.
Also under 'Measures of treatment effects', we have analysed the results as risk ratios rather than odds ratios as was planned in the pro-
tocol; this is in line with Cochrane Skin Group policy and has been explained in the text. We also added that for continuous outcomes we
would use standardised mean differences (SMD) when different instruments were used.
To align with the current Cochrane methodology, we assessed risk of bias in the update using the Cochrane 'Risk of bias' tool (Higgins
2011). We also assessed heterogeneity using the I2 statistic and planned to create funnel plots to explore reporting bias (however, we could
not do this as the meta-analyses did not include 10 or more studies). We planned to perform subgroup analysis according to infection
status and to perform sensitivity analyses examining the effects of excluding study subgroups, e.g. those studies with low methodological
quality, but there were insufficient studies to do so. For the meta-analyses, we used a random-effects model as studies were considered
to be clinically heterogeneous. We also included a 'Summary of findings' table to summarise our most important comparisons, and used
the GRADE methodology to assess the certainty of evidence for important outcomes within these comparisons.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
*Staphylococcus aureus;   Anti-Bacterial Agents   [adverse eLects]   [therapeutic use];   Anti-Infective Agents, Local   [therapeutic use];
   Antifungal Agents   [therapeutic use];   Clothing;   Dermatitis, Atopic   [*drug therapy]   [microbiology];   Drug Resistance, Bacterial;
  Randomized Controlled Trials as Topic;  Silver Compounds  [therapeutic use];  Soaps  [adverse eLects]  [therapeutic use];  Staphylococcal
Skin Infections  [*drug therapy]
MeSH check words
Humans
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